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Head and neck cancer in general
Head and neck cancer is the seventh most common type of cancer worldwide. (1) In 
2015 the incidence of head and neck cancer was 930,000 worldwide with 379,000 
deaths. (2) Two-thirds of the head and neck cancer occurs in developing countries due 
to the prevalence of risk factors such as smoking and alcohol consumption, while 
nasopharyngeal carcinoma is more common in endemic areas of northern Africa and 
Asia, due to the Epstein-Barr virus (EBV). (3) The incidence of head and neck cancer is 
3-fold higher among men than women. (3) In the Netherlands, over 3000 new patients 
with head and neck cancer were diagnosed in 2017. (4) Head and neck cancer 
encompasses tumours that arise in the paranasal sinuses, nasal cavity, oral cavity, 
pharynx (oropharynx, hypopharynx and nasopharynx), larynx, and salivary glands. 
Because the incidence of the subtypes of head and neck cancer is less than 6 per 
100.000, head and neck cancer belong to the rare cancers. Squamous cell carcinomas 
are the most frequent type of head and neck cancer (more than 90%), Notable, other 
malignancies can also present in the head and neck region, like salivary gland cancers, 
melanomas and sarcomas. (5) The term ‘head and neck cancer’ most often refer to 
squamous cell cancer of the oral cavity, oropharynx, hypopharynx or larynx.
Aetiology
Risk factors for squamous cell carcinoma of the head and neck (SCCHN) are tobacco 
and alcohol use. (5, 6) Compared to non-smokers and non-drinkers, those who smoke 
more than two packs of cigarettes and drink more than four alcoholic beverages a day 
have a 35-fold increased risk of head and neck cancer. (7, 8) Tobacco consumption 
during treatment is associated with poorer outcomes. Continued alcohol and tobacco 
use after treatment is a risk factor for developing second primary cancers and leads 
to decreased 5-year survival. (6) In oropharyngeal cancer, the human papillomavirus 
(HPV) has been recognized as another risk factor. (7, 9, 10)The incidence of non-HPV 
oropharyngeal cancer is declining, while the incidence of HPV-positive oropharyngeal 
cancer increases. (11, 12) There are nearly 200 genotypes of HPV, of which several 
high-risk HPV genotypes are considered causative agents in oropharyngeal cancer, 
including HPV16, 18, 31, 33, 45, 52, and 58. (13) Of these, HPV16 is most commonly 
detected in oropharyngeal cancer with a meta-analysis of global data demonstrating 
that 82% of all HPV-positive SCCHN worldwide were attributable to HPV16. (14) (7) 
HPV-positive oropharyngeal cancer is associated with younger age at sexual debut, 
lifetime number of sexual partners, male sex, and white race, but not with tobacco or 
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alcohol consumption. HPV positive tumours are associated with a better response to 
therapy and much better prognosis. (7)
Diagnosis
Early recognition of signs and symptoms of SCCHN is important, because advanced 
stage of disease requires more intensive (multimodality) and toxic treatment and 
nevertheless has a worse prognosis. Symptoms of head and neck cancer consist of 
hoarseness, sore throat, tongue pain, poorly fitting dentures, otalgia, dysphagia or 
stridor. (5) Symptoms are sometimes non-specific and not immediately recognized by 
patient or doctor, leading to a delay in diagnosis and treatment. About 60% of patients 
with SCCHN present with advanced stage disease, i.e. large primary tumour and/or 
lymph node metastases. Distant metastasis at initial diagnosis however is uncommon 
(in about 10% of the patients). (5)
Accurate staging is very important for the development of the best treatment plan as 
well as the prognosis. Staging methods include physical examination, a 
laryngopharyngoscopy under general anesthesia, radiographic imaging of the tumour 
(by CT-scan or MRI) and lymph nodes (by ultrasound) and chest imaging for possible 
Figure 1. Anatomy of the head and neck, in all of these sides head and neck cancer can originate.
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metastasis or detection of lung cancer as second primary tumour. (5) The diagnosis is 
confirmed by pathology findings obtained from the tumour and/or draining lymph 
nodes.  Currently, the 8th edition of the Tumour, Node, Metastasis (TNM) classification 
by the American Joint Committee on Cancer (AJCC) is used for staging. (15)
Treatment of locally advanced disease
Treatment of head and neck cancers differs depending on the subtype, stage and the 
primary site of the tumour, the age, co-morbidities and condition of the patient. Surgery, 
radiotherapy, and chemotherapy/targeted therapy are the main treatment modalities 
for curative management of locally advanced SCCHN (i.e., stage III or IV (without distant 
metastases)). Surgery is standard treatment for SCCHN, but is frequently limited by the 
anatomical extent of tumour and desire to achieve organ preservation. (5) Therefore, 
radiotherapy or concomitant chemoradiotherapy is the treatment of choice for locally 
advanced SCCHN located in the pharynx and larynx. In SCC of the oral cavity primary 
surgery is standard treatment followed by adjuvant radiotherapy or concomitant 
chemoradiotherapy in part of the patients. A meta-analysis by Pignon et al. showed an 
absolute overall survival benefit for chemoradiotherapy of 6.5% at 5 years compared 
with radiotherapy alone. (16) The benefit of chemoradiotherapy was shown for stage III 
and stage IV (without distant metastases) disease, each primary site and for primary as 
well as postoperative treatment in case of extra-nodal spread, vascular or perineural 
invasion, or microscopically irradical tumour resection. (17) The survival advantage is 
predominantly attributed to improved locoregional control, but has an non-significant 
effect on the development of distant metastases. (5) Especially for oropharyngeal and 
laryngeal cancers, concomitant chemoradiation improved overall survival significantly 
compared with (neo-)adjuvant chemotherapy followed by radiotherapy and the effect 
of chemotherapy was significantly higher with platinum than with other types of mono-
chemotherapies. (18)
Various chemoradiotherapy regimens are being used, of which cisplatin-containing 
regimens are generally viewed as the standard. Chemoradiotherapy with cisplatin is 
most often applied at a dose of 100mg/m2 every 3 weeks for 3 cycles (RTOG-regimen, 
(19)) or at a dose of 40mg/m2 every week for 6 or 7 cycles. (20) Concomitant chemo-
radio therapy with two-drug combinations has also been tested, but did not perform 
better than chemoradiotherapy with one single agent.(5) In patients not eligible for 
chemotherapy, cetuximab, an IgG1 chimeric monoclonal antibody directed against the 
epidermal growth factor receptor (EGFR), in combination with radiotherapy can be 
11
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considered. In a phase III study by Bonner et al. radiotherapy plus cetuximab showed 
improved locoregional control and overall survival compared with radiotherapy alone 
(overall survival at 3 years 55% with cetuximab and radiotherapy compared with 45% 
with radiotherapy alone, p=0.03). (21) 
Toxicity of concomitant chemoradiotherapy 
Concomitant chemoradiotherapy is known for high rates of acute and late side effects. 
Acute toxicities consist of mucositis, dermatitis, dysphagia, nausea, vomiting, ototoxicity, 
nephrotoxicity and bone marrow suppression. The incidence of these toxicities depends 
on the applied cisplatin schedule and radiotherapy technique, but incidences of 8-68% 
of nephrotoxicity, 40% of haematological toxicity, and 77% of mucositis are common.
(22-24) Dysphagia and aspiration are both frequently underreported during and after 
chemoradiotherapy. (25) The reported rate of aspiration is between 13-69%. (26, 27). 
Compared with radiotherapy alone, the incidence of grade 3 or 4 acute toxicities is 
47% with radiotherapy alone versus 77% with chemoradiotherapy. (23) Nephrotoxicity 
as well as ototoxicity are mainly cisplatin-induced. (20, 28) Nephrotoxicity can be 
characterized by an impaired glomerular filtration rate and/or tubulopathy, while 
ototoxicity mainly manifests itself by hearing loss, starting with a loss of high tones. 
(29, 30). Both ototoxicity and nephrotoxicity are dose- and schedule dependent and 
can be dose-limiting for prescribing cisplatin. (20, 28, 29)
Especially in LAHNC patients treated with chemoradiotherapy, infectious complications 
are seen relatively frequent, due to mucositis, dysphagia and aspiration. But also febrile 
neutropenia, as a side-effect of the platinum-based chemotherapy, can be a problem. 
Different prophylactic treatments are investigated to overcome these problems, like 
granulocyte colony-stimulating factors (G-CSFs) for the prevention of chemotherapy-
induced febrile neutropenia(31) and Selective Digestive Decontamination (SDD) with 
the oral, non-absorbable antimicrobial substances with or without systemtic antibiotics 
to reduce the risk of gastrointestinal tract derived infections in patients recieving high-
dose chemotherapy before autologous stem cell transplantation or to prevent aspirtion 
pneumonia in the Intensive Care population. (32, 33)
Even 5 years after the end of concomitant chemoradiotherapy, LAHNC patients have 
toxicities grade 3 in 52% and grade 4 in 25%. (34) Late toxicities comprise fibrosis of 
the subcutaneous tissue, xerostomia, dysphagia, swallowing problems and 
osteoradionecrosis. The late toxicities are significantly correlated with tumour site 
(tumours in the oropharynx and oral cavity have more grade 3 and grade 4 toxicities 
than tumours in the hypopharynx) and with T-stage (higher T-stage have more 
toxicities). (34)
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Concomitant chemoradiotherapy, as well as the disease itself, has a huge impact on 
Health Related Quality of Life (HRQoL). During treatment, there is a significant 
worsening of HRQoL. Four to six weeks after treatment, HRQoL declines even further, 
but improves gradually in the period thereafter. (35-37). One year after the end of 
treatment, most patients reported that HRQoL had recovered to baseline. (37, 38) The 
global health status, a score of the EORTC QLQ-C30 with higher scores indicating better 
functioning, is shown to be predictive of survival with increased mortality risk among 
SCCHN patients with lower functioning prior to the start of curative treatment. (39)
Treatment of recurrent or metastatic disease
Despite aggressive treatment for locally advanced disease, a substantial number of 
SCCHN patients will develop disease recurrence, with up to 60% risk of local failure 
and up to 30% risk of distant failure. (40) (5) In case of locoregional recurrence only, 
surgical treatment or re-irradiation with curative intent is possible in a minority of the 
patients. However, patients with incurable recurrent or metastatic (R/M) disease have 
a poor prognosis with a median overall survival of less than 1 year, frequently even 
less than 6 months. (41) The combination of cisplatin, cetuximab and 5-FU (the 
“EXTREME” regimen) was the first combination systemic therapy showing an overall 
survival benefit compared to cisplatin and 5-FU alone (10.1 months versus 7.4 months). 
(42) Although the investigators reported that the toxicity profile of the EXTREME 
regimen was manageable, the grade 3 or 4 toxicity rate was 82%. Most frequently 
reported grade 3 or 4 toxicities were neutropenia (22%), anemia (13%, thrombocytopenia 
(11%) and skin reactions (9%). However, adverse events of any grade (including grade 
1 and 2) were not reported in the article, but also long lasting grade 1 or 2 toxicities 
can have an impact on HRQoL. Also, in clinical practice this regimen is often too toxic 
for this vulnerable patient group, and frequently refused by the patient. Single agent 
therapy or combination therapy with methotrexate, docetaxel, paclitaxel, carboplatin 
or cetuximab has shown a better tolerance but did not show clinical benefit in terms 
of overall survival, (40, 41).
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Outline thesis
As described above, the primary treatment of HNSCC with concomitant 
chemoradiotherapy with cisplatin is challenging for patients as it often coincides with 
serious side effects.  Also the current standard with cetuximab and platinum/5FU in 
the metastatic setting treatment can induce high grade toxicities. Therefore, the aim 
of my thesis is to perform studies in HNSCC patients in the curative and palliative 
setting with a focus on reduction of early and late toxicity while maintaining treatment 
efficacy to obtain knowledge that may improve personalised care and shared decision 
making in future patients with head and neck cancer. 
In the phase II study “Efficacy and cost efficacy of Prophylactic treatment with Antibiotics 
during concomitant chemoradiotherapy in patients with locally advanced head and 
neck cancer to prevent Aspiration Pneumonia – PANTAP”, described in Chapters 2-4, 
the effect of prophylactic antibiotics in LAHNC patients treated with chemoradiotherapy 
will be studied.  Because aspiration and aspiration pneumonia have a negative influence 
on HRQoL and put an enormous burden on the healthcare-system, it was hypothesized 
that prophylactic antibiotics could reduce the number of aspiration pneumonias. 
Secondary endpoints of this randomised phase II study are hospitalisation rate, adverse 
events, costs and HRQoL. Furthermore, a cost-effectiveness analysis will be performed. 
The PANTAP study was awarded with a grant from The Netherlands Organisation for 
Health Research and Development (ZonMw).
Patients in the PANTAP study are included prior to the start of chemoradiotherapy, 
and are randomised between day 21 and 28 after the start of chemoradiotherapy, 
unless they have an infection or are on any antibiotic treatment 14 days prior to 
randomization. Patients are randomised between standard of care or prophylactic 
amoxicillin/clavulanic acid from day 29 after the start of chemoradiotherapy until 14 
days after the end of the chemoradiotherapy. In Chapter 2 I describe the main results 
of the PANTAP study: the effect of prophylactic antibiotics on aspiration pneumonias, 
hospitalisations, adverse events and the results of the cost-effectiveness analysis. In 
Chapter 3 I present the effects of prophylactic antibiotics on HRQoL, while in Chapter 
4 I describe the results of the results of the  sputum cultures collected during the 
PANTAP study.
As ototoxicity and nephrotoxicity are two of the well-known acute and late treatment 
toxicities related to chemoradiotherapy with cisplatin in the LAHNC population, it would 
be of great value if we could define predictive biomarkers to adjust the treatment 
timely, if necessary. In Chapter 5 results will be described of the PRONE study (“Genetic 
14
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variants as Predictive markers for Ototoxicity and Nephrotoxicity in patients with locally 
advanced head and neck cancer treated with cisplatin-containing chemoradiotherapy”) 
on genetic variants to predict ototoxicity and nephrotoxicity in patients treated with 
chemoradiotherapy. 
For patients with recurrent or metastatic disease there are currently limited treatment 
options available and their prognosis is poor, especially in patients not eligible for the 
EXTREME regimen. Therefore, “a phase Ib-II study of the Combination of Cetuximab 
and Methotrexate in recurrent or metastatic squamous cell carcinoma of the head and 
neck - COMMENCE”, was developed were patients with recurrent or metastatic 
squamous cell carcinoma of the head and neck and ineligible for or refusing the 
EXTREME regimen are randomly assigned to either methotrexate or cetuximab added 
to methotrexate. In Chapter 6 I will first describe the results of a phase Ib study with 
the combination of cetuximab and methotrexate with feasibility as primary objective. 
Therafter,  I will describe the COMMENCE study, a randomised phase II, with  PFS as 
the primary endpoint. Because especially frail or older patients are not eligible for the 
EXTREME regimen, and are therefore candidates for the COMMENCE study, important 
secondary objectives include the incidence and severity of adverse events and HRQoL.
In Chapter 7, I will summarize the results of these studies and discuss future 
perspectives.
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Abstract
Background
Platinum-based chemoradiotherapy for locally advanced head and neck cancer (LAHNC) 
induces a high rate of acute toxicity, including dysphagia and aspiration pneumonia. 
We hypothesised that prophylactic antibiotics can prevent pneumonia and 
hospitalisations and can be cost-effective. 
Patient and Methods
In this multicentre randomised trial, patients with LAHNC treated with 
chemoradiotherapy received prophylactic amoxicillin/clavulanic acid from day 29 after 
the start of treatment until 14 days after completion of chemoradiotherapy or standard 
care without prophylaxis. The primary objective was to observe a reduction in 
pneumonias. Secondary objectives were to evaluate the hospitalisation rate, adverse 
events, costs and health-related quality of life. 
Results
One hundred six patients were included; of which, 95 were randomised: 48 patients 
were allocated to the standard group and 47 patients to the prophylaxis group. A 
pneumonia during chemoradiotherapy and follow-up until 3.5 months was observed 
in 22 (45.8%) of 48 patients in the standard group and in 22 (46.8%) of 47 patients in 
the prophylaxis group (p=0.54). Hospitalisation rate was significantly higher in the 
standard group versus the prophylaxis group, 19 of 48 pts (39.6%) versus 9 of 47 pts 
(19.1%), respectively (p=0.03). Significantly more episodes with fever of any grade were 
observed in the standard group (29.2% vs 10.2%, p=0.028). A significant difference in 
costs was found, with an average reduction of €1425 per patient in favour of the 
prophylaxis group.
Conclusion
Although prophylactic antibiotics during chemoradiotherapy for patients with LAHNC 
did not reduce the incidence of pneumonias, it did reduce hospitalisation rates and 
episodes with fever significantly and consequently tended to be cost-effective.
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Introduction
Head and neck cancer affects almost 600 000 patients at a global level yearly. A 
substantial part of the patients has locally advanced disease at diagnosis.  Concomitant 
platinum-based chemoradiotherapy is the treatment of choice for locally advanced 
head and neck carcinoma (LAHNC) and can be applied as primary or as postoperative 
treatment (1). However, chemoradiotherapy induces a high rate of acute toxicities such 
as mucositis and dysphagia. 
Dysphagia can lead to aspiration, which is defined as passage of material below the 
level of the vocal cords (2). Dysphagia and aspiration during and after chemoradiotherapy 
for head and neck cancer are usually underreported (3-5). In patients with LAHNC, the 
incidence of aspiration at diagnosis ranges from 9-53% (3, 6), and the aspiration rate 
during and after chemoradiotherapy is between 13-69% (5-7). Aspiration pneumonia, 
defined as pneumonia secondary to inhalation of food particles, saliva or other foreign 
substances (4), often leads to (prolonged) hospitalisation and is a major cause of 
morbidity and mortality (8). Xu et al. demonstrated a 5-year cumulative incidence of 
aspiration pneumonia in head and neck cancer patients of 23.8%, with a hospital 
admission rate of 84% and 47% requiring an admission to an intensive care . The 
mortality rate after aspiration pneumonia varies between studies from 17% to 32.5% 
(4, 9). Because of this high incidence of aspiration pneumonia in patients with LAHNC 
treated with chemoradiotherapy, we hypothesised that prophylactic antibiotics could 
lower the number of pneumonias and hospitalisations. To our knowledge, this is the 
first prospective study that investigates the effect of prophylactic antibiotics in patients 
with LAHNC treated with chemoradiotherapy. The primary aim of this multicentre 
randomised study was to investigate the efficacy of prophylactic antibiotics versus 
standard treatment to prevent aspiration pneumonia during chemoradiotherapy in 
patients with LAHNC. Secondary aims were to investigate the effect on the number of 
hospitalisations and cost-effectiveness and to evaluate the adverse events and health-
related quality of life (HRQoL).
Methods
Patients and study design
Patients with LAHNC who were treated with chemoradiotherapy, as primary or as 
postoperative treatment, were eligible. Participating patients were included and 
registered before the start of chemoradiotherapy. Exclusion criteria for registration 
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included an allergy to amoxicillin, the use of maintenance antibiotics or immuno-
deficiency. Patients were randomised between day 21 and 28 after the start of 
treatment if there were no additional exclusion criteria including pneumonia, other 
infections or use of antibiotic treatment within the last 2 weeks before randomisation. 
Patients were allocated equally to the two treatment groups by minimisation, which is 
a method of adaptive stratification allowing higher numbers of stratification factors, 
for smoking, Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) 0-2 or GOLD 3-4), weight loss (more than 10% versus 
less than 10%), primary site of the tumour (oral cavity, oropharyngeal or hypopharyngeal 
and laryngeal cancer), participating centre and human papillomavirus positivity (10).
The trial was approved by the Medical Ethical Research Committee, in accordance with 
the Declaration of Helsinki, and registered at clinicaltrials.gov (NCT01598402). All patients 
signed written informed consent.
Laboratory and adverse events, scored by the Common Terminology Criteria for 
Adverse Events version 4.0, were registered every week during chemoradiotherapy 
and one week, three weeks and 3.5 months after completing chemoradiotherapy. 
Sputum cultures were obtained on day 29 and at 1 week, 3 weeks and 3.5 months after 
chemoradiotherapy. HRQoL questionnaires, among which was the EuroQol-5D (EQ-5D), 
were collected at baseline, day 28 (one day before starting prophylactic antibiotics), 
the last day of radiotherapy and 3.5 months after the end of chemoradiotherapy. For 
the EQ-5D, utilities were calculated, resulting in a score between zero and one. A score 
of one means perfect health, whereas zero means death (11).
The primary end-point was to evaluate the number of definite or suspected 
pneumonias. A definite pneumonia was defined as an infiltrate on chest radiography 
or the presence of 3 or more of the following 4 features: sustained fever (temperature 
>38.0 °C), rales or rhonchi on chest auscultation, sputum Gram stain showing 
substantial leukocytes (i.e. more than 5 leucocytes per high-power field, x100) or 
sputum culture growing a respiratory pathogen. A suspected pneumonia was defined 
as 2 of the 4 features (12). 
Secondary end-points were the number and duration of hospitalisations, toxicity, 
HRQoL and adverse events, cost-effectiveness and all-cause mortality.
Prophylactic antibiotics
The prophylaxis group received amoxicillin/clavulanic acid, oral suspension 625 mg 
three times a day (tid), from day 29 after the start of chemoradiotherapy until 14 days 
after completion, in addition to standard care. The standard group received no 
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prophylactic antibiotics. In case of a (suspected) lower airway infection, blood and 
sputum cultures were taken and chest radiography was performed, mostly followed 
by hospitalisation and intravenous antibiotics. 
Chemoradiotherapy
Chemotherapy consisted of cisplatin, given at a dose of 100 mg/m2 every 3 weeks for 
3 cycles or 40-50 mg/m2 weekly for 6 or 7 cycles. Radiotherapy was given as per local 
practice with intensity-modulated radiation therapy and an accelerated (68Gy in 34 
fractions of 2Gy in 5.5 weeks) or conventional scheme (70Gy in 35 fractions of 2Gy in 
7 weeks) (13) (1). If a postoperative patient was not eligible for cisplatin, carboplatin 
was given weekly.
Statistical analysis
Under the assumption that the percentage of definite and/or suspected pneumonia 
in the standard group was 50% (6) and in the intervention group was 25% (a reduction 
of 50%(14)), 46 patients in each group were needed to have a power of 80% to detect 
a lower percentage in the prophylaxis group based on a one-sided binomial test at 5% 
significance level. A 15% adjustment for data attrition resulted in a sample size of 53 
patients in each group. No power analysis was performed for the secondary endpoints. 
Efficacy analysis was conducted in the intention-to-treat population, that is, all 
randomised patients. Non-parametric tests were performed using the one-sided Fisher 
exact test to test for significant decrease in pneumonias in the prophylaxis group, the 
chi-squared test for differences in hospitalisation and adverse events and Mann-
Whitney tests for differences in costs. For the analysis of the EQ-5D questionnaire, an 
independent t-test was used.
Economic evaluation
An economic evaluation was performed alongside the clinical trial and was based on 
the general principle of a cost-effectiveness analysis. On patient level, volumes of care 
were measured prospectively. Per group, full cost prices were determined using activity-
based costing. The Dutch guidelines for cost analyses were used (15). The effects were 
measured using the earlier described EQ-5D HRQoL questionnaire.
Only three groups of medication were analysed: analgetics, antiemetics and proton 
pump inhibitors. The costs of the prophylactic treatment in the prophylaxis group were 
determined for amoxicillin/clavulanic acid suspension used for 4 weeks, with a total 
price of €20.16 per patient.
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Results
Patient characteristics 
Between January 2012 and July 2015, a total of 106 patients were included in 6 centres. 
At randomisation, 95 patients were randomised; 48 patients were allocated to the 
standard group and 47 patients to the prophylaxis group. Eleven patients could not 
be randomised (Figure 1).
One patient in the prophylaxis group refused further participation after randomisation 
and was included into the intention-to-treat analysis for the primary objective as well 
as the cost-effectiveness, but no further information for secondary objectives was 
available for this patient. 
The standard group and the prophylaxis group were well-balanced in terms of baseline 
characteristics (Table 1). The median age of patients was 58.5 years in the standard 
group and 57.0 years in the prophylaxis group.
Treatment
Prophylactic antibiotics
In the prophylaxis group, 29 patients (61.7%) completed the amoxicillin/clavulanic acid 
prophylaxis as planned, that is, 625 mg tid from day 29 after the start of 
chemoradiotherapy until 14 days after completion. Reasons for early discontinuation 
in the other 18 patients were toxicity in 9 patients, mainly due to gastrointestinal 
complaints, refusal of antibiotics in 3 patients,  non-compliance to the prescribed 
schedule in 4 patients and switch to alternative antibiotic treatment due to 
hospitalisation or febrile neutropenia during the course of prophylaxis in 2 patients.
Chemoradiotherapy
The chemoradiotherapy was delivered as stated in Table 1. In 4 patients of each 
treatment group the chemotherapy was adapted because of toxicity according to the 
treating physician. One patient in the standard group had a delay in radiotherapy 
during treatment, and one patient stopped prematurely. In the prophylaxis group, only 
one patient needed a delay in radiotherapy while on treatment.
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Efficacy of prophylactic antibiotics
Pneumonia
No decrease was found in the incidence of (definite or suspected) pneumonia in the 
standard group compared with the prophylaxis group, 45.8% versus 46.8%, respectively 
(p=0.54). In the standard group, 8 patients developed a definite pneumonia compared 
with 4 patients in the prophylaxis group (Table 2). There was no difference in the use 
of proton pump inhibitors between the two groups (39.6% versus 34.0% in the standard 
group and prophylaxis group, respectively, p=0.576).
Patient selection. IC, informed consent.
Figure 1. CONSORT Flow Diagram.
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Table 1. Patient characteristics. TNM, Tumour-node-metastasis; CRT, chemoradiotherapy 
Patient characteristics Standard group
(N=48)
Prophylaxis group
(N=47)
Age, yr (range) 58.5 (43-68) 57.0 (23-68)
Sex, no. (%)
      Female 14 (29.2) 11 (23.4)
      Male 34 (70.8) 36 (76.6)
WHO (%)
      0 35 (72.9) 32 (68.1)
      1 11 (22.9) 11 (23.4)
      Unknown 2 (4.2) 4 (8.5)
Tumour site (%)
    Oral cavity 14 (29.2) 13 (27.7)
    Oropharynx 20 (41.7) 20 (42.6)
    Hypopharynx 5 (10.4) 11 (23.4)
    Larynx 8 (16.7) 3 (6.4)
   Unknown primary 1 (2.1) 0
TNM
T
    1 5 (10.4) 4 (8.5)
    2 9 (18.8) 10 (21.3)
    3 15 (31.3) 13 (27.7)
    4 18 (37.5) 19 (40.4)
    x 1 (2.1) 1 (2.1)
N
   0 15 (31.3) 12 (25.5)
   1 5 (10.4) 7 (14.9)
   2a 4 (8.3) 3 (6.4)
   2b 16 (33.3) 13 (27.7)
   2c 7 (14.6) 10 921.3)
   3 1 (2.1) 1 (2.1)
   x 0 1 (2.1)
M
   0 46 (95.8) 45 (95.7)
   x 2 (4.2) 2 (4.3)
Indication CRT (%)
    Primary treatment 26 (54.2) 34 (72.3)
    Postoperative treatment 22 (45.8) 13 (27.7)
Chemotherapy administered (%)
     Cisplatin 100 mg/m2 thrice weekly 10 (20.8) 12 (25.5)
     Cisplatin 40-50 mg/m2 weekly 32 (66.7) 30 (63.8)
     Carboplatin AUC 1.5 weekly 2 (4.2) 1 (2.1)
     Adapted chemotherapy 4 (8.3) 4 (8.4)
Radiotherapy administered (%)
     Conventional 22 (45.8) 21 (44.7)
     Accelerated 26 (54.2) 26 (55.3)
      Total dose given at primary tumour and pathological lymph 
nodes (median, range)
68.0 (60-70) 68.0 (60-70)
      Total dose given at elective neck levels (median, range) 50.3 (46-66) 50.3 (46-60)
Tube feeding at Randomisation (%)
      No 39 (81.3) 38 (80.9)
      Yes 9 (18.8) 9 (19.1)
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Hospitalisation
The hospitalisation rate was significantly different between both groups; in the standard 
group, 19 patients (39.6%) were hospitalised versus 9 (19.1%) in the prophylaxis group 
(p=0.03). The median duration of hospitalisation was 5.0 days in both groups (p=0.96) 
(Table 2). The main reasons for hospitalisations in both groups were related to the 
chemoradiotherapy and were frequently multifactorial determined by a combination 
of, for example, pneumonia, dehydration, fever, pain, mucositis or dyspnoea (Table 3).
Toxicity
A significant difference in episodes of fever (higher than 38.0 °C) was found between 
the standard group and the prophylaxis group (29.2% versus 10.9%, respectively, 
p=0.028), with no difference in the frequency of neutropenia. With respect to other 
adverse events, no significant differences were found between both groups (Table 4).
Table 2. Efficacy outcomes on definite and suspected pneumonias, number and duration of 
hospitalisation and costs. p <0.05: significantly different 
Efficacy outcomes Standard group
(N=48)
Prophylaxis group
(N=47)
p
Incidence of pneumonia 22 (45.8) 22 (46.8) 0.544
Type of pneumonia
        Definite (%) 8 (16.7) 4 (8.5) 0.232
        Suspected (%) 14 (29.2) 18 (38.3) 0.346
Hospitalised patients 19 (39.6) 9 (19.1) 0.030
Total days of hospitalisation 0.96
      Median (range) 5.0 (2-41) 5.0 (1-9)
Costs
Hospitalisation 0.032
     Mean per patient €2076.48 €682.17
     Whole group €99671.00 €32062.00
Pain medication 0.382
     Mean per patient €78.34 €46.13
     Whole group €3760.22 €2167.94
Anti-emetics 0.388
     Mean per patient €306.17 €288.15
     Whole group €14696.31 €13543.16
Proton pump inhibitors 0.597
     Mean per patient €0.81 €0.65
     Whole group €39.27 €30.58
Prophylactic antibiotics 0.00
     Mean per patient €0.00 €20.16
     Whole group €0.00 €947.52
Total costs 0.046
     Mean per patient €2461.80 €1037.26
     Whole group €118166.79 €48751.20
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Mortality
One patient, who was included but not randomised because of antibiotic use 14 days 
before randomisation, died during the 3.5-month of follow-up due to progressive 
disease. All other patients were alive at the end of follow-up.
Economic evaluation and quality of life
The difference in costs of hospitalisation plus the medication used was significant 
between the standard group and the prophylaxis group, in favour of the prophylaxis 
group (p=0.046), with a mean difference of €1425 per patient (Table 2). The EQ-5D 
HRQoL showed no significant differences. Because no differences were found between 
the two groups regarding the number of pneumonias and HRQoL measured by the 
EQ-5D, the cost-effectiveness decision rule became ‘cost-minimisation’, meaning that 
the treatment with the lowest costs is to be preferred. Following that rule, the 
prophylaxis group turned out to be cost-effective.
The full report on HRQoL of this study will be published separately. 
Sputum cultures 
During the entire study period, there was no significant difference in the number of 
patients with positive sputum cultures between the standard group and the prophylaxis 
group (29 patients [60.4%] in the standard group and 32 [68.1%] in the prophylaxis 
group, p=0.441). Before the start of prophylactic antibiotics (day 29), after the end of 
chemoradiotherapy and 3 weeks after the end of chemoradiotherapy, no significant 
Table 3. Reasons for hospitalisation in both treatment groups. In the standard group two patients 
had a combination of 2 reasons for hospitalisation, and in the prophylaxis group one patients had a 
combination of 2 reasons for hospitalisation. 
Reason for hospitalisation Standard group
(19/48 patients hospitalised)
Prophylaxis group 
(9/47 patients hospitalised)
Pneumonia 1 2
Fever 5 1
Candida mucositis 1
Nausea and vomiting 2
Dehydration 7 4
Pain 1
Dysphagia 1
Dyspnoea 2
Hypercalcemia 1
Fatigue 1
Other 2
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differences were found in the number of performed cultures, in the number of positive 
cultures for bacteria and/or fungi or in the number of cultures with resistant bacteria. 
At the end of follow-up, 3.5 months after the end of chemoradiotherapy, more positive 
cultures were found significantly in the prophylaxis group, although more resistant 
bacteria were cultured significantly in the standard group. However, only few sputum 
cultures were performed in both groups, probably because patients did not have any 
complaints anymore (Table 5).
Discussion
In this prospective randomised controlled trial investigating the role of antibiotic 
prophylaxis in patients with LAHNC treated with chemoradiotherapy, no decrease in 
the incidence of pneumonia in the group treated with prophylactic antibiotics versus 
standard care was found but there was a significant reduction in hospitalisation rate, 
episodes with fever and costs. 
Table 4. Reported adverse events by the local investigator. CTCAE, Common Terminology Criteria for 
Adverse Events 
Standard group (N=48) Prophylaxis group (N=46) p
CTCAE 4.0 Any grade Grade 3-4 Any grade Grade 3-4
Allergic reaction 1 (2.1) 0 (0) 1 (2.2) 0 (0)
Fatigue 40 (83.3) 1 (2.1) 31 (67.4) 1 (2.2)
Fever 14 (29.2) 1 (2.1) 5 (10.9) 0 (0) 0.028
Weight loss 41 (85.4) 1 (2.1) 36 (78.3) 3 (6.5)
Rash/desquamation 16 (33.3) 1 (2.1) 13 (28.3) 2 (4.3)
Dermatitis radiation 33 (68.8) 4 (8.3) 31 (67.4) 9 (19.6)
Anorexia 28 (58.3) 17 (35.4) 23 (50.0) 5 (10.9)
Constipation 22 (45.8) 0 (0) 19 (41.3) 0 (0)
Diarrhoea 11 (22.9) 2 (4.2) 9 (19.6) 0 (0)
Oral mucositis 41 (85.4) 20 (41.7) 33 (71.7) 15 (32.6)
Nausea 25 (52.1) 2 (4.2) 25 (54.3) 0 (0)
Vomiting 20 (41.7) 3 (6.3) 14 (30.4) 0 (0)
Dry mouth 33 (68.8) 0 (0) 32 (69.6) 0 (0)
Dysphagia 40 (83.3) 21 (43.8) 33 (71.7) 13 (28.3)
Foetor ex ore 2 (4.2) 0 (0) 2 (4.3) 0 (0)
Cough 15 (31.3) 0 (0) 13 (28.3) 0 (0)
Dyspnoea 8 (16.7) 0 (0) 3 (6.5) 1 (2.2)
Pneumonitis 1 (2.1) 0 (0) 1 (2.2) 1 (2.2)
Creatinine increased 35 (72.9) 2 (4.2) 30 (65.2) 0 (0)
Tumour pain 7 (14.6) 0 (0) 14 (30.4) 0 (0)
Pain head/neck 24 (50.0) 2 (4.2) 20 (43.5) 1 (2.2)
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A reduction in episodes of fever as well as a reduction in hospitalisations is important, 
first, not only for the patients who already undergo an intensive treatment but also 
for the oncology services as patients with LAHNC treated with chemoradiotherapy are 
referred relatively often to acute and emergency departments where these unplanned 
admissions are an extra burden. In this patient population, different attempts have 
been made in the past to reduce acute admissions, such as an intensive nurse-led 
intervention or the use of percutaneous endoscopic gastrostomies to prevent aspiration 
pneumonias (16, 17). To the best of our knowledge, the use of antibiotic prophylaxis 
has not been investigated before in a randomised way in this patient population, and 
the positive effect on the incidence of fever and hospitalisation is a novel and relevant 
result. Despite the fact that the difference in hospitalisation rate was not totally well 
understood, prophylactic antibiotics seem to improve general well-being with effect 
on multiple aspects, such as fever, mucositis, pain and dyspnoea.
There may be different reasons why the primary endpoint of the study, a significant 
reduction in the incidence of pneumonias, was not reached. First, the hypothesis that 
prophylactic antibiotics could lower the number of pneumonias in patients with 
LAHNC by 50% was possibly overestimated. This estimation was based on a Cochrane 
review on prophylactic antibiotics in adult Intensive Care Unit patients who showed 
a significant reduction of 50% in respiratory tract infections and mortality in adult 
patients, half of which received mechanical ventilation support. Second, in the 
prophylaxis group, only 61.7% completed the amoxicillin/clavulanic acid prophylaxis 
as planned, predominantly caused by poor compliance, which is partly due to this 
specific patient population. Whether this has influenced a lack of difference in 
incidence of pneumonias is unclear as it did not prevent the prophylaxis group from 
having a lower rate of episodes with fever. Third, non-significantly, more patients in 
the prophylaxis group received chemoradiotherapy as primary treatment, whereas, 
in the standard group, relatively more patients received chemoradiotherapy as 
postoperative treatment. However, in both groups, aspiration can occur. Finally, other 
risk factors,  such as alcoholic consumption, poor oral hygiene, and the use of sleeping 
pills, for aspiration pneumonia were not used as stratification factors and could have 
been confounders in this study (18).
There was a positive outcome for the secondary end-point cost. Antibiotic prophylaxis 
intervention was cost-effective, with an average cost-saving of €1425 per patient. For 
the Netherlands, with an estimation of 300 patients with LAHNC treated with 
chemoradiotherapy each year, this could lead to a reduction of about €425,000 per 
year. To prevent the emergence of bacterial resistance, prudent use of antibiotics, 
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particularly broad-spectrum agents such as amoxicillin/clavulanic acid, is warranted 
(19). Although we did not observe any increase in bacterial resistance due to the use 
of prophylactic antibiotics, we realise that the study included a low number of patients 
to look for this end-point. Although the number of positive sputum cultures 3.5 months 
after the end of chemoradiotherapy was significantly higher in the prophylaxis group, 
the absolute number of cultures was too low to draw any meaningful conclusions. In 
addition, the long-term (> 1 year) effects on resistance and related costs are unknown. 
In conclusion, this randomised study suggests that the use of prophylactic antibiotics 
by patients with LAHNC during chemoradiotherapy does not reduce the number of 
pneumonias but does reduce the number of patients with fever and hospitalisations 
and costs and can, therefore, be considered in this population.  
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Abstract
Objectives
The recent PANTAP trial showed that administration of prophylactic antibiotics in locally 
advanced head and neck carcinoma (LAHNC) patients treated with chemoradiotherapy 
reduced fever, hospitalization and costs. The current study describes the effect of 
prophylactic antibiotics on health-related quality of life (HRQoL), another secondary 
endpoint of the trial.
Materials and Methods
In this multicenter randomized trial, LAHNC patients treated with chemoradiotherapy 
received prophylactic antibiotics or standard care. HRQoL was assessed at baseline 
(before chemoradiotherapy), day 28 of chemoradiotherapy (one day before starting 
prophylactic antibiotics), the final day of radiotherapy, and 3.5 months after the end 
of chemoradiotherapy, using the European Organisation for Research and Treatment 
of Cancer (EORTC) QLQ-C30, EORTC H&N35 module, and the Performance Status Scale 
for Head & Neck cancer patients (PSS-HN).
Results
Ninety-five patients were randomized: 48 patients were allocated to the standard group 
and 47 patients to the prophylaxis group. Thirty-four patients in the standard group 
(70.8%) and 28 patients in the prophylaxis group (59.6%) completed the questionnaires 
at baseline and at follow-up. No significant differences in HRQoL were found at baseline 
and at day 28. At the end of radiotherapy, the prophylaxis group performed better on 
almost all functional subscales of the EORTC QLQ-C30 and reported less symptoms. 
At the end of follow up, almost no differences were seen between the two treatment 
groups.
Conclusion
Prophylactic antibiotics during chemoradiotherapy for LAHNC patients improved 
HRQoL at the end of the radiotherapy, however no differences were found 3.5 months 
after the end of chemoradiotherapy.  
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Introduction
Head and neck cancer is the sixth most common type of cancer with an annual 
incidence of 686,328 new cases worldwide (1, 2). Locally advanced head and neck 
cancer (LAHNC) itself, as well as the side effects of treatment, can negatively influence 
health-related quality of life (HRQoL). Social and emotional interactions are important 
aspects of an individual’s HRQoL and largely depend on structural and functional 
capacity of organs in the head and neck region that are affected by the tumour and its 
treatment (3). Rettig et al. showed that HRQoL begins to decline in the 2-5 years before 
a diagnosis of LAHNC with a steep reduction in the 24 months before diagnosis (4). At 
presentation, disease-related symptoms may comprise of hoarseness, pain, otalgia, 
dysphagia, cough and stridor (5), which likely to account for decreased HRQoL prior to 
diagnosis.
The treatment for LAHNC often consists of concomitant platinum-based chemo-
radiotherapy. However, this treatment is associated with a high rate of acute toxicities. 
Radiotherapy causes mucositis, dermatitis, dysphagia, anorexia and pain (6,7), whereas 
chemotherapy may cause nausea, neutropenia and thrombocytopenia and worsen 
radiotherapy-related toxicities, in particular mucositis and dysphagia (6). In a previous 
study, the incidence of grade 3 or 4 acute toxicities among LAHNC patients treated 
with radiotherapy alone was 47%, while this was 77% among patients treated with 
concomitant chemoradiotherapy (6). Due to these acute adverse events, there is a 
significant deterioration of HRQoL during treatment(8), that may be worse for patients 
treated with chemoradiotherapy compared to those treated with radiotherapy alone 
(9). Immediately (4-6 weeks) after radiotherapy HRQoL declines even further (10, 11), 
however gradual improvement is during the following period (4, 9-12). In general, most 
HRQoL domains recover to baseline levels around 12 months after treatment (9, 13). 
Dysphagia and aspiration during- and after chemoradiotherapy for head and neck 
cancer are usually underreported (14-16). In LAHNC patients, the incidence of aspiration 
at diagnosis ranges from 9-53% (14, 17), and the aspiration rate during and after 
chemoradiotherapy is between 13-69% (16-18). As a consequence, aspiration 
pneumonia during chemoradiotherapy is a relatively frequent complication (46%) (19). 
In the recently conducted PANTAP-trial, prophylactic antibiotics during 
chemoradiotherapy in LAHNC did not result in a reduction in the number of patients 
with a pneumonia (45.8% of the patients in the standard group versus 46.8% of the 
patients in the prophylaxis group), however prophylactic antibiotics led to a significant 
reduction in the rate of hospitalization, episodes of fever and costs per patient (19, 20). 
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It could be hypothesized that prophylactic antibiotics have a protective effect on HRQoL 
as they may reduce acute toxicities such as mucositis and pain, which were previously 
shown to have a negative impact on HRQoL (21). One of the secondary objectives of 
the PANTAP trial, and the aim of the current study, was to assess the effects of 
prophylactic antibiotics during chemoradiotherapy on the HRQoL among LAHNC 
patients compared with those who did not receive prophylactic antibiotics. We 
hypothesized that the group receiving prophylactic antibiotics would report a better 
HRQoL at the end of radiotherapy due to the positive effects of prophylactic antibiotics. 
In addition, our study aims to describe HRQoL changes during treatment in both 
treatment groups. 
Methods
Patients and study design
The PANTAP-study was a randomized, multicenter phase II study for patients with 
LAHNC who were treated with chemoradiotherapy, either as primary treatment or 
postoperative treatment. Chemotherapy consisted of cisplatin, given at a dose of 100 
mg/m2 every 3 weeks for 3 cycles, or 40-50 mg/m2 given every week for 6 or 7 cycles. 
Radiotherapy was given with intensity-modulated radiation therapy and an accelerated 
(68Gy in 34 fractions of 2Gy over 5.5 weeks) or conventional scheme (70Gy in 35 
fractions of 2Gy over 7 weeks) (6, 7). Patients were enrolled before start of the 
chemoradiotherapy. Exclusion criteria for registration included an allergy to amoxicillin, 
the use of maintenance antibiotics or immunodeficiency. Patients were randomized 
after 21-28 days of chemoradiotherapy, unless  complications such as pneumonia, 
other infections or antibiotic treatment had occurred within the 14 days preceding 
randomization. Patients were randomized to receive either standard care alone, (the 
standard group), or to receive prophylactic oral amoxicillin/clavulanic acid 625 mg three 
times daily from day 29 until 14 days after the end of chemoradiotherapy in addition 
to standard care (the prophylaxis group). Patients were allocated equally to the two 
treatment groups by minimization, which is a method of adaptive stratification allowing 
a higher numbers of stratification factors: smoking, Chronic Obstructive Pulmonary 
Disease (Gold 0-2 or Gold 3-4), weight loss (more than 10% versus less than 10%), 
primary site of the tumour (oral cavity, oropharyngeal, or hypopharyngeal and laryngeal 
cancer), participating centre, and human papillomavirus positivity (22).
The primary endpoint was to evaluate the number of patients who developed 
pneumonia. Secondary endpoints were to determine the number and duration of 
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hospital admissions, to assess toxicity and adverse events including side effects of 
amoxicillin/clavulanic acid, to evaluate cost-effectiveness, and to explore HRQoL. 
The study protocol was approved by the local ethical committee and registered at 
clinicaltrials.gov (NCT01598402).
Assessments
HRQoL was assessed at baseline, day 28 of chemoradiotherapy (one day before starting 
prophylactic antibiotics), on the final day of radiotherapy, and 3.5 months after the 
end of chemoradiotherapy. Questionnaires included the 30-item core European 
Organization for the Research and Treatment of Cancer Quality-of-Life Questionnaire 
(EORTC QLQ-C30) (23), the EORTC QLQ Head and Neck Cancer-Specific Module (EORTC 
H&N35) (23), and the Performance Status Scale for Head & Neck cancer patients (PSS-
HN)(24).  
The EORTC QLQ-C30 is a 30-item questionnaire that assesses HRQoL in cancer patients 
across five functioning scales (physical functioning, role functioning, emotional 
functioning, cognitive functioning, social functioning), three multi-item symptom scales 
(fatigue, pain, nausea and vomiting), six single-item symptom scales (dyspnoea, 
insomnia, appetite loss, constipation, diarrhoea, and financial problems) and global 
QoL (23). Patients provide their answers on a 4-point scale (from 1 [not at all] to 4 [very 
much]), except for global QoL, which has a 7-point scale (from 1 [very poor] to 7 
[excellent]). By linear transformation the raw scores are standardized, so that overall 
scores range from 0 to 100. A higher score on the functioning scales and on global QoL 
represent a better level of quality of life and functioning, and a higher score on the 
symptom scales means a worse level of symptoms (25). According to EORTC Quality 
of Life Group guidelines, clinically important differences between the two treatment 
groups were divided into four classes based on size: large (representing unequivocal 
clinical relevance), medium (likely to be clinically relevant, but to a lesser extent), small 
(subtle but, nevertheless, clinically relevant) and trivial (circumstances unlikely to have 
any clinical relevance, or where there was no difference). For each subscale criteria to 
fit each of the four classes were composed (26). Within each treatment group clinical 
relevant differences over time were defined as a difference of at least 10 points (27). 
The EORTC H&N35, a disease-specific HRQoL questionnaire, comprises 35 questions 
assessing symptoms and side effects of treatment, social function and body image/
sexuality, and incorporates seven multi-item scales (pain, swallowing, senses (taste 
and smell), speech, social eating, social contact, sexuality), and 11 single item scales 
(teeth, opening mouth, dry mouth, sticky saliva, coughing, felt ill, pain killers, nutritional 
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supplements, feeding tube, weight loss, weight gain). After linear transformation, all 
symptom scales range in score from 0-100, where a higher score means more 
complaints (23). A difference of at least 10 points between the two treatment groups, 
as well as within the groups, was considered to be a clinically significant difference (27). 
The PSS-HN was designed to measure unique disabilities of head and neck cancer 
patients. Surgery and/or systemic therapies in head and neck cancer patients often 
introduce cosmetic and functional deficits leading to problems with speech and 
eating(28). The PSS-HN was developed as a simple and practical assessment and 
consists of three subscales: ‘normalcy of  diet’, ‘understandability of speech’, and ‘eating 
in public’. Each is rated from 0 to 100, with higher scores indicating better performance, 
and 100 representing normal function (24). The ‘normalcy of diet’ subscale assesses 
the extent to which the patient is able to eat a regular diet. The ‘understandability of 
speech’ subscale rates the degree to which a listener is able to understand the patient’s 
speech. The ‘eating in public’ subscale scores swallowing-related QoL issues by 
documenting the patient’s ability to share a meal with others, and in which type of 
environment. The PSS-HN has been shown to have adequate inter-rater reliability and 
to be sensitive to differences in performance and change over time(24). There are no 
studies performed to determine clinically relevant differences on the three subscales, 
as with the QLQ-C30 and QLQ-H&N35, however, a score of 50 or less on the different 
scales seems to correlate with a lower Karnofsky performance scale (24).  Norman’s 
rule of thumb was used for the PSS-HN, whereby a ±0.5 standard deviation difference 
(i.e. 12.8 points) indicated a clinically relevant difference (29,30). 
Statistics
Differences between the groups were calculated at every time point. Independent 
t-tests were performed to find any statistical significant differences between the two 
treatment groups for each symptom or functioning scale. For HRQoL during treatment 
compared with baseline (both groups) no statistical tests were performed and therefore 
results are descriptive. As described above, for all the separate questionnaires, we 
have not only reported statistical significant differences, but also (minimal) clinically 
important differences, because statistical significance does not provide information 
about clinical meaningfulness i.e. whether the observed effect is larger than the 
smallest clinically important effect (31,32).
The change in HRQoL and symptom burden (separate models for each scale) by 
treatment group was analyzed using linear mixed-effects models (i.e. covariance 
pattern model with an unstructured error variance matrix and maximum likelihood 
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estimation) (33). This technique uses data efficiently by including incomplete cases in 
the analysis. As a result, bias is limited and statistical power is preserved. Time was 
analyzed as a regular categorical predictor with four levels (i.e. four time points). The 
interaction of treatment group and time was tested separately. Analyses were 
performed in IBM SPSS 22.0 with a significance level of α=0.05.
Results
Patients
A total of 106 patients were included from six centres between January 2012 and July 
2015. At randomization, 48 patients were allocated to standard group and 47 patients 
to the prophylaxis group. Nine included patients could not be randomized (e.g. due to 
the use of antibiotics 14 days prior to randomization). Both groups were well balanced 
with respect to baseline clinical and sociodemographic characteristics (Table 1).
Table 1. Patient characteristics at baseline (no statistically significant differences between the study 
groups).
All patients Patients with complete 
HRQoL questionnaires
Standard
group (N=48)
Prophylaxis 
group (N=47)
Standard 
group (N=34)
Prophylaxis 
group (N=28)
Age- yr (range) 58.5 (43-68) 57.0 (23-68) 58.5 (48-68) 58.1 (29-68)
Sex – no. (%)
      Female 14 (29.2) 11 (23.4) 10 (29.4) 7 (25.0)
      Male 34 (70.8) 36 (76.6) 24 (70.6) 21 (75.0)
WHO– no. (%)
      0 35 (72.9) 32 (68.1) 26 (76.5) 19 (67.9)
      1 11 (22.9) 11 (23.4) 7 (20.6) 7 (25.0)
      Unknown 2 (4.2) 4 (8.5) 1 (2.9) 2 (7.1)
Tumor site– no. (%)
    Oral cavity 14 (29.2) 13 (27.7) 9 (26.5) 6 (21.4)
    Oropharynx 20 (41.7) 20 (42.6) 14 (41.2) 14 (50.0)
    Hypopharynx 5 (10.4) 11 (23.4) 4 (11.8) 7 (25.0)
    Larynx 8 (16.7) 3 (6.4) 7 (20.6) 1 (3.6)
   Unknown primary 1 (2.1) 0 0 0
Indication CRT– no. (%)
   Primary treatment 26 (54.2) 34 (72.3) 19 (55.9) 20 (71.4)
   Postoperative treatment 22 (45.8) 13 (27.7) 15 (44.1) 8 (28.6)
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HRQoL completion rate and baseline scores
Only patients who completed the questionnaires at baseline as well as at follow up 
were included in analyses (complete case analysis). Therefore, a total of 34 patients in 
the standard group (70.8%) and 28 patients in the prophylaxis group (59.6%) were 
included in final analyses. At baseline 34 patients in the standard group and 28 patients 
in the prophylaxis group completed the questionnaires, before the start of prophylactic 
antibiotics (at day 28) 34 and 26 patients respectively, at the end of radiotherapy 25 
and 19 patients and at the end of follow up 34 and 28 patients respectively. However, 
this could be different patients who completed the questionnaires at any time point. 
At baseline, we found small clinically relevant differences between the two treatment 
arms  in some of the EORTC QLQ-C30 scales. However, none of these were statistically 
significant. 
Three items on the EORTC-HN35 were clinically relevant different with a difference of 
more than 10 points. The prophylaxis group scored higher on ‘swallowing’ (28.7 vs. 
16.3) and ‘social eating’ (24.2 vs. 13.1) than the standard group and lower on ‘painkillers’ 
(37.0 vs. 48.5) than the standard group.  However, only the differences on ‘swallowing’ 
(p=0.024) and ‘social eating’ (p=0.027) were statistically significant in favour of the 
standard group (Table 2). 
The scores on the EORTC QLQ-C30 were comparable with EORTC reference data from 
patients with stage III or IV head and neck cancer (34).
HRQoL between treatment groups during treatment
At day 28 of chemotherapy, before the start of prophylactic antibiotics, there was no 
statistically significant difference between the standard and prophylaxis group (Table 3).
After radiotherapy, at which point the prophylaxis group were still taking antibiotics 
and acute toxicities of treatment are generally the highest, the prophylaxis group 
reported fewer symptoms on almost all subscales of the QLQ-C30, QLQ-H&N35 and 
PS-HN, though  almost no items were significantly different to the 0.05 level (Table 3). 
‘Cognitive functioning’ and ‘social functioning’ from the EORTC QLQ-C30 and ‘social 
contact’ from the QLQ-H&N35 were significantly different in favour of the prophylaxis 
group (Figure 1). 
At 3.5 months after the end of chemoradiotherapy, the standard group scored lower 
on ‘social eating’ (17.6 vs. 34.3, p=0.017) and ‘teeth’ (10.1 vs. 26.9, p=0.019) to a strong 
clinically relevant level compared to the prophylaxis group in favour of the standard 
group (Table 3).
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Table 2: Baseline scores in HRQoL measured by the EORTC QLQ-C30 and QLQ-H&N35. 
Baseline
EORTC
stage III-IV 
(mean)₣ 
Standard 
group
(N=34)
Prophylaxis 
group
(N=28)
∆ p
PSS-HN
Normalcy of diet (N) NA 77.5 (32) 68.8 (25) -8.7 .253
Eating in public (N) NA 93.8 (32) 84.0 (25) -9.8 .126
Understandability of speech(N) NA 89.8 (32) 90.0 (25) 0.2 .977
QLQ-C30
Physical functioning (N) 81.2 89.4 (34) 89.0 (28) -0.4 .895
Role functioning (N) 78.8 74,0 (34) 79.8 (28) 5.8 .413
Emotional functioning(N) 71.2 77.7 (34) 82.1 (28) 4.4 .382
Cognitive functioning(N) 86.4 89.7 (34) 94.0 (28) 4.3* .267
Social functioning(N) 82.2 79.4 (34) 88.7 (28) 9.3* .104
Global health status(N) 63.1 72.2 (33) 72.0 (28) -0.2 .968
Fatigue(N) 27.6 16.7 (34) 21.0 (28) 4.3 .415
Nausea/vomiting(N) 5.2 0.5 (33) 5.4 (28) 4.9* .075
Pain(N) 24.9 18.1 (34) 18.5 (28) 0.4 .962
Dyspnoea(N) 18.0 8.8 (34) 6.0 (28) -2.8 .548
Insomnia(N) 28.5 27.5 (34) 23.8 (28) -3.7 .629
Appetite loss(N) 19.4 10.8 (34) 19.0 (28) 8.2 .230
Constipation(N) 11.7 12.7 (34) 10.7 (28) -2 .719
Diarrhea(N) 6.1 1.0 (34) 6.0 (28) 5* .068
Financial problems(N) 18.8 18.6 (34) 11.9 (28) -6.7* .289
QLQ-H&N35a
Pain(N) NA 18.8 (34) 25.3 (27) 6.5 .203
Swallowing(N) NA 16.3 (34) 28.7 (27) 12.4† .024‡
Senses problems(N) NA 16.2 (34) 7.4 (27) -8.8 .090
Speech problems(N) NA 16.5 (33) 14.0 (27) -2.5 .643
Social eating(N) NA 13.1 (33) 24.4 (26) 11.3† .027‡
Social contact (N) NA 4.0 (33) 7.7 (27) 3.7 .302
Sexuality(N) NA 20.6 (30) 13.8 (23) -6.8 .428
Teeth(N) NA 13.7 (34) 14.7 (25) 1 .891
Opening mouth(N) NA 26.5 (34) 24.4 (26) -2.1 .800
Dry mouth(N) NA 17.6 (34) 18.5 (27) 0.9 .886
Sticky saliva(N) NA 21.6 (34) 20.5 (26) -1.1 .887
Coughing(N) NA 24.5 (34) 22.2 (27) -2.3 .704
Felt ill(N) NA 6.9 (33) 6.2 (26) -0.7 .890
Pain killers(N) NA 48.5 (33) 37.0 (27) -11.5† .110
Nutritional supplements(N) NA 27.3 (33) 37.0 (27) 9.7 .427
Feeding tube(N) NA 9.1 (33) 7.7 (26) -1.4 .851
(N) after each subscales means the number of available questionnaires. *= small clinically important difference; 
†=clinically relevant difference of more than 10 points; ‡= statistically significant. ₣: EORTC reference data  from 
patients with stage III or IV head and neck cancer (34). NA = not available
aWeight gain and weight loss not reported due to difficult interpretation
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Table 3. Scores in HRQoL at four time points during the study measured by the EORTC QLQ-C30 and 
QLQ-H&N35.
Baseline Day 28
Standard 
group
(N=34)
Prophylaxis 
group
(N=28)
∆ p Standard 
group
(N=34)
Prophylaxis 
group
(N=28)
∆
PSS-HN
Normalcy of diet (N) 77.5 (32) 68.8 (25) -8.7 .253 45.5 (31) 37.6 (25) -7.9
Eating in public (N) 93.8 (32) 84.0 (25) -9.8 .126 67.5 (30) 56.8 (22) -10.7
Understandability of 
speech(N)
89.8 (32) 90.0 (25) 0.2 .977 79.8 (31) 80.0 (25) 0.2
QLQ-C30
Physical functioning (N) 89.4 (34) 89.0 (28) -0.4 .895 82.0 (34) 84.2 (26) 2.2
Role functioning (N) 74.0 (34) 79.8 (28) 5.8 .413 62.3 (34) 64.7 (26) 2.4
Emotional functioning(N) 77.7 (34) 82.1 (28) 4.4 .382 81.4 (34) 78.2 (26) -3.2
Cognitive functioning(N) 89.7 (34) 94.0 (28) 4.3* .267 81.9 (34) 86.5 (26) 4.6*
Social functioning(N) 79.4 (34) 88.7 (28) 9.3* .104 73.0 (34) 75.6 (26) 2.6
Global QoL(N) 72.2 (33) 72.0 (28) -0.2 .968 57.4 (34) 59.6 (26) 2.2
Fatigue(N) 16.7 (34) 21.0 (28) 4.3 .415 41.5 (34) 41.9 (26) 0.4
Nausea/vomiting(N) 0.5 (33) 5.4 (28) 4.9* .075 27.0 (34) 15.4 (26) -11.6¥
Pain(N) 18.1 (34) 18.5 (28) 0.4 .962 28.9 (34) 34.0 (26) 5.1
Dyspnoea(N) 8.8 (34) 6.0 (28) -2.8 .548 7.8 (34) 11.5 (26) 3.7
Insomnia(N) 27.5 (34) 23.8 (28) -3.7 .629 22.2 (33) 18.7 (25) -3.5
Appetite loss(N) 10.8 (34) 19.0 (28) 8.2 .230 49.0 (34) 50.7 (25) 1.7
Constipation(N) 12.7 (34) 10.7 (28) -2 .719 22.5 (34) 23.1 (26) 0.6
Diarrhea(N) 1.0 (34) 6.0 (28) 5* .068 9.8 (34) 7.7 (26) -2.1
Financial problems(N) 18.6 (34) 11.9 (28) -6.7* .289 15.7 (34) 12.8 (26) -2.9
QLQ-H&N35a
Pain(N) 18.8 (34) 25.3 (27) 6.5 .203 39.2 (34) 44.3 (25) 5.1
Swallowing(N) 16.3 (34) 28.7 (27) 12.4† .024‡ 45.9 (34)  46.7 (25) 0.8
Senses problems(N) 16.2 (34) 7.4 (27) -8.8 .090 51.0 (34) 40.7 (25) -10.3†
Speech problems(N) 16.5 (33) 14.0 (27) -2.5 .643 25.7 (34)  28.4 (26) 2.7
Social eating(N) 13.1 (33) 24.4 (26) 11.3† .027‡ 35.9 (34) 39.4 (26) 3.5
Social contact (N) 4.0 (33) 7.7 (27) 3.7 .302 12.7 (34) 9.6 (26) -3.1
Sexuality(N) 20.6 (30) 13.8 (23) -6.8 .428 38.0 (32) 41.7 (22) 3.7
Teeth(N) 13.7 (34) 14.7 (25) 1 .891 13.7 (34)  14.5 (23) 0.8
Opening mouth(N) 26.5 (34) 24.4 (26) -2.1 .800 37.3 (34) 34.7 (25) -2.6
Dry mouth(N) 17.6 (34) 18.5 (27) 0.9 .886 52.0 (34) 50.7 (25) -1.3
Sticky saliva(N) 21.6 (34) 20.5 (26) -1.1 .887 58.8 (34) 68.0 (25) 9.2
Coughing(N) 24.5 (34) 22.2 (27) -2.3 .704 35.3 (34) 38.7 (25) 3.4
Felt ill(N) 6.9 (33) 6.2 (26) -0.7 .890 32.4 (34) 25.3 (26) -7.1
Pain killers(N) 48.5 (33) 37.0 (27) -11.5† .110 76.5 (34) 88.5 (26) 12
Nutritional 
supplements(N)
27.3 (33) 37.0 (27) 9.7 .427 72.7 (33) 76.0 (25) 3.3
Feeding tube(N) 9.1 (33) 7.7 (26) -1.4 .851 23.5 (34) 38.5 (26) 15†
(N) after each subscales means the number of available questionnaires. At baseline, 34 questionnaires in the 
standard group (70.8%) and 28 in the prophylaxis group (59.6%) could be analysed, at day 28, 70.8% and 55.3%, 
at the end of radiotherapy 52.1% and 40.4% and at follow up 70.8% and 69.6% in the standard group and 
prophylaxis group, respectively.
*= small clinical important difference; ¥ = medium clinical important difference;  ₣ = large clinical important 
difference; †=clinical relevant difference of more than 10 points; ‡= statistically significant (p<0.05); #clinical 
relevant difference of more than 12.8 points
aWeight gain and weight loss not reported due to difficult interpretation
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After RT FU
p Standard 
group
(N=34)
Prophylaxis 
group
(N=28)
∆ p Standard 
group
(N=34)
Prophylaxis 
group
(N=28)
∆ p
.294 39.2 (24) 28.9 (18) -10.3 .210 72.0 (32) 56.9 (26) -15.1# 0.090
.274 69.6 (23) 68.8 (16) -0.8 .946 87.5 (32) 72.9 (24) -14.6# .094
.981 71.9 (24) 84.7 (18) 12.8# .175 91.9 (31) 90.0 (25) -1.9 .607
.539 76.0 (25) 83.2 (19) 7.2* .167 87.1 (34) 84.6 (28) -2.5 .473
.708 55.3 (25) 68.4 (19) 13.1* .127 73.5 (34) 73.8 (28) 0.3 .965
.536 78.7 (25) 83.8 (19) 5.1 .335 85.9 (33) 81.3 (28) -4.6 .304
.382 77.3 (25) 89.5 (19) 12.2¥ .047‡ 88.4 (33) 91.7 (28) 3.3* .389
.693 66.7 (25) 86.0 (19) 19.3₣ .023‡ 84.3 (33) 83.3 (28) -1 .851
.679 50.3 (25) 59.6 (19) 9.3* .194 71.7 (33) 64.9 (28) -6.8* .179
.950 46.7 (25) 38.6 (19) -8.1* .267 28.9 (34) 27.0 (28) -1.9 .736
.091 29.3 (25) 27.2 (19) -2.1 .808 6.9 (34) 5.4 (28) -1.5 .659
.440 35.3 (25) 37.7 (19) 2.4 .782 17.6 (34) 18.5 (28) 0.9 .897
.390 8.0 (25) 8.8 (19) 0.8 .864 7.8 (34) 11.9 (28) 4.1* .384
.642 22.7 (25) 15.8 (19) -6.9* .443 16.7 (34) 28.4 (27) 11.7* .158
.854 53.3 (25) 42.1 (19) -11.2 .284 22.5 (34) 33.3 (28) 10.8 .176
.927 29.3 (25) 29.8 (19) 0.5 .955 6.9 (34) 9.5 (28) 2.6 .583
.618 10.7 (25) 15.8 (19) 5.1* .390 1.0 (33) 4.8 (28) 3.8* .136
.614 20.0 (25) 12.3 (19) -7.7* .343 17.2 (33) 21.4 (28) 4.2* .552
.418 46.2(24) 41.2 (18) -5 .501 26.5 (34) 28.7 (27) 2.2 .704
.907 53.8 (24) 47.2 (18) -6.6 .396 22.7 (34) 29.9 (27) 7.2 .263
.159 46.5 (24) 40.7 (18) -5.8 .468 28.4 (34) 30.9 (27) 2.5 .729
.690 42.4 (25) 26.9 (19) -15.5† .051 14.4 (34) 19.0 (28) 4.6 .354
.487 41.9 (25) 38.7 (19) -3.2 .643 17.6 (34) 34.3 (27) 16.7† .017‡
.479 22.1 (25) 9.4 (19) -12.7† .041‡ 6.3 (34) 8.8 (28) 2.5 .446
.711 43.5 (23) 42.2 (17) -1.3 .908 29.6 (31) 27.8 (24) -1.8 .845
.888 26.4 (24) 21.6 (17) -4.8 .616 10.1 (33) 26.9 (26) 16.8† .019‡
.764 47.2 (24) 35.2 (18) -12 .165 30.4 (34) 34.6 (27) 4.2 .583
.881 52.8 (24) 48.1 (18) -4.7 .643 54.9 (34) 56.8 (27) 1.9 .835
.255 66.7 (24) 70.4 (19) 3.7 .682 45.1 (34) 43.2 (27) -1.9 .789
.627 29.2 (24) 29.6 (18) 0.4 .951 24.5 (34) 29.6 (27) 5.1 .431
.329 41.7 (25) 24.1 (19) -17.6† .054 12.7 (34) 14.8 (28) 2.1 .740
.224 76.0 (25) 84.2 (19) 8.2 .515 29.4 (34) 28.6 (28) -0.8 .943
.783 72.0 (25) 57.9 (19) -14.1† .340 41.2 (34) 46.4 (28) 5.2 .684
.227 36.0 (25) 50.0 (18) 14† .371 26.5 (34) 32.1 (28) 5.6 .632
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On the bottom three symptom subscales, showing an increase in symptoms during radiotherapy, with improvement of 
symptoms at follow up, except for some specific subscales like dry mouth. The prophylaxis group felt less ill during 
chemoradiotherapy.
Figure 1. On the top three functional items of the QLQ-C30 showing a decrease during 
chemoradiotherapy, and an increase at follow up, whereas the prophylaxis group in general had a 
less steeper decline after radiotherapy compared with the standard group.
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HRQoL during treatment compared with baseline in both groups
The standard group had a lower score to a clinically relevant level on all functional 
subscales of the EORTC-QLQ-C30, except for ‘emotional functioning,’ at the end of 
radiotherapy compared to baseline, while the prophylaxis group had a lower score to 
a clinically relevant level only on ‘role functioning’ and ‘global QoL’ (Fig. 1). Scores on 
all functional subscales returned to baseline values at 3.5 months follow up for both 
treatment groups. In both groups, patients experiences a clinically relevant increase 
in symptoms after chemoradiotherapy compared to baseline that persisted until 3.5 
months follow up on  the items ‘senses problems’, dry mouth’, ‘sticky saliva’, and 
‘feeding tube’ (Table 3). On the other symptom subscales of the EORTC QLQ-C30 and 
QLQ-H&N35, there was a clinically meaningful increase in scores during 
chemoradiotherapy measured at day 28 and at the end of radiotherapy compared 
with baseline, which recovered to baseline levels at 3.5 months follow up for both 
groups (Table 3). 
Course of HRQoL
At a group level, the EORTC QLQ-C30 functioning scales ‘physical functioning’, ‘role 
functioning’, and ‘global QoL’ significantly decreased between baseline and the end of 
chemoradiotherapy, indicating problems increased by the end of chemoradiotherapy. 
These changes were similar in both treatment groups (Table 4).  Patients scored 
statistically significantly higher on  ‘fatigue’, ‘pain’, ‘constipation’, and ‘diarrhea’ of the 
EORTC QLQ-C30 at the end of radiotherapy compared to baseline and 3.5 months 
follow-up, with no difference between the two treatment groups. Patients also scored 
significantly higher on ‘Nausea and vomiting’ at the end of radiotherapy compared with 
all other timepoints. The symptoms of the EORTC QLQ-H&N35 ‘pain’, ‘swallowing’, ‘sticky 
saliva’, changed significantly between the end of radiotherapy and baseline and end 
of radiotherapy and end of follow-up, with significantly higher scores at the end of 
radiotherapy. The symptoms ‘senses problems’, ‘speech problems’, ‘social eating’, 
‘sexuality’, ‘dry mouth’, ‘coughing’, ‘felt ill’ and the need of ‘a feeding tube’ scores all 
significantly higher at the end of radiotherapy compared with baseline. On the ‘cognitive 
functioning’ and ‘social functioning’ scales of the EORTC QLQ-C30 and the ‘social contact’ 
and ‘feeling ill’ symptom scales of the EORTC QLQ-H&N35 the standard group 
experienced significantly more problems over time compared to the prophylaxis group 
(Table 4).
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Discussion
HRQoL was an important secondary objective of the PANTAP-study, which showed that 
prophylactic administration of amoxicillin/clavulanic acid reduced the number of 
hospital admissions, episodes of fever and healthcare costs without lowering the 
incidence of pneumonias. This study showed that prophylactic antibiotics also seemed 
to improve most aspects of HRQoL at the end of radiotherapy compared to standard 
care alone, although not all subscales were statistically significantly different.
At baseline some small clinically relevant differences were found between the two 
treatment groups, though most disappeared before the start of the prophylactic 
antibiotics at day 28. However, at the end of radiotherapy, when patients in the 
prophylaxis group were still taking the prophylactic antibiotics, the prophylaxis group 
reported a better HRQoL on most items compared to the standard group. At the end 
of follow up, 3.5 months after the end of chemoradiotherapy, few differences still existed 
between the two treatment groups. This suggests the advantage of the prophylaxis, 
with respect to the HRQoL, is experienced between the start of the antibiotics and the 
end of radiotherapy, as seen in the decreased decline in functional subscales. During 
the study, HRQoL deteriorated from baseline to day 28 and the end of radiotherapy; 
patients experienced a significantly higher symptom burden at the end of radiotherapy 
compared to baseline on 10 of the 18 symptoms covered by the EORTC QLQ-H&N35 
reflects the high level of toxicity at the end of chemoradiotherapy. This confirms findings 
in the literature that show a decline in HRQoL during and at the end of (chemo)
radiotherapy (9,11).  This deterioration can be explained by treatment toxicities. 
Interestingly, we observed no difference in reported levels of diarrhoea in the 
prophylaxis group compared to the standard group. This is surprising given the 
relatively long use of antibiotics in the prophylaxis group. 
At follow-up, 3.5 months after the end of chemoradiotherapy, most subscales returned 
to baseline-values or better, which  has been previously described in other studies 
(4,9,12). Only the ‘senses problems’, ‘dry mouth’, and ‘sticky saliva’ symptom scales saw 
no improvement at follow up. This is also agrees with previous studies by Vergeer et 
al. and Jellema et al. that showed dry mouth, sticky saliva and diminished taste can be 
long lasting or even permanent (10,35), due to permanent damage to the salivary 
glands caused by the radiotherapy. The fact that patients in the prophylaxis group 
scored significantly higher on the subscales ‘social eating’ and ‘teeth’ at follow-up, 
cannot be explained by the use of prophylactic antibiotics. This may be due to statistical 
issues related to the small number of completed questionnaires.
50
C h a p t e r  3
Slightly more patients included in the prophylaxis group had hypopharyngeal cancer, 
although not statistically different. Hypopharyngeal cancer is associated with a greater 
risk of aspiration and pneumonia. This may have influenced the number of aspiration 
pneumonias in both groups. But as the number of pneumonias were not different 
between the two groups, it likely would not have had any consequence on the HRQoL 
outcomes. 
To the best of our knowledge, the PANTAP study is the first study to investigate the 
effect of prophylactic antibiotics on the occurrence of pneumonias, the number of 
hospital admissions and healthcare costs in LAHNC patients treated with 
chemoradiotherapy. The strength of the current study is the focus on the effect of 
prophylactic antibiotics on HRQoL in this patient group. As far as we know, only one 
other study has looked at the effect of antibiotics on HRQoL. Braimah et al. investigated 
the effect of oral antibiotics on HRQoL after mandibular third molar surgery and 
showed that extended oral use of amoxicillin/clavulanic acid was correlated with a 
better, though not statistically significant, HRQoL (36). 
A limitation of this study is the relative low compliance of completed HRQoL 
questionnaires, particularly at the end of radiotherapy. In addition, fewer questionnaires 
were completed by the prophylaxis group (at baseline 70.8% versus 59.6% for standard 
versus prophylaxis groups, respectively). Because of this, the number of included 
questionnaires was too low to perform multivariate analyses and no conclusions could 
be drawn on the impact of pneumonia or hospital admission on HRQoL. The explorative 
nature of this study also made it impossible to correct for multiple comparisons or 
confounders such as comorbidity. Furthermore, the last follow-up questionnaire was 
at 3.5 months after the end of chemoradiotherapy, limiting our ability to assess the 
long-term effects of prophylactic antibiotics on HRQoL. However, as HRQoL largely 
returned to baseline values at 3.5 months follow up with almost no differences between 
the groups, no large clinically relevant differences would be expected in future. 
In conclusion, prophylactic antibiotics in LAHNC patients treated with chemoradiotherapy 
may mitigate deterioration of HRQoL  at the end of the radiotherapy compared to 
standard care alone. However, no differences were found between groups at the end 
of follow up. This study should be replicated with larger numbers and more potential 
covariates. However, given the fact that prophylactic antibiotics, compared to standard 
treatment, reduced the number of hospital admissions and costs and also seemed to 
help maintain HRQoL at the end of the chemoradiotherapy, prophylactic antibiotics in 
this patients group can be considered.
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Abstract
Objectives
In locally advanced head and neck cancer (LAHNC) patients treated with concomitant 
chemoradiotherapy, a randomised study to antimicrobial prophylaxis lead to a 
reduction in the hospitalisation rate but not to a reduction in the number of pneumonias 
(the PANTAP study). Here, we aim to study the effect of prophylactic antibiotics on 
sputum cultures.  
Methods
LAHNC patients treated with concomitant chemoradiotherapy were randomised 
between standard care or antimicrobial prophylaxis with amoxicillin/clavulanic acid 
from day 29 until 14 days after the end of chemoradiotherapy. Sputum cultures were 
collected at day 29, at the end of chemoradiotherapy (ranging from day 40 to 47), and 
3 weeks and 14 weeks after the end of chemoradiotherapy.  Sputum culture positivity, 
the spectrum and resistance pattern of microorganisms cultured were studied. 
Results
Forty-eight patients were allocated to receive standard care and 47 to receive 
prophylactic antibiotics. There were no differences in the number of cultures performed 
between the treatment groups, nor in the number of sputum cultures positive for 
bacteria and/or fungi. At the end of the chemoradiotherapy, 9.1% of the cultured 
bacteria in the standard care group were resistant to amoxicillin/clavulanic acid 
compared with 53.3% in the prophylaxis group (p=.006).
Conclusions
In LAHNC patients treated with chemoradiotherapy and receiving prophylactic 
antibiotics, there is no increase in appearance of atypical bacteria or fungi, and only 
at the end of chemoradiotherapy, more bacteria were resistant to amoxicillin/
clavulanic acid.
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Introduction
Head and neck cancer is the seventh most common type of cancer worldwide.(1) The 
treatment for locally advanced head and neck cancer (LAHNC) often consists of 
concomitant platinum-based chemoradiotherapy, which induces a high rate of toxicity, 
like mucositis, dermatitis, anorexia, pain, and dysphagia (2). At presentation, up to 40% 
of patients have dysphagia, and during chemoradiotherapy, the aspiration rate is 
between 13 and 69% (3-6). Aspiration pneumonia is a relatively frequent complication 
in LAHNC patients treated with chemoradiotherapy, with a 5-year cumulative incidence 
of 23.8%, leading to a substantial higher risk of death (7, 8). Recently, we performed 
the PANTAP-study to investigate the use of antimicrobial prophylaxis during 
chemoradiotherapy in LAHNC patients to prevent aspiration pneumonia (9). Secondary 
objectives were to investigate the number of hospitalisations, adverse events including 
side effects of amoxicillin/clavulanic acid, quality of life, to evaluate cost-effectiveness 
and to determine the influence of receiving antimicrobial prophylaxis on the sputum 
cultures with respect to the microbial isolates and resistance. 
As reported elsewhere, hospitalisation rate was significantly reduced in the prophylaxis 
group, as well as the number of febrile episodes, leading to a significant reduction in 
costs of €1425 per patient in favour of the prophylaxis group. No significant difference 
was found in the incidence of aspiration pneumonias between the standard group and 
the prophylaxis group (9).
Except for the difference in number of febrile episodes (episodes of fever of any grade 
in 29.2% of patients in the standard group compared to 10.9% in the prophylaxis group, 
p=0.028), no other significant differences were found in numbers of adverse events, 
such as neutropenia, diarrhoea or rash.
However, to prevent antibiotic resistance, antimicrobial prophylaxis should only be 
prescribed when relevant clinical benefit has been demonstrated, and it has been 
shown that even a single dose of amoxicillin leads to selection of resistant strains in 
the oral microflora (10). Therefore, the aim of this study was to investigate the effect 
of the antimicrobial prophylaxis on sputum culture positivity, and the spectrum and 
resistance pattern of microorganisms cultured.
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Patients and methods
A multicenter randomised trial was performed in LAHNC patients, who were treated 
with concomitant chemoradiotherapy. Patients were included into the study before 
the start of chemoradiotherapy. Selection criteria included an indication for 
chemoradiotherapy, no known allergy to amoxicillin, no use of maintenance antibiotics 
and no HIV/immunodeficiency. Chemoradiotherapy was given as primary treatment 
or as postoperative treatment and consisted of 6 to 7 weeks of radiotherapy (35 
fractions of 2.0 Gy) with concomitant weekly or 3-weekly platinum based chemotherapy.
Randomisation took place between days 21 to 28 of chemoradiotherapy, unless there 
were a pneumonia or other infections or antibiotic treatment within 14 days prior to 
randomisation.
Antimicrobial prophylaxis 
The standard group received standard care (no antimicrobial prophylaxis), including 
blood and sputum cultures and a chest radiography in case of a (suspected) lower 
airway infection, mostly followed by hospitalisation and intravenous antibiotics. The 
prophylaxis group received amoxicillin/clavulanic acid suspension 625mg three times 
daily on top of the standard care. In case of hepatic injury or an allergic reaction, 
treatment with amoxicillin/clavulanic acid had to be stopped and could be replaced by 
clindamycin 450 mg three times daily and metronidazol 500 mg three times daily. The 
antimicrobial prophylaxis was prescribed from day 29 after the start of 
chemoradiotherapy until 14 days after the end of the chemoradiotherapy.  The total 
duration of antibiotic treatment was 25-32 days, depending on which cisplatin regimen 
was given (i.e. 6 or 7 cycles of cisplatin). 
Sputum 
Sputum samples were collected at day 29 (before the start of antimicrobial prophylaxis), 
at the end of chemoradiotherapy (within 1 week), 3 weeks and 14 weeks after 
chemoradiotherapy. When clinically indicated, additional sputum samples were taken. 
Gram stains were performed, and substantial leukocytosis was defined as ≥5 leucocytes 
per high-power field. Sputum was streaked on two agar plates (Columbia Blood agar 
and chocolate agar), incubated at 36 °C for 2 days and bacterial identification was done 
by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-
TOF MS, Bioptyper version 3, Bruker, Bremen, Germany). Antibiotic susceptibility testing 
was done according to (Clinical & Laboratory Standards Institute (CLSI) guidance (11).
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Statistical analysis
The chi-square test was performed to test for significant differences between the 
treatment groups. P-values were tested two-sided and were considered as statistically 
significant when <0.05. SPSS statistics version 22 was used for performing the analyses. 
Results
Between January 2012 and July 2015, 106 patients were included in this study. The main 
results of the PANTAP trial have been published elsewhere (9). In summary, a total of 
95 patients were randomised; 48 patients received standard care and 47 patients 
received antimicrobial prophylaxis. Seven patients could not be randomised due to 
infections or use of antibiotics within 14 days before randomisation, and 4 patients due 
to other reasons. The baseline characteristics were well balanced (Table 1).
Antimicrobial prophylaxis 
Twenty-nine patients (61.7%) in the prophylaxis group completed the amoxicillin/
clavulanic acid prophylaxis as planned. Reasons for early discontinuation in the other 
18 patients were toxicity in 9 patients, mainly due to gastro-intestinal complaints, 
refusal of antibiotics in 3 patients, noncompliance to the prescribed schedule in 4 
patients, and switch to alternative antibiotic treatment due to hospitalization or febrile 
neutropenia during the course of prophylaxis in 2 patients. The mean duration of 
antimicrobial prophylaxis was 21.7 days (range 0-34 days).
Sputum culture results 
At baseline, i.e. 29 days after the start of chemoradiotherapy, at the end of 
chemoradiotherapy and 3 weeks after the end of chemoradiotherapy, no differences 
were found in the number of sputum culture samples that were positive for bacteria 
and/or fungi in the prophylaxis group compared to the standard care group. At 14 
weeks after the end of chemoradiotherapy, sputum cultures were performed in only 
31.2% of patients in the standard group and in 25.5% in the prophylaxis group. In these 
sputum samples, more cultures were positive for bacteria and/or fungi in the 
prophylaxis group (Table 2). 
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Table 1. Patient characteristics. 
Standard group
(N=48)
Prophylaxis group
(N=47)
Age- yr (range) 58.5 (43-68) 57.0 (23-68)
Sex – no. (%)
      Female 14 (29.2) 11 (23.4)
      Male 34 (70.8) 36 (76.6)
WHO performance status (%)
      0 35 (72.9) 32 (68.1)
      1 11 (22.9) 11 (23.4)
      Unknown 2 (4.2) 4 (8.5)
Tumour site (%)
    Oral cavity 14 (29.2) 13 (27.7)
    Oropharynx 20 (41.7) 20 (42.6)
    Hypopharynx 5 (10.4) 11 (23.4)
    Larynx 8 (16.7) 3 (6.4)
   Unknown primary 1 (2.1) 0
TNM Classification
T
    1 5 (10.4) 4 (8.5)
    2 9 (18.8) 10 (21.3)
    3 15 (31.3) 13 (27.7)
    4 18 (37.5) 19 (40.4)
    x 1 (2.1) 1 (2.1)
N
   0 15 (31.3) 12 (25.5)
   1 5 (10.4) 7 (14.9)
   2a 4 (8.3) 3 (6.4)
   2b 16 (33.3) 13 (27.7)
   2c 7 (14.6) 10 (21.3)
   3 1 (2.1) 1 (2.1)
   x 0 1 (2.1)
M
   0 46 (95.8) 45 (95.7)
   x 2 (4.2) 2 (4.3)
Indication for CRT (%)
    Primary treatment 26 (54.2) 34 (72.3)
    Postoperative treatment 22 (45.8) 13 (27.7)
Chemotherapy (%)
     Cisplatin 100 mg/m2 three-weekly 10 (20.8) 12 (25.5)
     Cisplatin 40-50 mg/m2 weekly 32 (66.7) 30 (63.8)
     Carboplatin AUC 1.5 weekly 2 (4.2) 1 (2.1)
     Adapted chemotherapy 4 (8.3) 4 (8.4)
Radiotherapy (%)
     Conventional 22 (45.8) 21 (44.7)
     Accelerated 26 (54.2) 26 (55.3)
      Total dose given at primary tumour and 
pathological lymph nodes (median, range)
68.0 (60-70) 68.0 (60-70)
     Total dose (Gy) given at elective neck levels 
(median, range)
50.3 (46-66) 50.3 (46-60)
Tube feeding at randomisation (%) 9 (18.8) 9 (19.1)
WHO performance status range between 0-5 , with a score of 0 meaning “Able to carry out all normal activity 
without restrictions ”and a score of 5 “death”, TNM=tumour, node, metastasis, CRT=chemoradiotherapy.
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Bacteria
Before the start of antimicrobial prophylaxis, 7 of 34 sputum cultures (20.6%) in the 
standard care group were positive for bacteria compared with 10 of 31 (32.3%) sputum 
cultures in the prophylaxis group (p=.285). At the end of chemoradiotherapy, when 
patients in the prophylaxis group were still on prophylactic antibiotics, 13 of 37 (35.1%) 
sputum cultures in the standard care group versus 13 of 29 (44.8%) in the prophylaxis 
group grew bacteria (p=.424). At three weeks after the end of chemoradiotherapy, 11 
of 37 (29.7%) and 14 of the 35 (40.0%) sputum cultures yielded bacteria in the standard 
care group and prophylaxis group, respectively (p=.360). At the end of follow up, 14 
weeks after the end of chemoradiotherapy, 6 of 15 (40.0%) sputum cultures performed 
in the standard care group versus 5 of 12 (41.7%) in the prophylaxis group were positive 
(p=.930) (Table 2). In some patients more than one pathogen was found in the sputum 
cultures (Figure 1). Detailed culture results are presented Supplemental Table 1. 
Fungi 
There were no significant differences in the numbers of fungi cultured from the sputum 
samples in the two groups, except at the end of follow up. At baseline, 14.7% of the 
sputum cultures performed in the standard group contained fungi or yeast compared 
with 25.8% of sputum cultures in the prophylaxis group (p=.264). At the end of 
chemoradiotherapy, fungi were found in 21.6% of sputum cultures in the standard 
group and in 34.5% in the prophylaxis group (p=.244), at 3 weeks after chemoradiotherapy 
this was 21.6% versus 25.7% (p=.683), and 14 weeks after chemoradiotherapy 26.7% 
versus 66.7% (p=.038) (Table 2). Fungal isolates are specified in Supplemental Table 1. 
Susceptibility testing for fungi was not performed. More non-albicans Candida species 
were found in the prophylaxis group. There was no significant difference between the 
use of fluconazole or other antifungals between the treatment groups; 13 of 48 (27.1%) 
patients in the standard group and 19 of 47 (40.4%) in the prophylaxis group (p=.169) 
had used fluconazole. All non-albicans Candida isolates were found in patients using 
fluconazole, except for the patient with a Candida inconspicua. 
Antimicrobial susceptibility 
Table 2 provides the incidence of resistance to amoxicillin, amoxicillin/clavulanic acid 
and ceftriaxone. At the end of the chemoradiotherapy, when patients in the prophylaxis 
group were still on prophylactic, 2 of 22 bacterial isolates in the standard care group 
were resistant to amoxicillin/clavulanic acid, compared with 8 of 15 isolates in the 
prophylaxis group (p=.006). At 3 and 14 weeks after the end of chemoradiotherapy, 
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after discontinuation of antimicrobial prophylaxis, no differences were found in the 
prevalence of resistance against amoxicillin/clavulanic acid, except at 14 weeks after 
the end of chemoradiotherapy, where a higher rate of resistance to amoxicillin/
clavulanic acid in the standard group was suggested. However, only few sputum 
cultures were performed at that time point (Table 2).
Susceptibility of bacterial isolates during pneumonia
In each study arm, 22 patients developed a pneumonia. No trends toward selection of 
resistant organisms were observed in sputum cultures of patients with pneumonia, 
when compared to the baseline pathogens before the start of antimicrobial prophylaxis 
(Table3).  
Discussion
To the best of our knowledge, the PANTAP study has been the first to investigate not 
only the efficacy of antimicrobial prophylaxis in LAHNC patients receiving 
chemoradiotherapy, but also the bacterial isolates and antimicrobial susceptibility. 
A reduction in hospital admissions and episodes with fever were observed in the 
prophylaxis group, while no differences in incidence of pneumonia and adverse effects 
were found (9).  
T1=Day 29, T2=At end of CRT, T3=3 weeks after CRT, T4=14 weeks after CRT
Figure 1. Type of pathogens found in the sputum cultures during the study.
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With respect to the numbers of sputum culture samples positive for bacteria, there 
were slightly more positive sputum cultures in the prophylaxis group compared with 
the standard group during the study, although not statistically significantly different. 
At the end of the chemoradiotherapy and 3 weeks after chemoradiotherapy, more 
Serratia and Enterobacter species were found in the prophylaxis group, possibly at least 
in part due to selection by amoxicillin/clavulanic acid. However, several of these isolates 
had been present before the start of the prophylactic antibiotics.
After the end of chemoradiotherapy, when patients randomised to the prophylaxis 
group were still on antimicrobial prophylaxis, significantly more bacteria isolated from 
the prophylaxis group were resistant to amoxicillin/clavulanic acid. Three weeks and 
14 weeks after the end of chemoradiotherapy no differences were found in resistance 
to amoxicillin/clavulanic acid between the two treatment groups.
With respect to fungi, no significant differences were found between the two groups, 
except at the end of follow up when only few sputum culture samples were obtained. 
This is a remarkable finding, as selection of Candida species in the oral flora was 
anticipated during amoxicillin/clavulanic acid use. 
Amoxicillin/clavulanic acid as prophylactic antibiotic was chosen because the organisms 
causing aspiration pneumonia were anticipated to be, streptococci, enterobacteriacae, 
and anaerobe bacteria, as previously demonstrated by Lakshmaiah et al. (12). 
Amoxicillin/clavulanic acid seemed well chosen as prophylactic antibiotic as a significant 
reduction in episodes of fever was found with only slightly more sputum cultures 
Table 3. Antimicrobial resistance of bacteria from initial sputum cultures and during pneumonia.
Standard group At the time of pneumonia
Initial sputum culture (N) Susceptible Resistant# Negative Not performed
Susceptible (4) 3/22 1/22 - -
Resistant# (1) - 1/22 - -
Negative (10) 5/22 2/22 3/22 -
Not performed (7) 2/22 2/22 2/22 1/22
Prophylaxis group At the time of pneumonia
Initial sputum culture (N) Sensitive Resistant# Negative Not performed
Sensitive (4) 3/22 1/22 - -
Resistant# (3) - 2/22 1/22 -
Negative (11) 3/22 3/22 5/22 -
Not performed (4) 1/22 - 3/22 -
In both groups, 22 pneumonias were observed. # Resistant bacteria were defined as bacteria with resistance 
for amoxicillin, amoxicillin/clavulanic acid or ceftriaxone.
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positive for bacteria and/or fungi and no excess of fungi were isolated.
A pilot study among head and neck cancer patients applying an antimicrobial lozenge 
containing bacitracin, clotrimazole, and gentamicin found elimination of Candida in all 
patients, and reduction in gram-negative flora in most patients (13). However, in a 
successive phase 3 trial, this antimicrobial lozenge did not lead to a reduction in 
mucositis (14).
A limitation of the current study, is that no sputum culture samples were obtained 
from all patients at all time points. From around 30% of patients in both treatment 
groups, no sputum culture was performed at the specific time points, mainly due to 
the patients’ incapability to produce sputum. At 14 weeks after the end of 
chemoradiotherapy, sputum samples could be obtained from 30% of patients only. In 
addition, culture results may at least in part have represented oral colonization rather 
than lower airway flora. This is supported by the spectrum of bacterial and fungal 
isolates, and by the fact that squamous cell epithelia was present in more than the half 
of the sputum culture samples.
Another potential limitation of this study is the limited duration of follow up until 14 
weeks after chemoradiotherapy, and no conclusions can be drawn about the longer-
term effects of prophylactic antibiotics on the colonising flora.
In conclusion, this study showed that with the use of 5-6 weeks of antibiotic treatment, 
while there is a significant reduction in hospital admissions and cost, there was a 
transient increase of resistant bacterial flora at the end of chemoradiotherapy, but no 
significant impact on resistant flora at subsequent follow-up during 14 weeks. 
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Abstract
Ototoxicity and nephrotoxicity are potentially irreversible side effects of 
chemoradiotherapy with cisplatin in locally advanced head and neck cancer (LAHNC) 
patients. Several predictive genetic variants have been described, but as yet none in 
LAHNC patients. The aim of this study is to investigate genetic variants as predictors 
for ototoxicity and nephrotoxicity in LAHNC patients treated with cisplatin-containing 
chemoradiotherapy. Our prospective cohort of 92 patients was genotyped for 10 
genetic variants and evaluated for their association with cisplatin-induced ototoxicity 
(ACYP2, COMT, TPMT and WFS1) and nephrotoxicity (OCT2, MATE and XPD). Ototoxicity 
was determined by patient-reported complaints as well as tone audiometrical 
assessments. Nephrotoxicity was defined as a decrease of ≥25% in creatinine clearance 
during treatment compared to baseline. A significant association was observed between 
carriership of the A allele for rs1872328 in the ACYP2 gene and cisplatin-induced 
clinically determined ototoxicity (p=0.019), and not for ototoxicity measured by tone 
audiometrical assessments (p=0.449). Carriership of a T allele for rs316019 in the OCT2 
gene was significantly associated with nephrotoxicity at any time during 
chemoradiotherapy (p=0.022), but not with nephrotoxicity at the end of the 
chemoradiotherapy. In conclusion, we showed prospectively that in LAHNC patients 
genetic variants in ACYP2 are significantly associated with clinically determined 
ototoxicity. Validation studies are necessary to prove the added value for individualized 
treatments plans in these patients. 
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Introduction
Head and neck cancer is a common type of cancer worldwide(1, 2). The most frequently 
used treatment for patients with locally advanced head and neck cancer (LAHNC) is 
concomitant chemoradiotherapy with cisplatin, which improves loco-regional control 
as well as overall survival compared to radiotherapy alone (3, 4). Chemoradiotherapy 
can also be applied as adjuvant treatment in case of a high recurrence risk after surgery. 
Concomitant chemoradiotherapy with cisplatin however, induces a high rate of acute 
toxicities such as mucositis, dysphagia and dermatitis, most of which will recover with 
time, but can also induce irreversible ototoxicity and nephrotoxicity (3, 5-7).
Ototoxicity, characterized by sensorineural hearing loss, can be an adverse effect of 
either systemically administered cisplatin or radiotherapy to the inner ear. Both 
chemotherapy and radiotherapy cause lesions in the cochlea, which may lead to 
ototoxicity (8). Ototoxicity caused by cisplatin begins with high frequency loss and is 
often bilateral, permanent and can be progressive also after the end of administration 
of cisplatin (8, 9). Chemotherapy with cisplatin is most often applied either at a dose of 
100mg/m2 every 3 weeks for 3 cycles (high dose) or at a dose of 40mg/m2 every week 
for 6 or 7 cycles (intermediate dose (5, 6).  The incidence of ototoxicity in patients treated 
with high dose cisplatin is 79%.(10) Besides ototoxicity, another common side effect of 
cisplatin is nephrotoxicity that also can be irreversible. However, unlike ototoxicity, part 
of the nephrotoxicity can be reduced by hyperhydration with high natriumchloride. The 
occurrence and the severity of nephrotoxicity is also related to the cisplatin dose; 100% 
of the patients treated with high dose cisplatin experienced nephrotoxicity of any grade 
compared with 75% of the patients with intermediate dose cisplatin (7).
With the aim to prevent ototoxicity and nephrotoxicity, several studies have been 
performed to identify risk factors and predictive markers. Known clinical risk factors 
for ototoxicity after chemoradiation in LAHNC patients are the cumulative dose of 
cisplatin and cumulative radiation dose to the cochlea, younger age, good pretreatment 
hearing, administration of furosemide and low levels of serum albumin and hemoglobin 
(11, 12).  However, cisplatin-induced toxicity can only partly be predicted by these 
factors. Recently, various studies found genetic variants, i.e. single nucleotide 
polymorphisms (SNPs), that are associated with cisplatin-induced side-effects. Genetic 
variants in ACYP2 (Acylphosphatase 2) and WFS1 (Wolframin ER transmembrane 
glycoprotein) were identified as predictive markers for hearing loss (13-17). The ACYP2 
gene is expressed in the cochlea (14). Mutations in WFS1 can cause progressive deafness 
after administration of cisplatin (18). Cisplatin-induced ototoxicity could be related to 
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increased levels of S-adenosylmethionine through reduced TPMT (thiopurine 
S-methyltransferase) or COMT (catechol O-methyltransferase) activity. However, their 
predictive value for ototoxicity is controversial (19, 20). With respect to nephrotoxicity, 
genetic variants in OCT2 (organic cation transporter 2), MATE1 (multidrug and toxin 
extrusion 1) and XPD (xeroderma pigmentosum group D), are believed to be of 
predictive value (21-24). OCT2 and MATE1 are expressed in the human kidney at the 
basolateral membrane of renal proximal tubules, and are involved in the secretion of 
various cationic substances from the circulation into tubular cells. In that way OCT2 
and MATE1 are involved in the cellular uptake of cisplatin (21, 23). XPD is part of the 
nucleotide excision repair pathway and is involved in removal of cisplatin and 
radiotherapy induced DNA damage (24, 25).
However, most of the above-mentioned studies showed correlations in a limited 
number of patients and thus confirmation of the association between the SNPs and 
cisplatin related side effect is needed. Furthermore, the studies were performed in 
patients with other cancers than LAHNC. Therefore, the aim of this study is to investigate 
the relationship between the different SNPs and cisplatin-induced ototoxicity and 
nephrotoxicity in LAHNC patients. 
Materials and methods
Patients and treatment
A cohort of Dutch patients with pathologically proven LAHNC and treated with cisplatin-
based chemoradiotherapy was prospectively recruited at the Radboud university 
medical center and the Erasmus University Medical Center in the Netherlands. Eligibility 
criteria included a minimum age of 18 years and a WHO performance score of 0 or 1. 
Patients with renal dysfunction defined as a creatinine clearance below 60 mL/min. 
were not considered eligible. Before inclusion, written informed consent was obtained 
from all patients. The local ethical committee waived the study from ethical approval.
Patients were treated with cisplatin-based chemoradiotherapy for either primary 
treatment or adjuvant treatment. Concomitant chemoradiotherapy was administered 
in three different treatment schedules; 1. Conventional radiotherapy in combination 
with cisplatin 100 mg/m2 on days 1, 22 and 43; 2. Accelerated radiotherapy combined 
with cisplatin 40 mg/m2 on a weekly basis for 6 weeks; 3. Conventional radiotherapy 
combined with cisplatin 40 mg/m2 on a weekly basis for 7 weeks. Intensity-modulated 
radiation therapy (IMRT) was mandatory. Dose to gross tumor volume was 68-70 Gy 
and dose to elective nodal areas 46-50.3 Gy. 
73
Genetic predictors for ototoxicity and nephrotoxicity
5
Cisplatin was given by infusion in combination with standard prehydration, 
posthydration and anti-emetics. If during the treatment the creatinine clearance was 
below 60 mL/min because of dehydration, cisplatin was only administered if the 
creatinine clearance recovered to 60 mL/min after rehydration. Dose modifications 
and discontinuation of cisplatin were performed according to standard local practice. 
Measurements
Tone audiometry was performed according to standard procedures under standardized 
conditions. Air-conduction and thresholds were determined at 1, 2, 4, 8, 10, 12.5 and 
16 kHz. Bone-conduction thresholds were measured, from 1 kHz to 8 kHz. According 
to the study protocol, audiometry was carried out at baseline, during chemoradiotherapy 
after 100 mg/m2 or 120 mg/m2 cisplatin as total dosage at that moment and within 2 
months after completion of treatment. 
Ototoxicity was scored utilizing two different approaches. In the first approach, 
clinically determined ototoxicity, physicians asked their patients to the hearing loss 
according to the CTCAE 4.03. In the second approach, hearing loss was classified using 
the tone audiometric data from baseline and end of treatment based on the ear with 
the worst hearing loss. Hearing loss was defined by threshold shifts at 2,4 or 8 kHz of 
≤ 25 dB (grade 1), threshold shift of 26-40 dB (grade 2) or threshold shift of ≥ 40 dB 
(grade 3) (15).
Additionally, weekly laboratory tests were performed including the creatinine clearance 
by use of calculation of the Modification of Diet in Renal Disease (MDRD). Nephrotoxicity 
was defined as a decrease of 25% or more in creatinine clearance by the MDRD at any 
point during treatment compared to baseline, based on the international accepted 
Risk, Injury, Failure, Loss and End Stage Renal Disease (RIFLE) criteria (7).    
Blood or saliva (Oragene saliva collection kit (DNA Genotek, Kanata, Ontario, Canada)) 
were used for DNA extraction. 
Genotyping
Genotyping of genetic variant in TPMT (rs12201199, rs1800460, rs1142345) and COMT 
(rs9332377) were performed using Taqman SNP genotyping according to the 
instructions of the manufacturer (ThermoFisher, Nieuwerkerk aan den IJssel, The 
Netherlands). The other genetic variants (COMT rs4646316, ACYP2 rs1872328, OCT2/
SLC22A2 rs316019, WFS1 rs62283056, XPD/ERCC2 rs13181 and MATE1 rs2289669) were 
genotyped using Kompetitive Allele Specific PCR (KASPTM) (KASPar-On_Demand assays 
(Laboratory of the Government Chemist (LGC) Genomics, Hoddesdon, UK)) according 
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to the instructions of the manufacturer (13, 26). Analysis of the Taqman and KASP assay 
was carried out on a 7500FAST Real-Time PCR System (ThermoFisher). Genotypes were 
scored using 7500 software (v2.0.6, ThermoFisher). Negative controls as well duplicates 
(8%) were included as quality controls for genotyping.
Statistics
A sample size calculation showed that inclusion of 100 patients in our study would give 
80% power to identify a statistically significant association between a SNP and 
ototoxicity, assuming a 40% ototoxicity rate, an alpha of 0.05, an allelic OR of 3, and a 
minor allele frequency of 10% (19, 20). The association between the SNPs and clinically 
relevant hearing loss (“yes” versus “no”) and between the SNPs and nephrotoxicity 
(“yes” versus “no”) were analyzed with a Pearson’s chi-square or Fisher-exact tests. 
P-values were tested two-sided and were considered as statistically significant when 
<0.05. SPSS version 22 was used for performing the analyses. 
Meta-analysis of the data of ototoxicity and ACYP2 was performed using a fixed-effects 
model in review Manager version 5.3 (The Cochrane Collaboration, Oxford, UK). 
Results
Between August 2013 and February 2017, 103 patients were included in this study. 
One patient withdrew consent. In 10 cases no blood or saliva samples were available 
for DNA analysis. Thus, in total 92 patients were included in the final analysis. Fifty-
seven patients were treated with intermediate dose cisplatin 40mg/m² weekly for 6 or 
7 weeks, and 35 patients were treated with high dose cisplatin 100mg/m² on days 1, 
22 and 43. Baseline characteristics are shown in Table 1. 
Ototoxicity
In all 92 patients, data on clinically-determined ototoxicity were available, whereas 
hearing loss after treatment based on tone audiometric measurements was available 
for 79 patients. Of the 92 patients, six patients reported new grade 2 hearing loss and 
one patient reported grade 3 hearing loss at end of treatment (Table 2). Of these 7 
patients, 4 were treated with cisplatin 40 mg/m2 and 3 were treated with cisplatin 100 
mg/m2. Based on audiometric measurements, of the 79 patients included in the 
analysis, 52 patients (65.8%) had grade 1 hearing loss, whereas 16 patients (20.3%) and 
11 patients (13.9%) had grade 2 and 3 hearing loss, respectively (Table 2). Nine of the 
11 patients with grade 3 hearing loss were treated with cisplatin 100 mg/m2. There was 
no statistically difference in cumulative cisplatin dose in patients with or without 
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hearing loss when measured clinically or audiometrically (p=0.231 and p=0.142). 
Unfortunately, bone conduction was only available in 55 patients. Of these 41 patients 
(74%) showed no hearing loss, 11 patients (20%) showed mild hearing loss, 3 patients 
(6%) suffered moderate-profound hearing loss (Table 2).
Nephrotoxicity
Of the 92 patients, 53 patients (58%) had nephrotoxicity any time during treatment 
(Table 2). Cumulative cisplatin dose was not different between those patients 
intentionally treated with high dose or intermediate dose cisplatin  (p=0.107). In 86 
patients end of treatment creatinine clearance was available. Of these patients, 8 (9%) 
had nephrotoxicity relative to baseline. All these 8 patients (100%) were treated with 
cisplatin 100 mg/m2.  
Table 1. Patient characteristics of the 92 patients analyzed.
Number of patients (%)
Age mean (range) 57.8 (28-69)
Gender
Male 67 (72.8)
Female 25 (27.2)
WHO score 
0 63 (68.5)
1 28 (30.4)
2 1 (1.1)
Treatment indication
Primary treatment 62 (67.4)
Postoperative treatment 29 (31.5)
Primary treatment tumor, postoperative 1 (1.1)
treatment for lymph nodes
Primary site                  
 Oral cavity 21 (22.8)
Oropharynx 42 (45.7)
Hypopharynx 10 (10.9)
Larynx 13 (14.1)
Unknown primary 4 (4.3)
Nasal vestibule 2 (2.2)
Cisplatin dose 
 40 mg/m2 57 (61.3)
 100 mg/m2 35 (37.6)
Cumulative cisplatin dose (median, range) 240mg (80-300)
 WHO: World Health Organisation
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SNP and ototoxicity
Nine patients were heterozygous GA for the ACYP2 variant rs1872328; all other patients 
(n=83) were homozygous GG. Forty-three percent of the patients reporting clinically 
hearing loss grade 2 or 3 (3 out of 7 patients) were carrying an A allele, whereas 7% of 
the patients without clinically hearing loss (grade 0 or 1) were carrier of the A allele. 
Association analysis showed a statistically significant difference between the groups 
(p=0.019, OR 9.9 95%CI [1.8-54.7]). We found no differences between carriership of the 
A allele and ototoxicity based on tone audiometrical measurements (Table 3).  A meta-
analysis of the cohorts of the previous published studies performed in humans also 
indicated a significant association of the ACYP2 variant with ototoxicity. For this analysis 
we used the data of the audiometrical assessments in our patients to compare with 
the other studies (Figure 1).
For the tested genetic variants in TPMT, COMT and WFS1 no statistically differences were 
found in either clinically or tone audiometrically assessed hearing loss (Table 3). Also, 
the association analysis in patients with hearing loss using bone conduction as 
outcome, showed no statistically significant difference. 
Table 2. Ototoxicity and nephrotoxicity. MDRD: Modification of Diet in Renal Disease.
Number of Patients (%)
Ototoxicity clinically at the end of treatment (n=92)    
None (grade 0 or grade 1) 85 (92.4)
Hearing loss without hearing aid indicated (grade 2) 6  (6.5)
Hearing loss with hearing aid indicated (grade 3) 1 (1.1)
Ototoxicity by tone audiometry (n=79)             
Grade 1 (≤25 dB loss) 52 (65.8) 
Grade 2 (26-40 dB loss) 16 (20.3)
Grade 3 (≥40 dB loss) 11 (13.9)
Ototoxicity by audiometry, only bone conduction (n=55)          
Grade 1 (≤25 dB loss) 41 (74.5)
Grade 2 (26-40 dB loss) 11 (20)
Grade 3 (≥40 dB loss) 3 (5.5)
Nephrotoxicity any time during study (n=92)
MDRD < 25% decrease 39 (42.4)
MDRD ≥25 % decrease 53 (57.6)
Nephrotoxicity at the end of study (n=86)          
MDRD < 25% decrease 78 (84.8)
MDRD ≥25 % decrease 8 (8.7)
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Meta-analysis of published cohorts in humans and present study using a fixed-effects model. 95% CI, 95% confidence 
interval of odds ratio; M-H, Mantel-Haenszel method.
Figure 1. Forest plot of meta-analysis of ACYP2 rs1872328.
Table 3. Significance levels for genetic variants related to ototoxicity.
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TPMT:rs12201199
     AA 77 (91.6) 7 (8.3) p=1.0 47 (66) 14 (20) 10 (14) p=0.863
     AT/TT 8 (100) 0 (0) 5 (63) 2 (25) 1 (12)
TPMT:rs1142345
     TT 77 (91.6) 7 (8.3) p=1.0 47 (66) 14 (20) 10 (14) p=0.863
     TC/CC 8 (100) 0 (0) 5 (63) 2 (25) 1 (12)
TPMT:rs1800460 
     CC 77 (91.6) 7 (8.3) p=1.0 47 (66) 14 (20) 10 (14) p=0.863
     CT/TT 8 (100) 0 (0) 5 (63) 2 (25) 1 (12)
COMT:rs4646316
       CC 50 (94) 3 (6) p=0.452 31 (66) 11 (23) 5 (11) p=0.459
       CT/TT 35 (90) 4 (10) 21 (66) 5 (15) 6 (19)
COMT:rs9332377
     CC 66 (93) 5 (7) p=0.657 40 (66) 11 (18) 10 (16) p=0.410
     CT/TT 19 (90) 2 (10) 12 (67) 5 (28) 1 (5)
ACYP2:rs1872328
     GG 79 (95) 4 (5) p=0.019* 48 (67) 15 (21) 9 (12) p=0.499
     GA 6 (67) 3 (33) 4 (57) 1 (14) 2 (29)
WFS1:rs62283056
     GG 54 (89) 7 (11) p=0.091 35 (66) 12 (23) 6 (11) p=0.600
     GC/CC 31 (100) 0 (0) p=0.091 17 (66) 4 (15) 5 (19)
*=significantly different (p<0.05).
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SNP and nephrotoxicity
Data on the OCT2 gene were available in 92 patients. Eighteen patients were 
heterozygous GT for the OCT2 variant rs316019; 2 patients were homozygous TT and 
all other 72 patients were homozygous GG. Thirty percent of the patients with 
nephrotoxicity during treatment were carrying a T allele, whereas 10% of the patients 
without nephrotoxicity, which was significantly different (p=0.049, OR 3.78 95%CI [1.1-
12.4]). No association was found between carriers of the T allele and nephrotoxicity at 
end of treatment compared to baseline (p=0.845). Nephrotoxicity was not significantly 
associated with the analyzed genetic variants in MATE1 and XDP (Table 4).
Discussion
Since a high percentage of LAHNC patients treated with cisplatin-based chemo-
radiotherapy develop irreversible ototoxicity and nephrotoxicity, it would be worthwhile 
to add predictive biomarkers for toxicity to treatment decision-making to avoid these. 
In this study we investigated whether germline genetic variants were associated with 
ototoxicity and nephrotoxicity. We focused on 10 SNPs in 7 genes which were 
previously reported to be related to these adverse effects (15, 16, 19, 21). We could 
confirm the association between a genetic variant in ACYP2 and clinical reported 
hearing loss, but not with tone audiometrical measurements. Moreover, we found an 
association with OCT2 and nephrotoxicity during treatment with cisplatin, but not with 
Table 4. Significance levels for genetic variants related to nephrotoxicity. *=significantly different (p 
<0.05).
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OCT2/
SLC22A2:rs316019
     GG 35 (48.6) 37 (51.4) p=0.049* 61 (91.0) 6 (9.0) p=1.00
     GT/TT 5 (24.0) 16 (76.0) 18 (89.5) 2 (10.5)
MATE1:rs2289669
     GG 15 (42.9) 20 (57.1) p=1.00 29 (90.6) 3 (9.4) p=1.00
     GA/AA 25 (43.1) 33 (56.9) 50 (90.9) 5 (9.1)
XPD/ERCC2:rs13181
     TT 20 (55.6) 16 (44.4) p=0.085 32 (96.9) 1 (3.1) p=0.146
     TG/GG 20 (35.7) 36 (64.3) 46 (86.8) 7 (13.2)
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nephrotoxicity at end of treatment, which makes it not useful in clinical practice. 
With our findings we are the fifth to report on the association between genetic variation 
in the ACYP2 gene and cisplatin-induced ototoxicity (13-16). The initial studies of Xu and 
Vos reported that the A allele of the genetic variants rs1872328 in the ACYP2 gene was 
only present in patients with ototoxicity, i.e.  13.8% and 6.5%, respectively, carried the 
A allele.  More recent studies, also identified the A allele in patients without hearing 
loss, but only in a low percentage (1%) (15).  In contrast to these studies we found that 
57% of the patients without audiometrical measured ototoxicity carried the A allele and 
43% of the patients with mild to moderate audiometrical measured ototoxicity. A study 
by Fang et al. described an increased risk of esophageal carcinoma associated with the 
genetic variant rs11125529 in the ACYP2 (27). Although another variant of the A allele 
was found and a Chinese population was studied, a genetic variant of the A allele could 
be related to head and neck cancer and therefore found more often in our cohort.
We could not find an association between the other variants investigated and 
ototoxicity. This is in line with previous studies that showed equivocal results (15, 19, 
20) (Table 5). A possible confounder in ototoxicity rate in our patient population is 
radiation in the head and neck region, because radiation can induce conductive hearing 
loss as a result of inflammation and edema as well as sensorineural hearing loss caused 
by radiation on the inner ear (11). Although some patients in the studies by Xu et al. 
and Ross et al. received cranial radiation as well (14, 19).
There is a great variance in the applied scoring systems for ototoxicity between the 
studies, as the initial studies were done in children, most systems are only validated 
in children (28). We decided to perform two analyses, one based on clinical hearing 
loss and the other on objective audiometrical assessments. For the audiometrical 
assessments we used the same scoring system as Drogemoller, because this system 
can be applied to adults, in contrast to the Chang scoring system which is only used 
for children (13, 15). We are the first to use clinically-determined ototoxicity as well, as 
this is a clinically relevant outcome measure reflecting the patients’ perspective. 
However, it remains a subjective outcome, which can be influenced by the interpretation 
of different investigators. Interestingly we could detect an association between the 
genetic variant in ACYP2 when using the clinical measure but not for audiometrically 
determined ototoxicity. The reason for the discrepancy between clinical and 
audiometrical determined ototoxicity is speculative. Audiometrical determined 
ototoxicity is obviously more objective, but clinical assessed ototoxicity is probably 
more relevant for the patient. In the meta-analysis that we performed, our study had 
the same direction of effect (OR>1)  as the other studies.
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Cisplatin-induced sensorineural hearing loss can best be evaluated with bone 
conduction measurements as this specifically measures the hearing of the inner ear/
cochlea (29). 
Theunissen et al. argued that air conduction thresholds represent the functionality of 
the whole auditory system, including both air and bone conduction, and felt that the 
grading criteria should comprehend the overall hearing loss due to treatment as this 
is eventually the clinically relevant hearing loss the patient experiences.
However, to address the underlying mechanism of cisplatin-associated hearing loss 
and the relation with genetic variants, we decided to perform an association analysis 
using both air and bone conduction hearing tests, but we did not find any association 
between the studied genetic variants and the two ototoxicity outcomes. 
With respect to SNPs as predictive markers for nephrotoxicity, the genetic variant in 
OCT2 was found to be significant associated with nephrotoxicity at any point during 
chemoradiotherapy, but not with nephrotoxicity at end of treatment. To our knowledge, 
only two studies have been performed to assess the relationship between OCT2 and 
cisplatin-induced nephrotoxicity in humans (21, 30). Filipski et al. investigated the effect 
of the rs316019 variant in OCT2 in 78 cancer patients receiving cisplatin. Renal function 
was determined 1 day before and 1-8 days after the first dose cisplatin. Iwata et al. 
investigated the rs316019 variant of OCT2 in 53 patients receiving cisplatin during more 
cycles. Remarkably, both Iwata et al. and Filipski et al. showed that the presence of T 
of the genetic variant rs316019 in OCT2 was ameliorating cisplatin-induced 
nephrotoxicity, whereas our study found the opposite. The variation in the results 
might be related to the different endpoints for nephrotoxicity that have been used. 
Based on the previous studies and ours, we believe that at the moment  the use of this 
SNP is not relevant for clinical practice. 
In our study, patients treated with high dose cisplatin and intermediate dose cisplatin 
were taken together, because of the small number of patients treated with the high 
dose schedule. Therefore we cannot draw conclusion regarding association between 
SNPs and toxicity for specific cisplatin dosages, while we know from previous studies 
that high dose cisplatin induces higher rates of ototoxicity as well as nephrotoxicity. 
These data could be of particular interest, as several studies demonstrated the ability 
to enhance chemosensitivity to cisplatin in HNC, thus reducing the dosage needed, 
through the down-regulation of molecules related to cell death (31, 32).
A limitation of our study is that we were not able to reach the planned sample size of 
100 patients, due to lack of DNA of 10 patients, resulting in a somewhat smaller patient 
cohort. Furthermore, because of the relative small patient population, we did not 
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correct for multiple testing and could not perform subgroup analyses. Therefore this 
study should be viewed as the first steps in the link between the studied genes and 
toxicities in LAHNC patients.
Conclusions
This is the first study to the association of ACYP2 and cisplatin-induced ototoxicity in 
LAHNC patients and the fifth to describe the possible predictive value of ACYP2 
regarding (clinical determined) cisplatin-induced ototoxicity. These findings should be 
validated in a large cohort, to finally determine the predictive value of ACYP2 in 
ototoxicity. As personalized medicine is getting more important, these findings could 
eventually provide better tailored, individualized treatment for LAHNC patients 
considering both oncologic efficacy as well as toxicity and quality of life, as other 
treatment regimens are available such as radiotherapy with cetuximab or carboplatin.
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Table 5. Overview of performed studies to ototoxicity and cisplatin.
Discovery Xu
[14]
Replication 
Xu[14]
Vos
[13]
Thiesen
[16]
Drogemoller
[15]
Our study
Patients Children with 
brain tumours
Children with 
brain tumours
Children 
(3-43 yrs) with 
osteosarcoma
Children with 
different 
tumours
Testicular 
cancer
Head and neck 
cancer
Number of 
patients
238 68 156 149 229 92
Cummulative 
dose cisplatin 
(median, range)
287 mg/m2
(unknown)
Unknown* 480 mg/m2
(140-720)
378 mg/m2
(60-800)
400 mg/m2
(200-920)
240mg/m2
(80-300)
Concomitant 
drugs 
Vincristine, 
amisfostine, 
cyclofosfamide
Vinblastin, 
carboplatin
Vincristine, 
carboplatin
in some pts
Vincristine, 
carboplatin
Etoposide, 
bleomycine
-
Radiation Craniospinal Focal in 
some pts
0 Some pts 0 IMRT
* But same cisplatin dose as discovery cohort. IMRT: Intensity-modulated radiation therapy.
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Abstract
Background
Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the head 
and neck (SCCHN) has limited progression-free survival (PFS) benefit. We hypothesized 
that adding cetuximab to methotrexate improves PFS. 
Methods
In the phase-Ib-study, patients with R/M SCCHN received methotrexate and cetuximab 
as first-line treatment. The primary objective was feasibility. In the phase-II-study 
patients were randomized to this combination or methotrexate alone (2:1). The primary 
endpoint was PFS. Secondary endpoints were overall survival (OS), toxicity, and quality 
of life (QoL).
Results
In six patients in the phase-Ib-study, no dose limiting toxicities were observed. In the 
phase II study 30 patients received the combination and 15 patients methotrexate. In 
the phase-II-study median PFS was 4.5 months in the combination group versus 2.0 
months in the methotrexate group (HR 0.37; p=0.002). OS, toxicity and QoL were not 
significantly different.
Conclusion
Cetuximab with methotrexate improved PFS without increased toxicity in R/M SCCHN-
patients.
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Introduction
Head and neck cancer is the seventh most common cancer type worldwide (1). Cure 
rates of patients with locoregionally advanced squamous cell carcinoma of the head 
and neck (SCCHN) vary between 30-60%, and in case of metastases or local recurrence, 
palliative treatment is often the only option (2). In this setting, the only approved 
treatment with significant overall survival (OS) benefit at the time this study was 
initiated was cetuximab added to platinum/5FU (OS of 10.1 months versus 7.4 months 
with platinum/5FU alone), but its toxicity is considerable (3). Other treatment options 
were single agent methotrexate (MTX) or docetaxel in patients unfit for platinum, or 
combination therapies of platinum combined with 5FU or taxane (4). MTX has a 
response rate (RR) of 10-25%, and a mean OS of 6-8 months (5-10), while combination 
therapy with platinum and 5FU or taxane has RRs of 45-50%, but without OS benefit 
compared with single agent treatment, and with more toxicity (4, 8, 10, 11). 
The epidermal growth factor receptor (EGFR) has shown to be up-regulated in 90-100% 
of the head and neck cancers (12). Cetuximab is a recombinant, human/mouse chimeric 
monoclonal antibody that binds specifically to EGFR and inhibits receptor activation 
by competing with epidermal growth factor. It is approved in the United States as single 
agent after failure to platinum-based therapy, based on a single-arm phase II study 
with a RR of 13% and median OS of 6 months (13).
No data are available on the combination of MTX and cetuximab. This combination 
could be beneficial for patients unfit for or unwilling to get platinum-based therapy in 
the recurrent or metastatic (R/M) setting. The aim of this study was to investigate in 
first-line R/M SCCHN patients the feasibility of adding cetuximab to MTX and to 
investigate whether the combination can improve progression-free survival (PFS) versus 
MTX alone. Secondary aims were to investigate the OS, RR, toxicity and health-related 
quality of life (HRQoL). 
Methods
Patients
Patients aged ≥ 18 years with previously untreated R/M SCCHN, who were unfit for or 
unwilling to get platinum-based chemotherapy, were eligible. Other inclusion criteria 
were at least one measurable lesion as determined by RECIST v1.1., time between prior 
treatment for locally advanced disease and inclusion in the study of at least 3 months, 
WHO performance status 0-2, and adequate organ function and laboratory tests. Main 
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exclusion criterion was prior treatment with EGFR-inhibitors or MTX. 
The study was approved by the Medical Ethical Research Committee of Radboudumc, 
the Netherlands and in accordance with the Declaration of Helsinki. All patients signed 
written informed consent. The ClinicalTrials.gov Identifier is: NCT02054442.
Study design of the Commence study
First, a phase Ib open-label non-dose-escalating study was performed to determine 
the safety and tolerability of the combination of cetuximab and MTX. Six patients should 
be treated first and if  0-1 dose limiting toxicities (DLT) in these six patients would occur, 
a phase II study could start. 
In the phase II study, patients were randomized between cetuximab and MTX or MTX 
alone. Participating institute, performance status (0 or 1 versus 2) and local or 
locoregional recurrence independently of distant metastatic disease (yes versus no) 
were used as stratification factors.
During treatment patients were seen every week for the first 4 weeks and thereafter 
every 2 weeks. At these visits adverse events (AEs) (scored by Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0), and laboratory measures were 
recorded. Patients were monitored for AEs during, and for 30 days after the last 
administration of study medication.
Tumor assessment, i.e. CT or MRI of the head and neck, and CT-scan of the thorax, was 
performed at baseline and every 8 weeks. HRQoL was assessed at baseline, after 8 
weeks, after 24 weeks, after 1 year and at progressive disease using the 30-item core 
European Organization for the Research and Treatment of Cancer Quality-of-Life 
Questionnaire (EORTC QLQ-C30)(14), the EORTC QLQ Head and Neck Cancer-Specific 
Module (EORTC H&N35) (14), and the Performance Status Scale for Head & Neck cancer 
patients (PSS-HN) (15). 
In oropharyngeal cancer patients human papillomavirus (HPV) positivity was determined 
with immunohistochemical staining p16 (16).
Treatment
In the phase Ib study, all patients were treated with cetuximab and MTX. The dosage 
of MTX was 40 mg/m2 weekly, delivered in 5-10 minutes iv. The dosage of cetuximab 
was 400 mg/m2 in a 2-hour infusion for the first infusion, followed by 250 mg/m2 in 1 
hour, weekly. 
Treatment was continued until progressive disease (PD), unacceptable toxicity or 
refusal by the patient.
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In case, despite standard precautions, grade 1 or 2 cetuximab-related hypersensitivity 
reaction occurred, infusion rate was reduced or stopped temporarily. In case of 
cetuximab-related grade 3 or 4 toxicity, cetuximab had to be discontinued permanently, 
but continuation of MTX was allowed. In case of MTX-related grade 4 toxicity in patients 
treated with the combination, cetuximab could be continued. If the absolute neutrophil 
count was <1.5 x 109/l and/or thrombocytes <100 x 109/l, MTX had to be postponed for 
1 week and if recovered, folinic acid needed to be prescribed.
Endpoint
The primary endpoints in phase Ib were toxicity and the incidence of DLTs after start 
of treatment. The primary endpoint of the phase II part of the study was PFS, defined 
as the time from randomization to PD or death. Secondary endpoints for the phase Ib 
and phase II study were OS (time from randomization to death), RR according to RECIST 
v1.1 (i.e. complete or partial response), the clinical benefit rate (i.e. complete or partial 
response or stable disease), toxicity according to CTCAE v4.0, HRQoL and HPV-status 
in relation to these outcomes.
Statistical analysis
In the phase Ib study, a minimum of 6 patients were needed, depending on the 
occurrence of DLT’s. The results are summarized using simple descriptive statistical 
methods. 
In the phase II study, 57 patients were needed in each treatment group to achieve 80% 
power at a 0.05 significance level to detect a hazard ratio of 0.6 assuming that the 
addition of cetuximab to MTX would improve PFS by 2 months from 3 months in the 
MTX alone group to 5 months in the combination group.
Unfortunately, due to financial constraints in the Netherlands in July 2015, after 
inclusion of six patients in the phase Ib study and 12 patients in the phase II study, the 
study had to be amended to a design with a total of 45 patients with a 2:1 randomization 
in the phase II study (30 patients in the MTX with cetuximab group and 15 patients in 
the MTX alone group). Kaplan-Meier curves were plotted and PFS and OS were 
compared by the log-rank test. Cox-regression models were fitted to estimate and test 
hazard ratios. Non-parametric tests were performed using the chi-square test to test 
for differences in patient characteristics and occurrence of AEs between the treatment 
groups. All statistical tests were two-sided, with an alpha level of 5% considered as 
statistically significant. HRQoL was only investigated and described exploratively. 
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Results
Patient characteristics
From February to June 2014, six patients were included in the phase Ib study in the 
Radboudumc, the Netherlands. All patients received the combination of cetuximab 
with MTX. The phase II study started in July 2014, but was on hold from July 2015 until 
August 2016 due to amendment of the study design. Last patient was included in 
January 2018. Forty-five patients were included in the phase II study in 6 participating 
hospitals in the Netherlands, of which 30 patients were allocated to cetuximab and 
MTX and 15 patients to MTX alone (Figure 1).
The baseline characteristics were well balanced between the two treatment groups 
(Table 1).
Figure 1. CONSORT Flow Diagram of the enrollment of patients in the phase II study.
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Efficacy
In the phase Ib study, median PFS was 5.8 months (range 1.9-13.0 months) and median 
OS 10.6 months (range 3.0-17.9 months). The cut-off date for the efficacy analysis of 
the phase II study was 1 October 2018. Median follow-up was 19.3 months, with a 
minimum follow-up of 8.9 months. Median PFS was 4.5 months (range 0.9-23.2+ 
months) in the cetuximab and MTX group and 2.0 months (range 0.9-9.0 months) in 
the MTX alone group (hazard ratio for progression, 0.37; 95% CI, 0.19 to 0.71; p= 0.002) 
(Figure 2a). One patient in the combination group, who had a resection of one lymph 
node metastasis which was growing during treatment without any progression of other 
lesions, was still on treatment with no signs of progressive disease. The main reason 
for discontinuation of treatment was PD in both groups.
The median OS in the phase II study was 8.0 months (range 0.9-23.8+ months) in the 
cetuximab and MTX group compared with 4.7 months (range 0.9-20.7+) in the MTX 
alone group (hazard ratio for death 0.67; 95% CI, 0.34 to 1.22; p=0.248) (Figure 2b). 
Table 1. Patient characteristics.
Phase 1
(N=6)
Phase 2
MTX+cetuximab 
(N=30)
Phase 2
MTX 
(N=15)
P value#
Age (median,range) 65.0 (58-71) 68.5 (46-80) 64.0 (49-77)
Sex .806
     Male (%) 5 (83.3) 23 (76.7) 11 (73.3)
     Female (%) 1 (16.7) 7 (23.3) 4 (26.7)
WHO .606
     0 4 (66.7) 6 (20.0) 5 (33.3)
     1 2 (33.3) 21 (70.0) 9 (60.0)
     2 0 3 (10.0) 1 (6.7)
Tumor site .205
     Oral cavity 1 (16.7) 11 (36.7) 2 (13.3)
     Oropharynx 2 (33.3) 8 (26.7) 7 (46.7)
       HPV positive 0 4 1
       HPV negative 2 3 5
       HPV unknown 0 1 1
     Hypopharynx 1 (16.7) 7 (23.3) 2 (13.3)
     Larynx 2 (33.3) 4 (13.3) 4 (26.7)
Loco-regional recurrence* .429
     Yes 6 (100) 25 (83.3) 11 (73.3)
     No 0 (0) 5 (16.7) 4 (26.7)
Distant metastases
     Yes 5 (83.3) 21 (70) 7 (46.7) .128
     No 1 (16.7) 9 (30) 8 (53.3)
* Loco-regional recurrence means local recurrence and/or metastases in locoregional lymphnodes. # The 
P-values are for the differences between the treatment groups in the phase II study.
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Eight and two patients were still alive in the combination group and MTX group, 
respectively. The addition of cetuximab to MTX improved the clinical benefit rate 
significantly from 40.0% to 76.7% (p=0.015). The RR showed no significant differences 
with 13.3% PR in the MTX and cetuximab group and 6.7% PR in the MTX alone group.
Toxicity
In the phase Ib study no DLT’s occurred and one serious adverse event (SAE) was 
reported, not related to the study medication. Three patients reported grade 3 toxicity 
(two patients had a hypophosphatemia and one syncope), no grade 4 toxicity was 
observed.
In the phase II study, the overall incidence of grade 3 or 4 AEs was 46.7% in the MTX 
and cetuximab group compared with 53.3% in the MTX group (p=0.673). Only the 
Figure 2. Kaplan-Meier estimates of Progression Free Survival (A) and Overall Survival (B) according 
to the two treatment groups.
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incidence of all grade skin AEs was significantly higher in the combination group 
compared with the MTX group (86.7% versus 40.0%, p=0.001). The incidence of 
dysphagia (6.7% in the combination group versus 16.7% in the MTX group, p=0.032) 
and dyspnea (3.3% in the combination group versus 10.0% in the MTX group, p=0.005) 
were significantly higher in the MTX group (Table 2).
Table 2. Most relevant and common (related and not related) adverse events according to the CTCAE 
4.0. 
MTX + cetuximab (N=30) MTX (N=15) P value# 
Any grade Grade 3-4 Any grade Grade 3-4 
Any event 30 (100) 14 (46.7) 15 (100) 8 (53.3) .673
Skin reactions* 26 (86.7) 3 (10.0) 6 (40.0) 0 (0) .001
Mucositis 14 (46.7) 1 (3.3) 5 (33.3) 1 (6.7) .393
Xerostomia 3 (10.0) 0 (0) 0 (0) 0 (0) .205
Dysphagia 5 (16.7) 2 (6.7) 7 (46.7) 2 (13.3) .032
Dyspnea 3 (10.0) 1 (3.3) 7 (46.7) 2 (13.3) .005
Cough 9 (30.0) 0 (0) 5 (33.3) 0 (0) .820
Pneumonia 5 (16.7) 2 (6.7) 2 (13.3) 0 (0) .771
Pneumonitits 1 (3.3) 1 (3.3) 0 (0) 0 (0) .475
Infusion reaction 6 (20.0) 0 (0) 0 (0) 0 (0) .063
Vomiting 4 (13.3) 0 (0) 1 (6.7) 0 (0) .502
Diarrhea 10 (33.3) 0 (0) 1 (6.7) 0 (0) .050
Anorexia 7 (23.3) 0 (0) 4 (26.7) 2 (13.3) .806
Weight loss 3 (10) 1 (3.3) 0 (0) 0 (0) .205
Anemia 3 (10) 0 (0) 0 (0) 0 (0) .205
Thrombocytopenia 3 (10) 1 (3.3) 2 (13.3) 0 (0) .737
Leucocytopenia 2 (6.7) 0 (0) 0 (0) 0 (0) .306
Neutropenia 3 (10.0) 0 (0) 0 (0) 0 (0) .205
Hypercalcemia 1 (3.3) 0 (0) 3 (20.0) 1 (6.7) .064
Hypomagnesemia 4 (13.3) 0 (0) 0 (0) 0 (0) .138
Hypophosphatemia 1 (3.3) 1 (3.3) 0 (0) 0 (0) .475
Hyponatremia 2 (6.7) 2 (6.7) 1 (6.7) 0 (0) 1.00
Hypokalemia 1 (3.3) 0 (0) 0 (0) 0 (0) .475
Hepatotoxicity 6 (20.0) 4 (13.3) 1 (6.7) 1 (6.7) .245
Pain tumor 6 (20.0) 0 (0) 2 (13.3) 0 (0) .581
Pain non-tumor 12 (40.0) 0 (0) 5 (33.3) 0 (0) .664
Tumor hemorrhage 4 (13.3) 0 (0) 0 (0) 0 (0) .138
Fatigue 16 (53.3) 2 (6.7) 9 (60.0) 2 (13.3) .671
Depression 3 (10.0) 0 (0) 2 (13.3) 0 (0) .737
Malaise 9 (30.0) 0 (0) 4 (26.7) 0 (0) .816
Cardiac event 2 (6.7) 0 (0) 0 (0) 0 (0) .306
*: skin reactions included fissures, rash acneiform, rash macula-papular, paronychia, blisters, nail changes, 
xerodermia, lymph edema and toxicity of the eyes. #: The P values are for the differences between the treatment 
groups for any grade toxicity, except for the difference in any event, where the P value is for the difference 
between grade 3-4 toxicity. 
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The total number of SAEs was 14 (in 12 out of 30 patients) in the combination group, 
compared to 8 ( 5 out of 15 patients) in the MTX group. None of the SAEs in the MTX 
group was related to MTX, while 3 of the 14 in the combination group were considered 
as possibly related to MTX or cetuximab. These 3 (possibly) related SAEs were pneumonia 
(grade 3), pneumonitis (grade 3) and an infusion-related reaction (grade 1).
HRQoL
At baseline, 93.3% and 86.7% of the patients completed the HRQoL questionnaires in 
the cetuximab and MTX group and MTX group, respectively. Only small clinical 
important differences were found between the two treatment groups at baseline. The 
compliance of completing the questionnaires during the study as well as at PD was 
low (Table 3). The HRQoL did not seem to deteriorate after the start of cetuximab and 
MTX. 
The 16 patients in the combination group who completed the questionnaires at 8 weeks 
after start of treatment, did not differ much in baseline scores from the patients who 
did not completed the questionnaires after 8 weeks. The only notable differences were 
that patients who completed the questionnaires after 8 weeks, felt less ill at baseline 
and had less problems of a dry mouth. 
HPV
Four out of 8 (50%) versus 1 out of 7 (14.3%) oropharyngeal carcinomas were HPV 
positive in the combination group and MTX group, respectively. Because of the small 
number of oropharyngeal cancers in both groups, no conclusions can be drawn about 
the effect of HPV-status on PFS and OS. 
Discussion
This phase Ib-randomized phase II study of first-line treatment of R/M SCCHN showed 
a significant increase in PFS by adding cetuximab to MTX with 2.5 months. The clinical 
benefit rate of 76.7% in the combination group was significantly higher compared with 
40.0% in the MTX group. 
The 2.5 months benefit in PFS by adding cetuximab to MTX, is in line with earlier studies 
showing benefits of adding cetuximab to platinum-based therapy (3, 17), however, this 
is the first study in combination with MTX. Although Vermorken et al. showed a clinically 
significant difference in OS with adding cetuximab to platinum-5FU, there was 
substantial toxicity, with grade 3/4 toxicity rate of 82%, whereas the patients in our 
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study treated with the combination of MTX and cetuximab reported grade 3/4 toxicity 
in 46.7%. The PFS of 2.0 months in the MTX alone group was slightly less than expected 
before the start of the study (power calculation was made with the consumption of a 
PFS of 3.0 months in the MTX alone group). The PFS and OS are in line with other studies 
comparing MTX with other chemotherapy regimens or tyrosine kinase inhibitors in 
first and second line (Table 4). 
The landscape  of the treatment of R/M SCCHN patients is rapidly evolving due to the 
introduction of immunotherapy. Nivolumab is already registered for patients with 
R/M SSCHN after platinum-failure, showing an improved 2-year OS rate of 16.9% 
versus 6.0% with investigator’s choice chemotherapy (HR 0.68; 95% CI, 0.54-0.86) (18). 
Recently, the results of the KEYNOTE-048 phase III study were presented in which the 
current standard cetuximab-platinum/5FU was compared with pembrolizumab 
monotherapy or pembrolizumab combined with platinum/5FU in first-line R/M head 
and neck cancer. This study showed that pembrolizumab alone improved OS compared 
with standard chemotherapy (14.9 months versus 10.7 months, HR 0.61, p=0.0007) 
in patients with ≥20 CPS (combined positive score; PD-L1 expression in tumour and/
or surrounding immune cells, divided by tumour cells) (19). Despite these 
developments, there will always be patients who are not suitable for immunotherapy 
because of auto-immune diseases or a PDL-1 negative cancer and who are too 
vulnerable for treatment with platinum-based chemotherapy. For these patients, the 
combination of MTX and cetuximab, as it has shown a PFS benefit at the price of 
limited and well manageable toxicities, can be an interesting treatment option. New 
studies in which this combination can be compared in first and/or second-line therapy 
in patients unfit for, or after failure of immunotherapy would increase the insight in 
this combination treatment.
Limitations of this study are the small number of patients included and the altered 
study design. Therefore, the results and statistical analyses should be interpreted with 
caution and should be seen as hypothesis generating for new studies in the future.
Another limitation is the small number of completed HRQoL questionnaires, which 
made it difficult to draw firm conclusions about the effect of adding cetuximab to MTX 
on HRQoL, while patient reported outcomes are getting more important. However, the 
fact that the HRQoL did not deteriorate after the start of cetuximab and MTX, is in line 
with Mesia et al., who showed that adding cetuximab to platinum-fluorouracil does 
not adversely affect QoL in patients with R/M SCCHN (20). As shown by the rapid decline 
in HRQoL at PD, a stable HRQoL after start of the treatment is of clinical relevance in 
this patient group. 
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Table 3. Scores in HRQoL at baseline, after 8 weeks of treatment and at progressive disease measured 
by the EORTC QLQ-C30, QLQ-H&N35, PSS-HN and Visual Analog Scale (VAS)-score. (N) after each 
subscales means the number of available questionnaires. 
Baseline
MTX + 
cetuximab
(N=28)
MTX
(N=13)
∆
PSS-HN
Normalcy of diet (N) 54.4 (27) 49.2 (12) 5.2
Eating in public (N) 63.0 (23) 83.3 (12) -20.3
Understandability of 
speech(N)
78.9 (26) 68.8 (12) 10.1
VAS-score (N) 2.3 (26) 3.4 (13) -1.1
QLQ-C30
Physical functioning 79.4 86.2 -6.8*
Role functioning 82.7 78.2 4.5
Emotional functioning 78.0 79.5 -1.5
Cognitive functioning 88.7 92.3 -3.6*
Social functioning 84.5 89.7 -5.2*
Global health status 67.3 73.1 -5.8*
Fatigue 23.4 22.2 1.2
Nausea/vomiting 6.5 3.8 2.7
Pain 22.0 23.1 -1.1
Dyspnea 13.1 7.7 5.4*
Insomnia 11.9 12.8 -0.9
Appetite loss 17.3 17.9 -0.6
Constipation 15.5 15.4 0.1
Diarrhea 8.3 10.3 -2.0
Financial problems 6.0 12.8 -6.8*
QLQ-H&N35a
Pain 23.5 20.1 3.4
Swallowing 24.3 21.2 3.1
Senses problems 23.2 20.5 2.7
Speech problems 24.8 22.2 2.6
Social eating 25.4 16.0 9.4
Social contact 10.5 4.6 5.9
Sexuality 40.6 35.9 4.7
Teeth 15.3 8.3 7.0
Opening mouth 29.6 35.9 -6.3
Dry mouth 26.2 33.3 -7.1
Sticky saliva 35.9 44.4 -8.5
Coughing 29.8 20.5 9.3
Felt ill 13.1 10.3 2.8
Pain killers 75.0 69.2 5.8
Nutritional supplements 48.1 30.8 17.3
Feeding tube 25.0 16.7 8.3
*= small clinical important difference; ¥ = medium clinical important difference;  ₣ = large clinical important 
difference [21]; #=clinical relevant difference of more than 10 points between baseline and 8 weeks after the 
start of treatment within one group 
aWeight gain and weight loss not reported due to difficult interpretation
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After 8 weeks At progressive disease
MTX + 
cetuximab
(N=16)
MTX
(N=3)
∆ MTX + 
cetuximab
(N=4)
MTX
(N=2)
∆
70.8 (13) 53.3 (3) 17.5 30.0 (3) 40.0 (2) -10.0
81.8 (11) 41.7 (3) 40.1 62.5 (2) 62.5 (2) 0.0
75.0 (13) 66.7 (3) 8.3 83.3 (3) 50.0 (2) 33.3
2.3 (26) 3.4 (13) -1.1 3.2 (5) 3.3 (2) -0.1
75.2 73.3# 1.9 45.0 83.3 -38.3
72.9 83.3 -10.4 22.2 58.3 -36.1
80.0 94.4# -14.4 75.0 83.3 -8.3
82.3 94.4 -12.1 58.3 83.3 -25.0
79.2 77.8# 1.4 50.0 83.3 -33.3
64.6 83.3# -18.7 33.3 70.8 -37.5
28.8 11.1# 17.7 52.8 22.2 30.6
1.0 11.1 -10.1 20.8 0.0 20.8
18.8 11.1# 7.7 45.8 42.7 3.1
20.8 11.1 9.7 16.7 0.0 16.7
14.6 11.1 3.5 25.0 50.0 -25.0
21.4 0.0# 21.4 77.8 0.0 77.8
18.8 0.0# 18.8 8.3 0.0 8.3
8.3 0.0# 8.3 16.7 33.3 -16.6
6.3 0.0# 6.3 8.3 0.0 8.3
17.7 11.1 6.6 45.8 41.7 4.1
21.4 11.1# 10.3 27.1 37.5 -10.4
20.8 25.0 -4.2 37.5 50.0 -12.5
28.5 0.0# 28.5 41.7 33.3 8.4
11.5# 33.3# -21.8 63.9 16.7 47.2
6.3 2.2 4.1 46.7 33.3 13.4
26.9# 11.1# 15.8 58.3 50.0 8.3
11.1 0.0 11.1 22.2 0.0 22.2
25.0 11.1# 13.9 41.7 66.7 -25.0
20.0 33.3 -13.3 33.3 33.3 0.0
44.4 0.0# 44.4 50.0 50.0 0.0
35.4 0.0# 35.4 25.0 33.3 -8.3
16.7 0.0# 16.7 50.0 16.7 33.3
81.3 100.0# -18.7 100.0 100.0 0.0
33.3# 66.7# -33.4 25.0 0.0 25.0
25.0 66.7# -41.7 25.0 50.0 -25.0
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In conclusion, in this small study the addition of cetuximab to MTX improved PFS in 
patients with R/M SCCHN, and could be considered as treatment option in patients not 
eligible or unfit for platinum-based therapy. 
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Table 4. Overview of studies, in which MTX monotherapy was compared with other chemotherapy 
regimens or oral tyrosine kinase inhibitors in R/M SSCHN patients.
Study Line of 
treatment
Regimen Number of 
patients
RR Median PFS 
(months)
Median OS 
(months)
Forastiere, 
1992[8]
First Cisplatin + 5FU
Carboplatin + 5FU
MTX
87
86
88
32
21
10
4.2
5.1
4.1
6.6
5.0
5.6
Stewart, 
2009[22]
Any Gefitinib 250mg
Gefitinib 500mg
MTX
158
167
161
2.7
7.6
3.9
-
-
-
5.6
6.0
6.7
Kushwaha, 
2015[6]
Any Gefitinib 500mg
MTX
MTX + 5FU
39
40
38
7.7
5.0
7.9
-
-
-
8.8
7.8
8.1
Machiels, 
2015[23]
Second Afatinib 40mg
MTX
322
161
10
6
2.6
1.7
6.8
6.0
Machiels, 
2016[24]
Second Cabazitaxel
MTX
53
48
0
0
1.9
1.9
5.0
3.6
This study First MTX + cetuximab
MTX
30
15
13.3
6.7
4.5
2.0
8.0
4.7
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Summary
Dysphagia and aspiration pneumonia are common toxicities of chemoradiotherapy 
for LAHNC. In a multicenter randomised phase II PANTAP-study the effect was studied 
of prophylactic amoxicillin/clavulanic acid during chemoradiotherapy for LAHNC on 
aspiration pneumonia, hospitalisation rate, HRQoL, adverse events and on sputum 
cultures and resistance. (Chapters 2-4) Patients were included before the start of 
chemoradiotherapy and randomised between day 22 and 28, unless they had received 
antibiotics or had an infection 14 days prior to randomisation. Patients were 
randomised between standard of care or prophylactic amoxicillin/clavulanic acid from 
day 29 after the start of chemoradiotherapy until 14 days after the end of 
chemoradiotherapy. One-hundred-and-six patients were included, of which 95 could 
be randomised; 48 patients were allocated to the standard group and 47 patients to 
the prophylaxis group. In Chapter 2 the main results of the PANTAP study are 
described; the use of prophylactic antibiotics did not reduce the incidence of definite 
or suspected aspiration pneumonias (45.8% versus 46.8%, p=0.544), but significantly 
reduced the hospitalisation rate (39.6% versus 19.1%, p=0.030), number of episodes 
with fever (29.2% vs 10.2%, p=0.028) and total costs per patient (€2462 versus €1037, 
p=0.046). In Chapter 3 the effect of prophylactic antibiotics on health related quality 
of life (HRQoL), one of the secondary endpoints of the study is described. Especially at 
the end of chemoradiotherapy, when the toxicity of treatment is most severe, patients 
treated with the prophylactic antibiotics performed better on all functional subscales 
(e.g. physical functioning, cognitive functioning, and social functioning) of the EORTC 
QLQ-C30 and reported less symptoms, except for the items ‘diarrhoea’ and ‘feeding 
tube’. Finally, the results of the effect of the prophylactic antibiotics on the number of 
positive sputum cultures, the bacterial spectrum including the resistance pattern, and 
the presence of fungi and yeast in these cultures are presented in chapter 4.  No 
differences were found in the number of performed cultures between the two 
treatment groups, neither in the number of sputum cultures positive for bacteria and/
or fungi. At the end of the chemoradiotherapy, 2 out of 22 of the cultured bacteria in 
the standard care group were resistant to amoxicillin/clavulanic acid compared with 
8 out 15 bacteria in the prophylaxis group, p=.006. However, this difference was not 
determinative for a clinical difference in infections and/or pneumonias, and disappeared 
3 weeks and 14 weeks after the end of chemoradiotherapy.
In Chapter 5 the results are described of a second study in LAHNC patients treated 
with chemoradiotherapy, the PRONE study. As ototoxicity and nephrotoxicity are 
potentially irreversible side effects of cisplatin containing chemoradiotherapy, the 
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PRONE study investigated genetic variants, which could serve as predictors for these 
toxicities in LAHNC patients. A significant association was observed between carriership 
of the A allele in the ACYP2 gene and cisplatin-induced clinically determined ototoxicity 
(p=0.019), which was not the case for ototoxicity measured by tone audiometrical 
assessments (p=0.449). Carriership of a T allele in the OCT2 gene was significantly 
associated with nephrotoxicity at any time during chemoradiotherapy (p=0.022), but 
not with nephrotoxicity at the end of the chemoradiotherapy. Validation studies are 
necessary to confirm these results, and until then the use of these predictive genetic 
variants is limited. 
In patients with recurrent or metastatic squamous cell carcinoma of the head and neck 
(SCCHN), first-line treatment consists of the combination of cetuximab and platinum-
5FU, but this combination has substantial toxicity. Methotrexate as single agent is often 
well tolerated, but improvement in progression-free survival (PFS) is limited. In the 
phase Ib-II COMMENCE study, firstly the feasibility was studied and subsequently the 
efficacy of the combination of cetuximab and methotrexate. With this study we aimed 
to improve PFS without adding significant toxicities, especially in patients unfit for or 
refusing platinum-based therapy. In the phase II study patients were randomised 
between the combination of cetuximab and methotrexate versus methotrexate alone. 
In Chapter 6 the results of the COMMENCE study are presented. In the phase I study 
the combination of cetuximab and methotrexate showed to be feasible and in the 
phase II study the addition of cetuximab to methotrexate significantly improved PFS 
(4.5 months versus 2.0 months, p=0.002). Overall survival (OS) (8.0 versus 4.7 months, 
p=0.248) was not significantly different. The toxicity profile of the combination of 
methotrexate and cetuximab was predictable and manageable (46.7% grade 3-4 
toxicity) and comparable to the known toxicity of single agent methotrexate. 
Unfortunately, due to an altered study design, less patients were included in the phase 
II study than originally planned and calculated in the power-analysis (45 patients instead 
of 114 patients). 
In conclusion: the results of the studies as described in this thesis show that the use 
of prophylactic antibiotics can be considered in patients with LAHNC treated with 
chemoradiotherapy. The prediction of ototoxicity and nephrotoxicity by genetic variants 
in LAHNC patients treated with cisplatin-containing chemoradiotherapy should be 
validated in a larger cohort before it can be implemented in daily clinical practice. At 
last, in patients with recurrent or metastatic SCCHN the combination of cetuximab and 
methotrexate improves PFS, without adding toxicity, but nevertheless the prognosis 
of these patients remains still disappointing. So small steps into improving personalised 
treatment are made, but definitely further research is necessary. 
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General discussion and Future perspectives
Treatment of locally advanced head and neck cancer (LAHNC) patients with concomitant 
chemoradiotherapy can induce high rates of acute toxicities, e.g. mucositis in up to 
70%, and late toxicities. Also, treatment of recurrent or metastatic squamous cell 
carcinoma of the head and neck (SCCHN) with the current first line standard of care 
with platinum, 5-FU and cetuximab, causes grade 3-4 toxicity in 82% of the patients. 
(1) Especially in patients with recurrent or metastatic SCCHN, prognosis remains poor 
with an overall survival (OS) of often only a couple of months, Health Related Quality 
of Life (HRQoL) is very important. Treatment induced toxicities should be avoided as 
much as possible. New treatment options with improved prognosis as well as reduced 
toxicities are therefore highly desirable.  
Recurrent or metastatic disease
Unfortunately, in case of recurrent or metastatic disease, the prognosis is poor, with 
a median overall survival of less than 1 year. (2) As stated before, in 2008 the 
combination of platinum, 5-FU and cetuximab (EXTREME-regimen) showed an OS-
benefit (OS of 10.1 versus 7.4 months with platinum and 5-FU alone) (1). However, it 
is an intensive treatment with significant toxicities and therefore can only be applied 
to fit patients. For this reason, in the Netherlands, this EXTREME-regimen is not often 
administered. An alternative is, for example, methotrexate as single agent, which never 
showed to be beneficial in terms of OS, but can improve QoL in the first period after 
start of treatment, has less adverse effects compared to cisplatin-based chemotherapy, 
and has an overall response rate (ORR) of around 16%. (3-5). Based on this knowledge 
and the lack of studies in the less fit metastatic HN cancer patients, the COMMENCE 
study was initiated, to investigate the efficacy and toxicity of the combination with 
methotrexate and cetuximab.
The efficacy of cetuximab as single agent, has only been investigated as second-line 
treatment, with an ORR of 13%, a median PFS of 2.3 months, and a median OS of 5.9 
months. Therefore, in the Netherlands, it is not allowed to prescribe cetuximab as 
single agent nor as first-line, nor as second-line. 
As investigated in the randomised phase II COMMENCE study, in which 45 patients 
received cetuximab and methotrexate and 15 patients methotrexate alone, the 
combination resulted in a PFS of 4.5 months and an OS of 8.0 months, both improved 
compared to methotrexate alone. However, an OS of 8.0 months is still disappointing, 
especially when the OS in untreated patients is around 6 months. And although the 
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grade 3-4 toxicity rate with cetuximab and methotrexate was almost the half of the 
toxicity rate of the EXTREME-regimen, it was still 46.7%. As the toxicity rate of 
methotrexate singe agent treatment was more or less the same as that of the 
combination treatment with cetuximab and methotrexate, but with improved PFS and 
OS, I believe the combination treatment could be an alternative for recurrent or 
metastatic SCCHN patients who are not eligible for the EXTREME schedule or are not 
willing  to receive it. Notably, this study was performed in a time period in which there 
was no access to immunotherapy.
New treatment modalities with improved PFS and OS but without much toxicity are 
therefore highly desirable. Immune checkpoint pathways, which are normally used by 
tumour cells to suppress the immune system, can be blocked by immune checkpoint 
inhibitors (ICI), causing an activation of the immune response in order to eliminate 
cancer cells. Examples of ICI are antibodies against cytotoxic T-lymphocyte antigen-4 
(CTLA-4) and to the programmed cell death protein 1 (PD-1) receptor.  They were first 
introduced in melanoma patients, with approval of ipilimumab for metastatic 
melanoma by the U.S. Food and Drug Administration (FDA) in 2011.(6) 
In recurrent or metastatic SCCHN patients, immunotherapy was firstly investigated as 
second-line therapy. In the Checkmate-141 phase III study, in recurrent or metastatic 
SCCHN patients, who had progressive disease <6 months after platinum containing 
treatment (either as palliative treatment or as primary treatment in combination with 
radiotherapy) nivolumab (an IgG4 fully human antibody targeting PD1) was compared 
with investigators choice (docetaxel, methotrexate or cetuximab). (7) After a minimal 
follow up of 24 months, median OS with nivolumab was 7.7 months compared with 
5.1 months with investigators choice -treatment (HR = 0.68). The ORR was 13.3% in the 
nivolumab group versus 5.8% in the investigators choice group. (8) Therefore nivolumab 
was approved in the United States in 2016 for the treatment of this patient population, 
followed by European approval following in 2017 (2), and approval by the “Commissie 
BOM” in the Netherlands in 2018. 
Thereafter, studies with immunotherapy as first-line treatment for recurrent or 
metastatic SCCHN were performed. In the 3-armed Keynote-048 phase III study patients 
were randomised between (i) pembrolizumab (a humanised monoclonal anti-PD-1 
antibody) as single agent or (ii) combination pembrolizumab with platinum-5FU or (iii) 
the EXTREME regimen. Chemotherapy was given for up to 6 cycles, pembrolizumab 
for a maximum of 24 months. Primary outcomes were PFS and OS in the total 
population as well as in a subgroup with a PD-L1 combined positive score (CPS) of ≥ 
20. CPS is a scoring method for PD-L1 expression, and is defined by the total number 
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of PD-L1 positive cells (tumour, lymphocytes, and macrophages) divided by the total 
number of tumour cells.(9) Pembrolizumab significantly improved OS compared with 
the EXTREME regimen in the subgroups with a PD-L1 CPS ≥ 20 (14.9 months versus 
10.7 months, HR 0.61) and ≥ 1 (12.3 months versus 10.3 months, HR 0.78) and was 
non-inferior in the total population. Pembrolizumab in combination with platinum-5FU 
significantly improved OS in the total population (13.0 months with pembrolizumab 
plus platinum-5FU versus 10.7 months with the EXTREME-regimen, HR 0.77). Toxicities 
of pembrolizumab with platinum-5FU were comparable with the EXTREME-regimen. 
Pembrolizumab as single agent was less toxic than the EXTREME-regimen. (10) In June 
2019, the FDA approved pembrolizumab for use in combination with platinum and 
5FU for all patients and as a single agent for patients whose tumours express PD-L1 
CPS ≥1. The European Medicines Agency (EMA) did not yet approve pembrolizumab 
as first-line treatment, but only in patients progressing on or after platinum-containing 
chemotherapy. In the Netherlands it is expected that “Commissie BOM” will approve 
pembrolizumab as single agent as first-line treatment in recurrent or metastatic SCCHN 
patients with tumours expressing PD-L1 CPS ≥20.
The CheckMate 651, in which nivolumab with ipilimumab is compared with the 
EXTREME regimen, and the Kestrel study, in which durvalumab versus durvalumab 
+tremelimumab versus EXTREME regimen is investigated, are two other ongoing first-
line studies with ICI in recurrent or metastatic SSCHN patients (NCT02741570, 
NCT02551159). 
A big advantage of immunotherapy is that it is relatively well tolerated, with reduced 
incidence of adverse events compared with chemotherapy regimens. In the Checkmate 
141 study with nivolumab the incidence of grade 3-4 toxicity was 13.1% versus 35.1% 
in the chemotherapy or cetuximab -group, and HRQoL remained stable after the start 
of nivolumab, while patients receiving chemotherapy had a clinically meaningful 
deterioration in HRQoL from baseline to weeks 9 and 15. (7, 11) 
However, despite these promising results and new treatment options, ORRs are still 
only 13.8% with nivolumab and 17% with pembrolizumab in the total population, 
compared with 36% with the EXTREME regimen. (8, 10) Despite the reduced RR with 
immunotherapy compared with chemotherapy, in patients who respond, the OS is 
significantly longer. Therefore, it would be of great clinical value if it is possible to 
predict responders and non-responders before start of the treatment, especially as a 
high response rate is important in patients with symptoms due to their local recurrent 
tumour or metastases, and it would be of great value to predict which patient should 
prescribed immunotherapy and which the EXTREME regimen. Ferris et al. tried to study 
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differences in responses between PD-L1 expressors (≥1%) and non-expressors (<1%) 
and also between HPV-positive and HPV-negative tumours. Nivolumab showed OS 
benefit in comparison with investigators choice treatment in both PD-L1 expressors 
and PD-L1 non-expressors. However, nivolumab provided a 45% reduction in the risk 
of death compared with investigators choice treatment in PD-L1 expressors, while in 
non-expressors nivolumab the reduction in the risk of death was only 27%. (8)  ORR 
was improved with nivolumab compared with investigator’s choice treatment in PD-L1 
expressors (17.7% versus 1.6%), while the ORR was similar in PD-L1 non-expressors 
between nivolumab and investigators choice treatment (11.8% versus 12.5%). In the 
KEYNOTE-048 Burtness et al. investigated the use of the PD-L1 CPS as predictive marker 
to differentiate which patients need pembrolizumab in combination with chemotherapy 
and those who can benefit with pembrolizumab as single agent. (10) As described 
above, pembrolizumab as single agent was superior compared with the EXTREME-
regimen in patients with a PD-L1 CPS ≥ 20 (HR 0.61, p=0.0007), while pembrolizumab 
in combination with platinum-5FU was superior to the EXTREME regimen in the total 
population (HR 0.77, p=0.0034). Further studies are necessary to determine which 
predictive markers are the best for this group of patients. 
With regard to the HPV status, the same OS benefit (40% reduction in the risk of death 
with nivolumab versus investigators choice treatment) was observed in HPV-positive 
and HPV-negative tumours. The ORR was improved with nivolumab compared with 
investigator’s choice treatment in HPV-positive tumours, as HPV-positive tumours 
frequently have higher PD-L1 expression, while ORR was similar in both treatment 
groups in HPV-negative tumours. (8)
As we know from treatment with immunotherapy in other types of cancer, and also 
from treatment with nivolumab in the CheckMate 141, time to response with 
immunotherapy is often more than 8 weeks (2.1 months in the CheckMate 141). Some 
patients do not have that time because of very aggressive tumour behaviour or because 
of a poor condition and performance status. Therefore, it is of clinical value and cost-
effective, if it is possible to predict who can benefit from potential effect from 
immunotherapy, and for whom the possible treatment effect will be too late. 
At this moment, in the Netherlands, only nivolumab is approved for recurrent or 
metastatic head and neck cancer, and only as second-line treatment after platinum 
failure. However, as the KEYNOTE-048 study showed improved outcomes with 
pembrolizumab in first-line, it is expected that pembrolizumab will be approved soon, 
at least in patients with CPS ≥ 20.
In patients who are ineligible for (e.g. have auto-immune diseases) or refuse 
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immunotherapy and platinum-based chemotherapy, but with a great motivation to 
start treatment, treatment with cetuximab and methotrexate could be a meaningful 
treatment option, certainly as first-line treatment. Treatment with the combination of 
cetuximab and methotrexate was not investigated in second-line, but currently there 
is no data at all of chemotherapy in combination with or without cetuximab as second-
line after immunotherapy. 
Other treatment options for recurrent or metastatic disease are targeted therapies 
such as tyrosine kinase inhibitors (TKI) against EGFR, HER2, PIK3CA or mammalian 
targets of rapamycin (mTOR). EGFR for example is overexpressed in around 90% of 
the SCCHN patients, but many patients are or become refractory to anti-EGFR 
treatment, due to different intrinsic or acquired mechanisms.  In tumours refractory 
to EGFR-inhibition, there is activation of the PIK3CA, AKT and mTOR pathway leading 
to enhanced cell survival. The exact incidence of the alterations in the different 
pathways is unknown and TKI’s against EGFR (erlotinib, gefitinib), HER2 (lapatinib) or 
EGFR and pan-HER (afatinib) only showed modest activity in recurrent or metastatic 
disease (12). In a phase III trial, in which patients were randomised between gefitinib 
250mg, gefitinib 500mg and methotrexate, gefitinib 500mg improved ORR, however, 
this was not significantly different, while the OS was the same in the three treatment 
groups. (13) In the phase 3 LUX-Head&Neck 1 study, afatinib was compared to 
methotrexate as second-line treatment after platinum-failure, with a significant longer 
PFS in the afatinib group (2.6 versus 1.7 months). Two phase II trials did not demonstrate 
a benefit in OS or PFS of adding PX-866, an agent targeting PI3K isoforms, to either 
cetuximab or docetaxel. (14, 15) Also, two mTOR inhibitors, everolimus and 
temsirolimus, had disappointing results as single agent therapies as well as combination 
therapies in phase I and phase II studies. (12)
Locally advanced disease
Chemoradiotherapy is the treatment of choice for LAHNC, as primary treatment or as 
post-operative treatment in case of extracapsular extension and/or microscopically 
involved surgical margins. (16) The addition of chemotherapy led to an absolute OS 
benefit of 4.5% in all patients treated with the combination of chemotherapy to 
radiotherapy (i.e. induction, concomitant, or adjuvant chemoradiotherapy) and 6.5% 
in case of concomitant chemoradiotherapy. (17) However, the benefit of chemoradio-
therapy in terms of OS is at the expense of extra toxicity. Chemoradiotherapy is 
characterized by a high incidence of toxicities, like dysphagia, aspiration pneumonia, 
nephrotoxicity and ototoxicity. The incidence of grade 3-4 acute toxicities was 47% with 
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radiotherapy alone versus 77% with chemoradiotherapy. (18) It is therefore important 
to find ways to reduce the toxicities without reducing efficacy. 
As immunotherapy is getting more and more important in the recurrent or metastatic 
setting, with improved OS in part of the patients and with reduced toxicity, it is a logical 
next step to study its contribution in LAHNC patients. Currently several studies are 
running with immunotherapy in combination with radiotherapy or chemoradiotherapy 
in LAHNC patients. These studies are performed as concomitant therapy with 
chemotherapy as definitive treatment (NCT03040999), or as adjuvant treatment 
(NCT02641093). Furthermore, a study in which chemoradiotherapy will be compared 
with immunotherapy-radiotherapy (so without chemotherapy) is in preparation. 
(NCT03383094)
Despite all these new developments, cisplatin-based chemoradiotherapy is still 
considered as the standard in most LAHNC patients. Because the high acute and late 
toxicity rate of cisplatin-based chemoradiotherapy, studies which investigate other 
effective, but less toxic treatments are of utmost importance to improve personalised 
care. 
Alternatives of cisplatin in combination with radiotherapy
Different kinds of therapies are combined with radiotherapy to improve efficacy and/
or to reduce toxicity. In a meta-analysis by Pignon et al. no significant difference in 
efficacy was seen between single agent chemotherapy and poly-chemotherapy. In the 
mono-chemotherapy group, efficacy of chemotherapy was significantly improved with 
platinum (i.e. cisplatin or carboplatin) compared with other types of chemotherapy. 
(17) A meta-analysis of the comparison between cisplatin and carboplatin, revealed 
better 5-year OS with cisplatin (HR=0.67, 95% CI, 0.49 to 0.91; P=0.01). Cisplatin-based 
chemoradiotherapy was associated with fewer haematological toxicities, but with more 
gastrointestinal toxicities and nephrotoxicity compared with carboplatin-based 
chemoradiotherapy. (19)
If a patient is not eligible for cisplatin-based chemoradiotherapy, due to performance-
status, age, renal function or hearing loss, cetuximab added to radiotherapy has shown 
to be beneficial as primary treatment in terms of locoregional control (LRC) and OS. 
(20) However, there are no good head to head studies comparing cisplatin-radiotherapy 
and cetuximab-radiotherapy. A retrospective study of Bauml et al. showed that 
cetuximab added to radiotherapy as primary treatment had inferior OS compared with 
cisplatin-radiotherapy, regardless of the use of high-dose or intermediate-dose 
cisplatin. (21) A recent study by Do et al. confirms these findings in a small retrospective 
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study, in which cetuximab-radiotherapy had reduced OS rate, LR rate, and 2-year organ 
preservation rate compared with cisplatin-radiotherapy. (22) Recently, in HPV positive 
patients, who in general have a better prognosis, cetuximab-radiotherapy was 
associated with worse OS and PFS compared to treatment with cisplatin-based 
radiotherapy. (23) The goal of this de-escalate study in HPV-positive oropharyngeal 
cancer was to improve patient’s quality of life and reduce acute and long-term toxicity, 
but without compromising efficacy. Unfortunately, not only the efficacy was worse, but 
also no differences in the overall rates of grade 3-5 toxicities were observed between 
the cetuximab-radiotherapy and cisplatin-radiotherapy group. 
Another interesting alternative for cisplatin-based chemotherapy can be poly ADP-
ribose polymerase (PARP) inhibitors in combination with radiotherapy. As PARP-
inhibitors increase the level of double-strand breaks by the inability to repair 
radiotherapy-induced single-strand breaks, they can increase cell death induced by 
radiotherapy.(24) This is currently tested in phase I studies in head and neck cancer 
patients, either alone or in combination with cisplatin. (25) (NCT02229656, 
NCT02308072). 
Prediction of cisplatin-toxicity
Another way to personalize treatment is to predict the risk of the most clinically relevant 
toxicities of cisplatin in each individual patient. Chemotherapy with cisplatin is most 
often applied either at a dose of 100mg/m2 every 3 weeks for 3 cycles (high dose) or 
at a dose of 40mg/m2 every week for 6 or 7 cycles (intermediate dose).(26) Several 
studies showed that intermediate dose cisplatin reduced the rate of acute toxicities, 
especially ototoxicity and nephrotoxicity, compared with high dose cisplatin without 
reduced efficacy. (27, 28) Although chemoradiotherapy with cisplatin still is the best 
treatment option, if it is possible to predict the cisplatin-induced toxicities, shared 
decision making is important to weigh up the toxicity and the efficacy. For example, 
treatment with an intermediate dose instead of high dose cisplatin can be considered, 
treatment with cetuximab or carboplatin instead of cetuximab, or even radiotherapy 
alone without concomitant chemotherapy. Personal circumstances and physical 
condition can be taken into account and justify to administer a possible less effective 
treatment with the benefit of less toxicity. 
Genetic variants to predict ototoxicity and nephrotoxicity were studied in the Prone 
study, in which only a significant correlation between the SNP ACYP2 and clinically 
determined ototoxicity was found. As clinically determined ototoxicity the is probably 
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more clinically relevant than audiometrically determined ototoxicity, in new studies 
there should be more attention to clinically determined ototoxicity measured by the 
Common Terminology Criteria for Adverse Events (CTCAE). However, for clinical 
practice, at this moment there are no reliable predictive tests for ototoxicity as well as 
nephrotoxicity, so larger multinational cohort studies are necessary to eventually can 
improve personalised care. In these studies, HRQoL should be an important aspect, 
because ototoxicity as well as nephrotoxicity can have a (huge) impact on HRQoL.
Antibiotics
In LAHNC patients treated with concomitant chemoradiotherapy there is a high rate 
of hospitalisation. To the best of our knowledge, the use of prophylactic antibiotics to 
prevent aspiration pneumonias or mucositis in patients with LAHNC has never been 
investigated before. In our PANTAP study almost 40% of the patients in the standard 
group were hospitalised. (29) Reasons for hospitalisation were for example mucositis, 
pain, fever, and dehydration, but frequently multifactorial. Besides that, there is a high 
incidence of dysphagia and aspiration in these patients with a reported aspiration rate 
of 13-69% (30, 31), therefore the PANTAP-study was performed, to investigate if 
prophylactic antibiotics could lower the number of aspiration pneumonias, which was 
the primary endpoint. Although this primary endpoint was negative, the reduced 
number of hospital admissions is clinically relevant from the patient’s perspective. 
Although pneumonias were the primary outpoint, the effect of prophylactic antibiotics 
could potentially have a positive effect on other side effect of the treatment, which 
often lead to hospitalisation (e.g. mucositis, fever, pain). Besides the fact that a lower 
hospitalisation rate is an advantage for the patient, reducing the number of admissions 
to the emergency department and to the in-patient ward is not only effective in 
reducing costs, but also for the burden on health care services. It would be of great 
value if there would be biomarkers, which can predict which patients would benefit 
most from prophylactic antibiotics. Because of the relative small number of patients, 
no subgroup analyses could be performed, but it would be very interesting to 
investigate if for example patients with chronic obstructive pulmonary disease (COPD) 
or aspiration before the start of chemoradiotherapy, could benefit more from 
prophylactic antibiotics. However, in the PANTAP study for these patient characteristics 
was stratified. 
Although prophylactic antibiotics to prevent aspiration pneumonia was never described 
before, we only found results of a pilot study which was performed in head and neck 
cancer patients with an antimicrobial lozenge instead of systemic antibiotics that 
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showed elimination of Candida in all patients and reduction in gram-negative flora in 
most patients.(32) However, a subsequent randomized phase 3 study failed to show 
a reduction in mucositis with the use of antimicrobial lozenge.(33) Until new studies 
are performed or new insights in the treatment with prophylactic antibiotics are 
presented, we suggest that in patients with high risk of aspiration pneumonia, e.g. 
COPD Gold 3-4, aspiration before start of the chemoradiotherapy and patients who 
continue smoking, administration of prophylactic antibiotics can be considered. Before 
initiating any new supportive care studies in this patient group, it should be considered 
that the primary endpoint, pneumonia, is a challenging one.
As mentioned above, new studies are currently being performed or in preparation with 
new treatment modalities including immunotherapy in LAHNC patients. If in future, 
immunotherapy possibly will replace chemotherapy in this setting, you could argue 
that prophylactic antibiotics will be of less importance. However, as aspiration and 
aspiration pneumonia will remain to be a critical issue in LAHNC patients due to the 
primary tumour localization and radiotherapy treatment, which will be a cornerstone 
of the treatment, all means to prevent (aspiration) pneumonia, are still important. 
Whether oral amoxicillin/clavulanic acid will be the best choice in this respect, can be 
discussed. Reasonable alternatives are selective digestive decontamination (SDD) or 
selective oropharyngeal decontamination (SOD), as used at intensive care units (ICU), 
to prevent infectious complications. SDD means the prophylactic treatment of patients 
with an oropharyngeal paste and enteral suspension containing antimicrobials as well 
as an intravenous antibiotic during the first 4 days of ICU admission. The purpose of 
the treatment is to eradicate potential pathogenic microorganisms from the oropharynx 
and digestive tract of patients at risk for nosocomial infections.  SOD consists of SDD 
without the enteral suspension and without intravenous antibiotics.(34)
Especially SOD could be an interesting treatment alternative in LAHNC patients to 
prevent pneumonia, but further studies are logically necessary.
Prevention of head and neck cancer 
Instead of reducing toxicities and improving outcomes, primary prevention of head 
and neck cancer would be even better. Alcohol and tobacco and HPV in oropharyngeal 
cancer are the major risk factors for head and neck cancer. Prevention and cessation 
of smoking and alcohol use are two principal strategies to reduce alcohol and tobacco 
addiction. Although for alcohol drinking, a long time period (36-39 years) of 
discontinuation is required to equal the risk of laryngeal and pharyngeal cancers to 
that of never drinkers, already after 5 years of drinking cessation a reduction of around 
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15% in the alcohol-related elevated risk of these cancers was seen. (35) Therefore, also 
alcohol drinking cessation should be encouraged. As for smoking, active programs at 
secondary schools are in high need to show its terrible late effects to lower the 
incidence of young people starting with this potentially lethal addictions.
As HPV vaccination in women, is safe and effective in preventing cervical cancer, HPV 
vaccination in male to prevent oropharyngeal cancer could be worthwhile. 
Unfortunately, in a recent review by Harder et al., no data were identified about the 
efficacy of HPV vaccination in men to prevent head and neck squamous cell cancer. 
However, HPV vaccination in males is moderately effective against persistent anogenital 
HPV infection and high-grade anal intraepithelial lesions. Vaccine effectiveness drops 
markedly in individuals who are already infected with the corresponding HPV type. 
This supports a recommendation for early vaccination of boys also with the goal of 
establishing optimal vaccine-induced protection before the onset of sexual activity. 
(36)  Recently, the “Gezondheidsraad” in the Netherlands has advised to vaccinate boys 
as well as girls, from an age of 9 years old.
Conclusion
Despite the progressions made in the treatment of patients with SCCHN over the last 
decades, there are still a lot of challenges to improve the care for these patients. 
Improving personalised care should consist of both improvements in efficacy and 
prognosis by developing new treatment modalities and similarly reducing toxicities 
leading to improving health-related QoL. 
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Nederlandse samenvatting en discussie 
Hoofd-hals kanker
Kanker in het hoofd-hals gebied kan voorkomen in de voorhoofdholtes, neusbijholte, 
mondholte, keelholte, strottenhoofd of speekselklieren. Er kunnen verschillende types 
kanker in het hoofd-hals gebied voorkomen, waarbij het meest voorkomende type 
plaveiselcel kanker is. Met de term ‘hoofd-hals kanker’ wordt dan ook meestal 
plaveiselcel kanker in de mondholte, keelholte of strottenhoofd bedoeld.
Hoofd-hals kanker is de zevende meest voorkomende type kanker wereldwijd. 
Wereldwijd waren er in 2015 930.000 patiënten die de diagnose hoofd-hals kanker 
kregen; in Nederland waren dat in 2017 meer dan 3000 patiënten. 
In de Westerse wereld ontstaat hoofd-hals kanker in twee derde van de patiënten als 
gevolg van roken en alcohol gebruik, en komt driekeer zo vaak voor bij mannen als bij 
vrouwen. Een andere risicofactor, met name voor kanker in de keelholte, is het humaan 
papillomavirus (HPV). Hoofd-hals kanker veroorzaakt door HPV komt meestal voor op 
jongere leeftijd, heeft een betere prognose en reageert over het algemeen beter op 
behandeling. 
Symptomen van hoofd-hals kanker kunnen zijn heesheid, keel- or oorpijn, moeite met 
slikken of een niet goed passend kunstgebit. Symptomen worden echter zowel door 
patiënt als de huisarts niet altijd goed herkend, waardoor de diagnose regelmatig pas 
laat gesteld wordt. Hierdoor is de kanker vaak al in een gevorderd stadium, met een 
slechtere prognose, waardoor er een  intensievere behandeling nodig is met meer 
bijwerkingen.
Een gevorderd stadium (in ongeveer 60% van de patiënten) kan bestaan uit een grote 
tumor, en/of uit uitzaaiingen in de lymfeklieren in de hals. Daarnaast zijn er in 10% van 
de patiënten al uitzaaiingen op afstand op het moment dat voor het eerst de diagnose 
hoofd-hals kanker wordt gesteld.
De diagnose wordt gesteld door lichamelijk onderzoek (inclusief een uitgebreid 
onderzoek door een KNO-arts of kaakchirurg), een CT-scan van de hals of MRI-scan 
van de tumor, een echo van de lymfeklieren in de hals en een CT van de longen, omdat 
roken een risicofactor is voor zowel hoofd-hals kanker als voor longkanker. Door middel 
van een biopt van de tumor en/of punctie van de lymfeklieren wordt het uiteindelijke 
tumor stadium bepaald. Zowel de behandeling als de prognose hangen af van dit tumor 
stadium.
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Behandeling gevorderde ziekte zonder uitzaaiingen
De behandeling hangt niet alleen af van de locatie van de oorspronkelijke tumor en 
het stadium van de ziekte, maar ook van de leeftijd, co-morbiditeit en conditie van de 
patiënt. Operatie, bestraling en chemotherapie zijn de drie voornaamste mogelijkheden 
van behandeling. Operatie heeft in een aantal patiënten de voorkeur, bijvoorbeeld bij 
kanker in de mondholte. Bij een aantal patiënten zou een operatie een grote impact 
op hun leven hebben, bijvoorbeeld door het kwijtraken van hun stembanden en 
daarmee hun stem-functie. In deze patiënten is aangetoond dat bestraling, al dan niet 
gecombineerd met chemotherapie, een even goede prognose oplevert en de functie 
van de stembanden kan behouden. In de literatuur is een absolute overlevingswinst 
van 6,5% aangetoond van behandeling met chemotherapie en bestraling ten opzichte 
van alleen bestraling bij patiënten met een lokaal uitgebreid hoofd-halskanker. 
Als chemotherapie is cisplatin het meest effectief gebleken. Dit kan in verschillende 
schema’s en met verschillende doseringen worden toegediend. Het wereldwijd meest 
gebruikte schema is een driewekelijkse kuur met een dosering van cisplatin van 100mg/
m2 (hoge dosis), waarbij in totaal 3 kuren worden toegediend. Een veel gebruikt 
alternatief is een wekelijkse kuur met een dosering van 40mg/m2 cisplatin (gemiddelde 
dosis), waarbij 6-7 kuren in totaal worden gegeven. Als alternatief voor cisplatin kan 
carboplatin of eventueel cetuximab, een monoklonaal antilichaam, worden 
gecombineerd met bestraling. De bestraling wordt dagelijks toegediend gedurende 
6-7 weken, waarbij er in sommige (kortere) schema’s twee keer per dag wordt bestraald 
op één dag in de week.
Gecombineerde behandeling met chemotherapie en bestraling kent echter veel 
bijwerkingen, zowel op de korte termijn, als op de lange termijn. Bijwerkingen 
gedurende de behandeling kunnen zijn slijmvlies aantasting, moeite en/of pijn met 
slikken, misselijkheid, gehoorverlies, nierschade of onderdrukking van het beenmerg. 
Hoe vaak deze bijwerkingen voorkomen hangt af van welke dosering cisplatin en welke 
schema gebruikt wordt. Nierschade wordt gemeld in 8-68% van de patiënten, beenmerg 
onderdrukking in 40%, en aantasting van het slijmvlies in 77% van de patiënten. Moeite 
en/of pijn met slikken worden vaak niet goed gerapporteerd. Moeite met slikken kan 
verslikken tot gevolg hebben, wat kan leiden tot een longontsteking. Het voorkomen 
van verslikken wordt in de literatuur beschreven in 13-69% van de patiënten.
Naast deze bijwerkingen op de korte termijn, kunnen er ook 5 jaar na de behandeling 
bijwerkingen ontstaan of sommige bijwerkingen kunnen blijvend zijn, zoals 
verlittekening van het behandelde gebied,  het hebben van een droge mond en moeite 
en/of pijn met slikken. 
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De behandeling zelf, maar ook de bijwerkingen op korte en lange termijn, hebben een 
grote impact op de ervaren kwaliteit van leven van patiënten. Tijdens behandeling 
daalt de kwaliteit van leven, waarbij deze 4-6 weken na het afronden van de behandeling 
zelfs nog verder daalt, terwijl na 1 jaar na afronden van de behandeling de kwaliteit 
van leven vaak weer op hetzelfde niveau is als voorafgaand aan de behandeling. 
Behandeling uitgezaaide ziekte
Ondanks deze intensieve behandeling voor gevorderde hoofd-hals kanker, krijgt een 
substantieel deel van de patiënten de ziekte terug; tot 60% van de behandelde 
patiënten krijgt lokaal de ziekte terug en tot 30% ontwikkelt uitzaaiingen elders in het 
lichaam. Helaas is lokale behandeling met operatie of opnieuw bestraling in geval van 
lokale ziekte terugkeer, slechts in een zeer klein percentage van de patiënten mogelijk. 
Voor het grootste deel van de patiënten, is er op het momenten dat de ziekte 
terugkeert geen genezing meer mogelijk. De gemiddelde overleving op het moment 
van ziekte terugkeer is minder dan 1 jaar. Indien patiënten nog fit genoeg zijn kan 
chemotherapie worden gegeven, waarbij er in het algemeen een combinatie van 
verschillende middelen (cisplatin, cetuximab en 5FU ; het “EXTREME-schema”) wordt 
gegeven omdat deze combinatie van chemotherapie het eerste schema was dat winst 
in overleving heeft aangetoond (van gemiddeld 7.4 maanden naar 10.1 maanden). 
Deze behandeling gaat echter gepaard met veel bijwerkingen. Hierdoor blijkt ook vaak 
in de dagelijkse praktijk dat dit schema niet haalbaar is in deze vaak kwetsbare 
patiëntengroep. Een alternatief is methotrexaat, waarvan geen overlevingswinst is 
vastgesteld, maar waarvan wel bekend is dat het de tijd tot toename van ziekte uitstelt 
en over het algemeen goed verdragen wordt zonder veel bijwerkingen. Uiteraard kan 
in plaats van behandeling met chemotherapie, ook alleen ondersteunende zorg een 
goede optie zijn.
Resultaten van onderzoek beschreven in dit proefschrift
Zoals eerder gezegd, zijn slikklachten en verslikken met een longontsteking als gevolg, 
veel voorkomende bijwerkingen van gecombineerde chemotherapie en radiotherapie 
voor patiënten met gevorderde hoofd-hals kanker. Daarom hebben wij de PANTAP-
studie bedacht en uitgevoerd, waarin het profylactisch voorschrijven van een 
antibioticum aan patiënten met gevorderde hoofd-hals kanker die behandeld werden 
met gecombineerde chemotherapie en bestraling werd vergeleken met standaard zorg 
in het voorkómen van longontsteking (al dan niet het gevolg van verslikken). In deze 
studie hebben we naast het effect op de longontsteking gekeken naar het effect van 
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de profylactische antibiotica op het aantal en de duur van de ziekenhuisopnames, de 
ervaren kwaliteit van leven, bijwerkingen, kosten en of bacteriën in slijmkweken 
ongevoelig werden voor het antibioticum. Patiënten werd gevraagd deel te nemen aan 
de studie vooraf aan de start van de behandeling met chemotherapie en bestraling 
waarbij ze, indien ze toestemden, werden gerandomiseerd (=geloot) voor wel of geen 
profylactische antibiotica. Deze antibiotica moesten ze gebruiken vanaf 29 dagen na 
start van de behandeling met chemotherapie en bestraling tot 14 dagen na het einde 
van de behandeling. In totaal hebben 106 patiënten deelgenomen aan de studie, 
waarbij er 48 patiënten geloot hebben om geen antibioticum te krijgen, en 47 patiënten 
om wel antibioticum te gebruiken. De overige 11 patiënten konden om verschillende 
redenen niet geloot worden tussen wel of geen antibioticum, meestal omdat ze al voor 
dag 29 van de behandeling een antibioticum hadden gekregen. 
In hoofdstuk 2 worden de voornaamste resultaten van de PANTAP-studie beschreven; 
er werd geen verschil gevonden in het aantal longontstekingen tussen patiënten die 
wel of geen profylactisch antibioticum hadden gebruikt. Wel was er een duidelijke 
afname in het aantal ziekenhuisopnames in de groep patiënten die wel het antibioticum 
had gekregen, evenals een afname in het optreden van koorts. Hierdoor waren de 
gemiddelde kosten voor een patiënt die wel antibioticum had gekregen duidelijk lager 
(€1425 minder) dan voor een patiënt die geen antibioticum had gekregen. In hoofdstuk 
3 wordt het effect van de profylactische antibiotica op de kwaliteit van leven beschreven. 
Vooral aan het einde van de gecombineerde behandeling met chemotherapie en 
bestraling, is de kwaliteit van leven op veel verschillende aspecten beter voor de groep 
die profylactisch antibioticum kregen. Als laatste worden de resultaten van de 
slijmkweken en het effect van het antibioticum hierop beschreven in hoofdstuk 4. Er 
was geen verschil in het aantal kweken waarin bacteriën of schimmels werden gekweekt 
tussen beide groepen. Er waren echter wel meer bacteriën ongevoelig voor antibiotica 
direct aan het einde van de gecombineerde behandeling met chemotherapie en 
bestraling in de patiënten die werden behandeld met profylactisch antibiotica, maar 
dit verschil was niet meer aantoonbaar 3 en 14 weken na het afronden van de bestraling 
en chemotherapie behandeling.
In hoofdstuk 5 worden de resultaten beschreven van de PRONE-studie. Aangezien 
behandeling met het cytostaticum cisplatin als onderdeel van de gecombineerde 
behandeling met bestraling en chemotherapie kan leiden tot zowel gehoorverlies als 
nierschade, heeft deze studie onderzocht of er genen zijn die kunnen voorspellen welke 
patiënten wel en welke patiënten geen last van deze bijwerkingen kregen. Gehoorverlies 
is op twee manieren te bepalen; enerzijds door wat de patiënt ervaart en rapporteert, 
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anderzijds door een gehoormeting. Een variatie in het ACYP2-gen bleek voorspellend 
voor gehoorverlies zoals deze wordt ervaren door de patiënt, maar niet voorspellend 
voor schade gemeten bepaald door gehoormetingen. Een variatie in het OCT2-gen 
bleek nierschade te kunnen voorspellen gedurende de behandeling, maar had geen 
voorspellende waarde voor nierschade aan het einde van de behandeling, wat 
uiteindelijk het meest relevant is. 
Tot slot heeft de COMMENCE-studie, beschreven in hoofdstuk 6, onderzocht of de 
combinatie van methotrexaat met cetuximab effectiever is dan behandeling met alleen 
methotrexaat in patiënten met teruggekeerde ziekte. Aangezien de 
standaardbehandeling met het EXTREME-schema, dat bestaat uit drie verschillende 
chemotherapie-middelen, meestal te intensief is voor deze patiënten en veel 
bijwerkingen kent, onderzocht de COMMENCE studie of behandeling met een nieuwe 
combinatie van twee middelen, methotrexaat en cetuximab, zowel effectief was als 
goed verdragen werd. In eerste instantie  werd gekeken of deze nieuwe combinatie 
veilig kon worden toegediend. Nadat dit het geval bleek te zijn in de eerste 6 patiënten, 
werd de studie vervolgens uitgebreid naar een studie waarin twee behandelingen 
werden vergeleken, namelijk methotrexaat en cetuximab met methotrexaat alleen. 
Dertig patiënten zijn vervolgens behandeld met methotrexaat en cetuximab en 15 
patiënten met methotrexaat alleen. Met de combinatie behandeling duurde het langer 
totdat de ziekte weer toenam in vergelijking met methotrexaat alleen (4,5 maanden 
versus 2,0 maanden). Er was geen verschil in overleving tussen de beide groepen en 
ook geen verschil in bijwerkingen. 
Nieuwe ontwikkelingen
Het is van belang te weten dat de COMMENCE studie is uitgevoerd in de periode 
voordat er de mogelijkheid was om immunotherapie toe te dienen aan patiënten met 
teruggekeerde hoofd-hals kanker die niet meer kunnen genezen. Inmiddels is er in 
Nederland goedkeuring om patiënten die toename van ziekte hebben, nadat ze 
behandeld zijn met cisplatin of carboplatin (bijvoorbeeld volgens het EXTREME-schema), 
te behandelen met immunotherapie. Dit laat in een relatief kleine groep patiënten een 
duidelijke overlevingswinst zien met daarbij relatief weinig bijwerkingen. Want ondanks 
dat slechts 13.3% van de patiënten in deze studie, die tot registratie leidde, baat heeft 
bij de behandeling, is de 1-jaars overleving van deze groep patiënten die respondeert 
wel duidelijk beter (1-jaars overleving van 36.0% in plaats van 16.6%). Daarnaast is er 
recent een studie verricht, waarbij patiënten die nog nooit behandeld waren voor 
teruggekeerde hoofd-hals kanker, werden geloot tussen het EXTREME-schema, 
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immuuntherapie alleen, of immuuntherapie gecombineerd met cisplatin of carboplatin 
en 5-FU. In die studie is onderscheid gemaakt naar patiënten met een hoge en lage 
Combined Positive PDL1 Score (CPS), waarvan gedacht wordt dat patiënten met een 
hoge CPS beter op immuuntherapie reageren. Daarin bleek dat patiënten met een 
hoge CPS een duidelijk betere overleving hadden met immuuntherapie vergeleken 
met de groep die alleen chemotherapie kreeg volgende het EXTREME-schema (14.9 
maanden versus 10.7 maanden). In de gehele groep, met ook patiënten met een lage 
CPS, bleek de combinatie van immuuntherapie en chemotherapie beter dan het 
EXTREME-schema (een overleving van 13.0 maanden versus 10.7 maanden). Het is dan 
ook waarschijnlijk dat deze behandeling voor patiënten met een hoge CPS binnenkort 
wordt goedgekeurd in Nederland. Desalniettemin, zullen er ook patiënten blijven die 
niet in aanmerking komen voor immunotherapie, en die niet fit genoeg zijn voor het 
intensieve EXTREME-schema, voor wie de combinatie van methotrexaat en cetuximab 
dan een waardevol alternatief kan zijn.
Gezien de ontwikkelingen van immunotherapie bij patiënten met teruggekeerde hoofd-
hals kanker, is het een logische stap om ook immunotherapie toe te voegen aan de 
behandeling van patiënten met lokaal gevorderde ziekte. Dit om te streven naar 
enerzijds minder bijwerkingen van de chemotherapie en anderzijds om de kans op 
terugkeer van ziekte zo klein mogelijk te maken. Deze studies worden momenteel 
uitgevoerd.
Ook als immuuntherapie in de toekomst chemotherapie zou kunnen gaan vervangen 
in combinatie met bestraling bij de eerste behandeling van patiënten met een 
gevorderd hoofd-hals carcinoom, zal het voorkomen van longontstekingen (al dan niet 
door verslikken) en het voorkomen van ziekenhuisopnames een belangrijke rol blijven 
spelen. Daarmee blijft de vraag of een profylactisch antibioticum standaard toegevoegd 
zou moeten worden aan de gecombineerde behandeling (immunotherapie en 
bestraling). Zeker in patiënten met een hoog risico op longontstekingen, zoals patiënten 
met een onderliggende longziekte of patiënten die roken, is dit een goed te verdedigen 
beleid. Bij voorkeur zou hier meer onderzoek naar gedaan moeten worden, waarbij 
ook onderzocht kan worden of andere antibiotica dan die in onze studie werden 
gegeven, of combinatie van middelen wellicht effectiever kan zijn met minder invloed 
op het ongevoelig worden van bacteriën voor antibiotica.
Wat betreft het voorspellen van bijwerkingen van cisplatin, zoals gedaan is in de PRONE-
studie, was dit het eerste onderzoek uitgevoerd in patiënten met hoofd-hals kanker. 
Voor de huidige praktijk kunnen we hier helaas dus nog geen consequenties aan 
verbinden, en zal vervolgonderzoek nodig zijn in grotere groepen patiënten.
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Waar nog veel winst te behalen is, is in het voorkómen van hoofd-hals kanker. Zo is 
stoppen met roken en stoppen met alcohol duidelijk effectief gebleken in het 
voorkómen van een tweede hoofd-hals kanker in patiënten die eerder al een hoofd-
hals kanker hadden ontwikkeld. Het is daarom van groot belang om jongeren al op 
jonge leeftijd op de risico’s van roken en alcohol te wijzen en om hiermee het ontstaan 
van hoofd-hals kanker te voorkómen.
Daarnaast worden meisjes inmiddels ingeënt om baarmoederhalskanker als gevolg 
van HPV te voorkomen, maar kiest helaas nog lang niet 100% van de meisjes ervoor 
om zich te laten vaccineren. Jongens worden nog niet gevaccineerd waardoor zij nog 
steeds het risico lopen om besmet te worden met HPV, en als gevolg hiervan hoofd-
hals kanker te ontwikkelen. Daarom heeft onlangs de Gezondheidsraad gepleit om 
niet alleen meisjes, maar ook jongens te gaan vaccineren tegen HPV. 
Conclusie
In dit proefschrift zijn de resultaten van onderzoeken beschreven bij patiënten met 
hoofd-hals kanker, waarvan enerzijds het doel was bijwerkingen te verminderen en 
aandacht te geven aan behoud van kwaliteit van leven en anderzijds de effectiviteit 
van behandelingen te verbeteren.  De in dit proefschrift nieuw verworven inzichten 
dragen bij aan de wereldwijde vooruitgang die er de laatste jaren is gemaakt in de 
behandeling van patiënten met hoofd-hals kanker. Er zijn echter nog veel uitdagingen 
om de zorg voor deze patiënten te verbeteren. Verbeteringen betreffen idealiter zowel 
een meer gepersonaliseerde zorg voor deze patiënten als ook effectievere 
behandelingen met minder bijwerkingen om betere uitkomsten zowel op de korte als 
langere termijn te bewerkstelligen.
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This thesis is based on the results of human studies, which were conducted in 
accordance with the principles of the Declaration of Helsinki. The medical and ethical 
review board Committee on Research Involving Human Subjects Region Arnhem 
Nijmegen, Nijmegen, the Netherlands has given approval to conduct these studies. 
  
The patient data for the analyses of the studies as presented in chapter 2, 3, and 4 are 
stored in clinical data management system “Trias” at the Integraal Kankercentrum 
Nederland (IKNL).  The patient data for the analyses of the studies as presented in 
chapter 5 are stored in clinical data management system “OpenClinica” at our 
Radboudumc Technology Center Clinical Studies. The patient data for the analyses of 
the studies as presented in chapter 6 are stored on the departments’ H-drive (H:\
Afdelingsmappen\Medische oncologie - ONCO\Hoofd-hals onderzoek\PRONE studie) 
in SPSS format.
The data will be saved for 15 years after termination of the study. Using these patient 
data in future research is only possible after a renewed permission by the patient as 
recorded in the informed consent. The datasets analyzed during these studies are 
available from the corresponding author on reasonable request.
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Dankwoord
Een proefschrift maak je nooit alleen. Daarom ben ik veel mensen dank verschuldigd, 
die op enige wijze hebben bijgedragen aan het tot stand komen van dit proefschrift. 
In de eerste plaats uiteraard de patiënten en hun familie, die geheel belangeloos 
hebben ingestemd met deelname aan de beschreven studies. Door hun deelname aan 
studies zijn wij in staat om de zorg voor patiënten met hoofd-hals kanker te verbeteren.
Niet iedereen kan ik met naam bedanken die heeft bijgedragen aan dit proefschrift. 
Toch wil ik enkele mensen specifiek noemen en bedanken.
Allereerst mijn promotoren.
Prof. dr. van der Graaf, beste Winette, tijdens mijn promotietraject ben je twee keer 
van werklocatie veranderd, maar desondanks wist je altijd tijd te maken om praktisch 
en inhoudelijk advies te geven en mee te denken over lopend onderzoek en te schrijven 
artikelen. Jouw commentaar maakte het artikel altijd beter. Ik heb daar veel van geleerd. 
Prof. dr. van Herpen, beste Carla, je bent altijd laagdrempelig bereikbaar om mee te 
denken en advies te geven. Wat enorm veel kennis van zowel kliniek als onderzoek 
heb je! Op beide gebieden heb ik dan ook enorm veel van je geleerd en doe dat nog 
steeds. 
De leden van de manuscriptcommissie, prof. dr. Bussink, prof. dr. Vermeulen en 
prof. dr. de Bree, wil ik bedanken voor het kritisch beoordelen en goedkeuren van 
mijn manuscript.
Alle mede-auteurs wil ik heel hartelijk bedanken voor hun bijdragen aan de artikelen 
die samen dit proefschrift vormen. De studies beschreven in dit proefschrift zijn 
uitgevoerd in meerdere hoofd-hals centra in Nederland, en zonder hun bijdrage 
was het nooit gelukt om deze studies te voltooien. Met name Dr. Esther van Meerten 
wil ik bedanken voor de bijdrage aan de COMMENCE studie. Binnen het Radboudumc 
wil ik graag Dr. Marianne Jonker bedanken. Ondanks het feit dat je vaak niet 
betrokken was bij de opzet van de studies, heb je wel veel geholpen bij de statistische 
analyses van zowel de PANTAP-studie als de COMMENCE-studie. Dr. Olga Husson, 
zonder jouw aanstekelijke enthousiasme over kwaliteit-van-leven-onderzoek, zou het 
artikel over QoL van de PANTAP-studie nooit van de grond zijn gekomen. Prof. dr. 
Kullberg, uw bijdrage aan het microbiologie stuk van de PANTAP-studie was 
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onmisbaar. De datamanagers van het IKNL wil ik bedanken voor hun inzet voor de 
PANTAP studie.
Alle leden van de werkgroep Hoofd Hals Oncologie van het Radboudumc, bedankt 
voor de ontzettend fijne samenwerking afgelopen jaren. Dankzij de korte lijnen in de 
keten en de onderlinge prettige samenwerking, wordt er topzorg geleverd aan 
patiënten met hoofd-hals kanker. 
Dankzij de subsidie van ZonMw was het mogelijk om de PANTAP-studie uit te voeren.
Ik wil alle medisch oncologen van de afdeling Medische Oncologie van het Radboudumc 
bedanken voor hun inzet en bijdrage om mij te vormen tot de oncoloog die ik nu ben. 
De fellows, met jullie heb ik tijdens mijn opleiding intensief en heel fijn samengewerkt. 
Mede-promovendi, fijn dat we samen in zowel de villa interna en later in de villa 
externa, menige frustratie over het doen van onderzoek konden delen. De research-
verpleegkundigen en het ondersteunend personeel wil ik graag bedanken voor het 
begeleiden van alle patiënten in de studies en voor het vele werk dat jullie mij uit 
handen namen. Dames van het secretariaat, bedankt voor jullie ondersteuning en 
opbeurende woorden.
Mijn paranimfen. Lieve Laura, we hadden al jaren samen gestudeerd, maar pas toen 
we begonnen aan onze co-schappen in Zwolle werd jij één van mijn beste vriendinnetjes. 
Ondanks dat we inmiddels verder bij elkaar vandaan wonen dan we zouden willen, 
kunnen we nog eindeloos praten over patiëntenzorg, onze beide gezinnen en alles wat 
ons dagelijks bezig houdt. Ik hoop dat nog heel lang samen vol te kunnen houden en 
vind het heel fijn dat jij vandaag naast me staat! Lieve Chantal, ik mocht van jou het 
lopende onderzoek bij patiënten met hoofd-hals kanker overnemen. Wat een enorme 
uitdaging was dat, want jij bent zowel een goede clinicus, goede onderzoeker, als enorm 
sociaal mens, waardoor het een hele uitdaging was om jou op een goede manier op te 
volgen. Maar jouw enthousiasme voor patiënten met hoofd-hals kanker heeft ook zeker 
mij aangestoken. Hoewel helaas straks niet meer in hetzelfde ziekenhuis,  hoop ik dat 
we nog vaak samen mogen sparren! Dank je wel dat je vandaag naast me wil staan!
Lieve vrienden en vriendinnen, veel te bang om iemand te vergeten, noem ik jullie 
niet allemaal bij naam. Afgelopen jaren heb ik jullie minder gezien dan ik wilde, maar 
dit heeft uiteindelijk wel geresulteerd in dit boekje en het afronden van mijn 
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specialisatie. Desondanks waren jullie altijd geïnteresseerd in waar ik precies mee bezig 
was. Dank jullie wel daarvoor! Hopelijk kan ik vanaf nu weer wat makkelijker borrelen, 
uit eten, thee drinken en naar feestjes komen, ik kijk er naar uit!
Beste Leni, Wim, Rianne, René, Annelies, Ferdinand, Wim en natuurlijk Jill, Siebe, 
Jette en Cato, heel fijn om jullie als schoonfamilie te hebben!
Lieve opa en oma van Velzen, ondanks dat jullie er beiden helaas niet meer zijn, zijn 
jullie nog steeds mijn grote voorbeeld. Als ik ook maar 1% van jullie doorzettingsvermogen 
heb geërfd, maakt me dat ontzettend trots.
Lieve Marieke, Anita, Thijs, Pieter, Bram en Daniel, van drie kleine zusjes door de 
jaren heen uitgegroeid tot drie hardwerkende, ambitieuze vrouwen met allemaal een 
prachtig gezin. Daardoor zien en spreken we elkaar minder dan we zouden willen, 
maar weten dat we altijd op elkaar kunnen bouwen, vertrouwen en voor elkaar klaar 
staan. Weet dat ik dat enorm waardeer, dank jullie wel!
Lieve papa en mama, er zijn geen woorden die jullie onvoorwaardelijke steun, 
vertrouwen en liefde goed beschrijven. Jullie zijn er altijd voor mij en ons. Heel veel 
dank voor alles wat jullie gedaan hebben. 
Lieve Jasper, door jou is alles relatief. Hard werken is opeens nog minder leuk. Maar 
wat geef jij mij veel liefde, plezier, relativiteit en positiviteit. Ik vind het geweldig om je 
groot te zien worden, en hoop dat je samen met je broertje geweldige avonturen 
tegemoet gaat. 
Liefste Niek, uiteraard zijn de laatste woorden voor jou. Je bent altijd geïnteresseerd 
in wat ik doe, vangt alles thuis op als ik weer eens iets voor werk of promotie moet 
doen, stimuleert me om verder te gaan, maar zet me tegelijkertijd ook met beide benen 
op de grond. Ik hou van jou!
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2019 wisselde zij haar opleiding tot internist-oncoloog en het promotietraject af. In 
2019 heeft zij haar opleiding tot internist-oncoloog afgerond. Momenteel werkt zij als 
junior staflid op de afdeling Medische Oncologie van het Radboudumc.
Janneke is getrouwd met Niek de Groot, samen hebben ze een zoon Jasper (2017) en 
verwachten ze in 2019 hun tweede kindje.
IMPROVING PERSONALISED CARE IN HEAD AND NECK CANCER PATIENTS        Janneke Ham
IMPROVING PERSONALISED
CARE IN HEAD AND NECK
CANCER PATIENTS
Janneke Ham
UITNODIGING
voor het bijwonen van
de openbare verdediging
van het proefschrift
IMPROVING 
PERSONALISED
CARE IN HEAD 
AND NECK CANCER 
PATIENTS
op dinsdag 5 november 2019
om 16.30 uur precies
in de Aula van 
de Radboud Universiteit, 
Comeniuslaan 2,
Nijmegen.
Janneke Ham
Janneke_ham@hotmail.com
PARANIMFEN
Chantal Driessen
Chantal.driessen@radboudumc.nl
Laura Derksen - van Nunspeet
lderksen2014@outlook.com
